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I. MICROBIAL INFECTIONS AND ANTIMICROBIAL AGENTS  
Although a declining infectious disease mortality rate has been marked in most of the 
20th century [1], the WHO recently warned that infectious diseases are spreading 
more rapidly than ever before [2]. The spread of infectious diseases around the world 
is accelerating due to many dynamic factors including population growth, the 
increasing international travel, under-resourced health care systems, intensive 
farming practices and degradation of the environment, while therapy is hampered due 
to microbial resistance to drugs. The development of effective novel antimicrobial 
drugs is emphasized as one of the new therapeutic and preventive strategies.  
A. Fungal infections  
The incidence of fungal infections has increased significantly in the past two decades 
and it is expected to continue to increase in the foreseeable future [3-5]. The increase 
of fungal infections is mainly due to the expanding population of immuno-suppressed 
and non-immuno-compromised critically ill patients [6]. Nosocomial fungal infections 
are becoming more common and are a significant cause of morbidity and mortality. 
Candida is one of the predominant pathogens in fungal infections.  
Candida 
Candida is ubiquitous yeast commonly found on the mucus membranes of 
mammals. Candida is a part of the normal oral flora in about 30% - 50% of the human 
population. Candida isolates can become pathogenic under specific conditions and 
produce opportunistic infections in the oral cavity of individuals, especially in people 
with immuno-deficiencies [7-9]. It has been demonstrated that HIV-positive patients 
carry more and a greater variety of yeasts, predominantly C. albicans (70%), than 
HIV-negative subjects [10]. The reported prevalence of oral candidiasis in African 
HIV-infected subjects varies up to the highest by 94% [9]. Candida species are now 
also recognized as major opportunistic pathogens of nosocomial infections. In recent 
years, there has been a marked increase in the incidence of treatment failures in 
candidiasis patients receiving long-term antifungal therapy. Serious problems have 
occurred, including the acquisition of drug resistance and increasing prevalence of 
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resistant Candida species. These effects were clearly observed in HIV-infected 
patients with oropharyngeal candida infections [11]. Recent epidemiological studies 
have shown a trend toward increasing numbers of infections and a shift toward 
infections caused by non-albicans Candida species [12]. The pathogenic Candida in 
probable descending order of virulence for humans are: C. albicans, C. tropicalis, C. 
glabrata, C. krusei, C. parapsilosis, C. guilliermondii and C. lusitaniae [13].  
Cryptococcus neoformans 
Cryptococcus neoformans is a soil fungus and a facultative intracellular pathogen 
capable of replication inside macrophages that causes life-threatening meningitis in 
immuno-compromised patients. With the advent of the AIDS pandemic, cryptococcal 
meningitis has emerged as a leading cause of infectious morbidity and mortality and a 
frequently life-threatening opportunistic mycosis among patients with AIDS [14]. 
Although the number of cryptococcal meningitis incidence among patients with AIDS 
has decreased in the past few years as a consequence of the introduction of highly 
active anti-retroviral therapy (HAART), they are still a major cause of morbidity and 
mortality in this patient group. The treatment of this disease remains difficult due to the 
high risk of recurrence, adverse effects and resistance to therapy [15]. A recent report 
from India showed that the prevalence of cryptococcal meningitis in the total HIV 
reactive cohort was 2.1% with a mortality rate of 25.6% [16]. The incidence of 
cryptococcosis in bronchopneumonia, lobar pneumonia, and meningoencephalitis 
varies from 15.7% in Thailand to 0.2% in Bahrain and Tunis [8].  
B. Conventional antifungal agents 
Four classes of conventional antifungal drugs currently available for clinical use are: 1) 
the polyenes, including amphotericin-B and nystatin, which inhibit the fungal 
membrane by impairing the function of ergosterol, 2) the azoles, including fluconazole, 
ketoconazole, itraconazole, imidazole, miconazole, voriconazole, posaconazole and 
the experimental agents ravuconazole, which inhibit the sterol synthesis and impair 
the fungal cell membrane integrity, 3) flucytosine (5-FC), the nucleoside analog which 
interferes with DNA and RNA synthesis and 4) the echinocandins, including 
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caspofungin, micafungin and anidulafungin, which increase the permeability by 
inhibiting the glucan synthesis [17-19]. 
C. Limitation of the antifungal agents 
Drugs currently used to combat fungal infections can be either toxic to or cause 
adverse interactions with host cells. Amphotericin B exacerbates the toxicity by 
induced renal insufficiency [20]. Antifungal azoles may cause adverse effects such as 
gastrointestinal, hepatic and endocrinological disorders [21]. Caspofungin, 
posaconazole and voriconazole are newer antifungal agents with potent activity 
against a number of fungal infections including those that are resistant to fluconazole 
with higher MICs [22]. However, reported serious adverse effects of posaconazole 
and voriconazole limit their clinical use for patients with high risk of renal or hepatic 
malfunction [23, 24].  
Moreover, the problem is intensified by the emergence of fungal pathogens 
resistant to available antifungals. The fungal population size and frequency of drug 
exposure are important factors that increase fungal resistance. A large population size 
will increase the frequency of encounters between yeasts and antifungal agents [11]. 
Due to a higher fungal population in the mouths of HIV-infected patients than in blood, 
as well as long periods of treatment with fungistatic agents, the probability of 
emerging resistance in oropharyngeal candidiasis [25, 26] is greater than that in 
candidemia [4].  
Some isolates of C. albicans and certain Candida spp show low amphotericin B 
susceptibility [27]. Resistance to azoles is emerging in Candida species [28] and in C. 
neoformans. The emergence of fluconazole resistance in C. albicans isolates in 
oropharyngeal candidiasis associated with HIV was striking before the era of HAART 
for HIV infection [11]. C. krusei and C. glabrata are intrinsically resistant to fluconazole 
[29]. 
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D. Bacterial infection  
Bacterial infectious diseases were the major cause of death as recently as the 1940s. 
After the introduction of antimicrobial drugs, the prevalence of infectious diseases has 
gradually declined worldwide. In the U.S., antibiotics were the most frequently 
prescribed class of therapeutic drugs in 1981 [30]. The six most commonly prescribed 
antibiotics were: erythromycin, amoxicillin, penicillin, tetracycline, ampicillin and 
sulfamethoxazole. However, these drugs have common side effects such as an upset 
stomach, diarrhea and vaginal yeast infections. Some side effects are more severe 
and may disrupt the function of the kidneys, liver, bone marrow and other organs. 
Antibiotics can also cause mild allergic reactions such as an itchy rash or slight 
wheezing and in some cases severe allergic reactions (anaphylaxis) that can be 
life-threatening and usually include swelling of the throat, inability to breathe and low 
blood pressure [31].  
Antimicrobial agents, including chlorhexidine, delmopinol hyrochloide and 
triclosan, are used to control dental plaque for the prevention of dental caries and 
periodontal diseases. Amoxicillin and metronidazole are sometimes applied for the 
treatment of periodontitis. Although these agents exhibit a broad spectrum of 
antimicrobial activity in vitro, the in vivo efficacy of some agents is not consistently 
proven. Moreover, the side-effects of these antimicrobial agents limit their therapeutic 
uses. Amongst the antimicrobials, chlorhexidine is regarded as the gold standard for 
plaque control [32, 33]. However, its clinical application is limited because of its side 
effects, such as a bitter taste, stains on teeth, hypersensitivity and generalized allergic 
reactions.  
The evolution of new pathogens, the increasing number of 
immunocompromised patients and the development of multi-drug-resistant bacteria 
have created an urgent need for new therapeutic interventions [34]. There has been 
an almost complete lack of new drugs that kill bacteria by a novel mechanism of 
action [35]. The need for the development of new antifungal agents is even greater. In 
contrast to the hundreds of antibiotics for treatment of bacterial infections, only a 
handful of antifungals are available. Some of these have a limited spectrum of activity 
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and are not rapidly fungicidal and some are toxic to mammalian cells. The occurrence 
of fungal infection has escalated significantly and is expected to continue to increase 
for the foreseeable future. There is therefore an urgent need to develop new classes 
of antibiotics. Antimicrobial peptides represent one promising class for novel drug 
development.  
II. ANTIMICROBIAL PEPTIDES  
Antimicrobial peptides (AMPs) are an abundant and diverse group of molecules 
produced by many tissues and cell types in a variety of invertebrate, plant and animal 
species [36]. As evolutionary components of the innate immune system, AMPs defend 
the host against invading bacteria, viruses and fungi through membrane or metabolic 
disruption. AMPs have a potential for the treatment of antibiotic-resistant microbial 
infections. To date, around 900 different natural antimicrobial peptides have been 
identified or predicted from nucleic acid sequences and most of them are cationic 
antimicrobial peptides (CAMPs). A small fraction of these are studied in detail. 
A. Molecular structural features, diversity and selectivity of CAMPs  
Cationic antimicrobial peptides (CAMPs) are gene-encoded and synthesized as 
precursors which are subsequently processed by specific proteases into active form 
either before or after secretion. In addition to being gene-encoded, CAMPs have other 
common features such as small size (1-5 kDa, 10-50 amino acids), they have 
hydrophilic and hydrophobic domains and cationic amino acids with an overall positive 
charge (generally +2 to +9). These features permit the peptide to fold into an 
amphipathic structure in non-polar solvent, often upon contact with membranes, so 
that they form separate patches rich in positively charged and hydrophobic amino 
acids. Natural CAMPs are composed of L-amino acids and are sensitive to proteases. 
Synthetic peptides with D-amino acids substituting L-amino acids are resistant to 
proteolysis while retaining full antimicrobial activity. More diversity is created by 
synthetic processing. 
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CAMPs have two unique characteristics in mammals: 1) they function as 
antimicrobial peptides or nature’s antibiotics, which quickly identify and eradicate 
foreign pathogens and 2) they act as host-defense peptides or innate immune 
modulators, which modulate the immune response through a variety of mechanisms 
[37]. Having evolved to act against distinct microbial targets in different physiological 
contexts, CAMPs show a remarkable degree of variability in both amino acid 
sequence and structure [38], but similarity is also often found within defined 
host-defense peptides from closely related species. CAMPs fall into four broad 
structural groups [39-41]: 1) ȕ-sheet peptides stabilized by two to four disulfide bridges, 
for example, human Į- and ȕ-defensins, containing three S-S bridges, fungal plectasin 
or porcine protegrins, containing two S-S bridges, 2) Į-helical peptides, examples 
include amphibian buforin, insect and porcine cecropins, insect melitin, frog magainins 
and human cathelicidin LL-37, 3) extended structures rich in glycine, proline, 
tryptophan, arginine and/or histidine, examples include human histatins, bovine 
indolicidin and porcine cathelicidins and proline-rich peptides produced by all classes 
of animals, and 4) loop peptides with one disulfide bridge, examples are bovine 
bacternecin, bovine and human lactoferrin. 
The selectivity of CAMPs between microbial and host cells is important and 
relates to differences between the external membranes of prokaryotic and eukaryotic 
cells. Because of the high selectivity for nonmammalian membranes, some CAMPs 
display high activity against a variety of bacteria but exhibit no toxicity to mammalian 
erythrocytes [42]. 
B. Mechanism of CAMPs action 
Action steps 
Antimicrobial peptide-mediated cell killing includes several specific steps: 
attraction, attachment, peptide insertion and membrane passage.  
1) Attraction: The cationic and amphipathic nature of CAMPs is associated with 
their activity. The overall positive charge ensures accumulation of CAMPs at 
polyanionic microbial cell surfaces that contain acidic polymers, such as 
General introduction and aim of the study  
 20 
lipopolysaccharide and teichoic acids in Gram-negative and Gram-positive bacteria. 
The CAMPs transit the bacterial outer membrane via self-promoted uptake [43]. 
2) Attachment: The peptides contact the anionic surface of the cytoplasmic 
membrane and insert into the membrane. They initially straddle the interface of the 
hydrophilic head groups and the fatty acyl chains of membrane phospholipids.  
3) Peptide insertion and membrane passage: After insertion into the 
cytoplasmic membrane, the physical integrity of the bilayer is disrupted via membrane 
thinning, transient poration and/or disruption of the barrier function or the peptide 
passes the membrane and act on internal targets [41]. 
In fact, microbe inactivation by CAMPs is complex, involving multiple and 
complementary modes of action. Although CAMPs display broad-spectrum activity, 
some preferentially kill Gram-positive or Gram-negative bacteria and some are 
effective against fungi [40]. In addition, a given CAMP may inhibit a pathogen by 
different mechanisms depending on factors such as growth phase, tissue localization, 
the presence or absence of other immune mechanisms or synergistic antimicrobial 
agents. Therefore, distinct peptides function optimally (e.g., with the greatest 
antimicrobial activity and least host cytotoxicity) in specific physiologic contexts. 
Transmembrane pore-forming mechanism 
Several modes of pore-forming action have been discussed in recent reviews 
[44-46], including 1) the reorientation of peptide molecules perpendicular to the 
membrane to form either barrel-stave or toroidal channels, 2) the breakdown of 
membrane integrity through swamping of the membrane charge with a 'carpet' of 
peptides at the interface, 3) the detergent-like dissolution of patches of the membrane 
and 4) the formation of peptide-lipid aggregates within the bilayer [45]. Each of these 
mechanisms explain the ability of CAMPs to break down the cytoplasmic membrane, 
but only the toroidal channel and aggregate models explain the action of certain 
peptides on cytoplasmic targets. Therefore, disruption of membrane permeability 
barriers is not the only mechanism of action. 
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Non-membrane targets 
There is increasing amount of evidence that CAMPs have activities targeted on 
intracellular components. The intracellular modes of killing include: alteration of the 
cytoplasmic membrane by inhibition of septum formation (PR39,PR-26, indolicidin, 
microcin 25), inhibition of cell-wall synthesis (mersacidin), binding to DNA (buforin II, 
tachyplesin), inhibition of nucleic acids and protein synthesis (pleurocidin, 
dermaseptin, PR39, HN-1,HNP-2, indolicidin) and inhibition of enzymatic activity 
(histatins, pyrrhocoricin, drosocin and apidaecin).  
CAMPs act as natural effectors for secondary host defense mechanisms [47]. 
CAMPs activate non-membrane external targets such as autolysins and 
phospholipases that lyse bacteria [44]. The high affinity of CAMPs for LPS of 
Gram-negative bacteria detoxifies their endotoxic activity. In addition, CAMPs can act 
in synergy with other cationic peptides of the host and also with conventional 
antibiotics. 
C. Human saliva and the host innate defense system 
Saliva is essential for the maintenance of oral health and the protection of our teeth 
[48]. These functions of saliva include: 1) continuous protection of the oral tissue 
surface by a film of salivary mucins and proline-rich glycoprotein, 2) enhancement of 
mineralization, 3) retardation of demineralization, 4) prevention of the adherence of 
microorganisms to the enamel pellicle and inhibition of their growth and 5) buffering of 
acids by the salivary bicarbonate/carbonate buffer system. Saliva contains 
antimicrobial components such as lactoferrin, lysozyme and peroxidase [49], as well 
as peptides such as cathelicidin LL-37, Į and ȕ-defensins, histatins and the histidine 
rich cationic peptides [50]. Salivary mucins together with other groups of salivary 
proteins (proline-rich proteins, cystatins, statherins and amylase) protect the oral 
cavity from microbial infections through more general protective mechanisms rather 
than the direct killing of microorganisms. However, peptides derived from the 
N-terminus of the low-molecular-weight salivary mucin, MUC7, also have a 
broad-spectrum in vitro fungicidal and bactericidal activity. 
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Histatins 
Human histatins are a family of low molecular weight, neutral to very basic, 
cationic, histidine-rich polypeptides. They are produced in human parotid and 
submandibular/sublingual glands. Their structures and functions have been well 
characterized during the last twenty years. The predominant peptides of the histatins 
family are the histatin 1, 3 and 5 consisting of 38, 32 and 24 residues, respectively [50] 
(Table 1). Each of these three histatins contributes approximately 20-30% to the total 
concentration of the histatin pool [51]. Their total concentration range is 30-150 µg/ml 
in pure parotid and submandibular/sublingual secretions, but is reduced to 2-4 µg/ml in 
whole saliva [52]. Histatin 1 and histatin 3 are encoded by the HIS1 and HIS2 genes, 
respectively [53], while histatin 5 is a posttranslational proteolytic product of histatin 3 
[54]. Histatins display a significant in vitro antimicrobial activity, especially against 
fungi such as Candida spp [50, 55]. Because histatins are relatively non-toxic and 
active against azole-resistant fungal species, the design of histatin-like peptides with 
enhanced activity and stability receive much attention [56]. Histatin 5 has the most 
potent anticandidal activity [57], being able to kill Candida species resistant to 
commonly used antimycotics, as well as C. neoformans and A. fumigatus [57-59].  
Table 1. Amino acid sequences of histatin peptides 
Histatin peptide Amino acid sequence Net + charge
 1           10            20           30         38  
Histatin 1 DSHERRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN 1 
Histatin 3 DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN 5 
Histatin 5 DSHAKRHHGYKRKFHEKHHSHRGY 5 
Histatin 5 12-mer 
(P-113) 
AKRHHGYKRKFH 5 
Net + charge: the difference of total positive charges (carried by amino acids marked in red) minus total negative 
charges (carried by amino acids marked in blue) of each peptide. 
Reference [50] [86]  
 
Histatins also exhibit antibacterial activity. It was first demonstrated that histatins 
exhibit bactericidal activity against mutans streptococci [60, 61]. In subsequent studies, 
histatin was also found to inhibit 1) hemagglutination of P. gingivalis [62], 2) 
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coaggregation between P. gingivalis and S. mitis [62], 3) proteases from P. gingivalis 
and the host matrix metalloproteinases [63, 64] and 4) leukotoxic activity of A. 
actinomycetemcomitans [65]. Moreover, a study also showed that the antibacterial 
effects of histidine-rich peptides including histatin 5 can be potentiated by zinc [66]. 
Smaller fragments of histatins also show antimicrobial activity. It was reported that 
a histatin 5-derived peptide named histatins 5 12-mer (Table 1) have retained in vitro 
antimicrobial activity comparable to that of the parent compound [67-69]. However, 
this peptide was not active in the presence of purulent sputum from CF patients. This 
may have resulted from the fact that histatin 5 is susceptible to proteolysis. 
Interestingly, when substituted with the amino acid residues in D-configuration, its 
mirror-image peptide, histatins 5 12-mer D (P-113D) was observed to retain significant 
activity [69]. This suggests that the peptide containing D-amino acid residues is 
resistant to proteolysis in sputum. 
Although the antifungal activity of histatins is well documented, the mechanism by 
which they kill or inhibit fungal growth is still not clear. Unlike other CAMPs, histatins 
adopt a random coil conformation in aqueous solvents and form Į-helices in 
non-aqueous solvents. In contrast to other CAMPs, the secondary structure and 
amphipathicity of histatins are not related to their killing activity [70, 71]. Veerman et al. 
(2007) reported that the physical state of the membrane is important for the antifungal 
activity of histatin 5. The susceptibility of C. albicans to histatin 5 decreased when 
fluidity of the membrane was diminished [72]. Histatins carry their antifungal action 
through a multi-step mechanism of binding, translocation and toxicity. It was also 
found that the killing pathway of C. albicans activated by histatin 5 shares many 
similar features with the cytotoxic action by human neutrophil defensin 1 [73]. Histatin 
5 first binds to the cell wall of C. albicans, possibly through histatin-binding proteins 
[74, 75]. The binding proteins facilitate transport to intracellular targets that are later 
destroyed. One of the possible targets for histatins are mitochondria and its cytotoxic 
activity depends on the metabolic activity of C. albicans [76] Other studies 
demonstrate that histatin 5 causes disordered volume regulation and cell cycle arrest 
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in C. albicans [77]. This phenomenon is closely coupled with the histatins-induced 
loss of intracellular ATP [78-80].  
Although many in vitro studies have reported on the efficacy of histatins, very few 
of them have mentioned its potential antimicrobial activity. Paquette et al. (1997) 
reported that histatin derivatives possess some efficacy against experimental 
gingivitis in beagle dogs [81]. Recently, Welling et al. (2007) demonstrated that 
histatin-derived monomeric and dimeric synthetic peptides exhibited a strong 
bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo [82]. 
Some efficacy of histatins has been reported in animal model vulvovaginal candidiasis 
[83] and in the treatment of experimental gingivitis in humans [84, 85]. To date, 
however, no therapeutic efficacy of histatins has been found.  
Mucins 
Mucins are generally high-molecular-weight proteins that are synthesized and 
secreted in many organs, such as gastrointestinal, respiratory reproductive tracts, oral 
cavity and salivary glands. Mucins form a mucous layer which acts as a viscous 
barrier to exert lubrication and protection of ducts and lumen epithelium from 
desiccation, mechanical injury, and microbial attack within the human body. On the 
other hand, they are also involved in pathological processes [87]. Mucins contain a 
high percentage of serine, threonine, proline, alanine and glycine residues and are 
heavily glycosylated (O-linked) [88, 89]. Mucins from different organ sites generally 
have similar but non-identical amino acid compositions. They usually have distinct 
physical and biochemical properties, including various oligosaccharide structure, 
sulfation, molecular weight, and viscoelastic properties [90]. The common structural 
feature among all mucins is the presence of tandem-repeat amino acid regions rich in 
serine and threonine. In general, the O-glycosylated tandem-repeat regions are not 
conserved between species in terms of either size or amino acid sequence; however, 
flanking amino-terminal and carboxyl-terminal regions typically show some similarity, 
presumably reflecting functional relatedness. Currently, fifteen genes encoding the 
backbone of mucin core protein have been identified in humans and designated 
MUC1-4, MUC5AC, MUC5B, MUC6-8, MUC11-13 and MUC15-17 [87]. Based on 
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their structural and functional characters, mucins are classified into two main 
categories: secreted gel-forming and non-gel-forming (MUC2, MUC5AC, MUC5B and 
MUC6) and membrane-bound (MUC1, MUC3, MUC4, MUC12 and MUC17). The 
products of some other MUC genes do not fit well into either class (MUC7, MUC8, 
MUC9, MUC13, MUC15 and MUC16) [91]. Each MUC mucin shows a characteristic 
distribution in different organs and cell types.  
Salivary mucins 
Human salivary glands secrete two types of mucins: oligomeric mucin (MG1) with 
a high molecular weight above 1000 kDa and monomeric mucin (MG2) with a low 
molecular weight of 200-250 kDa [92]. Salivary mucins have a dualistic character 
(either harmful or protective) [93]. Similar to secreted gel-forming mucins, MG1 not 
only coat mucosal and enamel surface, but also protect the mucosal surface from 
infection and physical trauma. It is likely that this heavy molecule can form aggregates 
around foreign bodies or selectively bind to microbial cells to eliminate them from the 
soft or hard tissue surface. On the other hand, when bound to tooth surface, they form 
an acquired enamel pellicle which may enhance formation of dental plaque by 
promoting attachment of microorganisms [94]. 
MUC7 
Following MUC1-MUC6, the MUC7 gene was the seventh mucin gene that has 
been cloned by Bobek’s group [95]. The low molecular weight salivary mucin MG2 
core is encoded by MUC7 gene and thus MG2 was renamed to MUC7 [95]. The 
MUC7 gene that was mapped to chromosome 4q13-q21 spans approximately 10.0 kb 
and comprises of three exons and two introns. The entire region encoding the 
secreted peptide is located on exon 3, spanning approximately 2.2 kb [96]. MUC7 
cDNA encodes a protein of only 377 amino acid residues with no sequence homology 
with other mucins. MG2 mRNA is about 2.5 kilobases long and its expression is 
species-, tissue-, and cell-specific [95]. Mucin gene is expressed specifically in the 
human submandibular gland and trachea [97] or in the submandibular-sublingual 
gland complex of mice [98]. MUC7 transcripts are localized only in mucous acinar 
cells [99]. MUC7 mucin expression can be induced or stimulated by cytokines and 
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bacterial lipopolysaccharide (LPS) in the normal human tracheobronchial epithelial 
cells at the air-liquid interface and in the airway tissues of MUC7-gene-transgenic 
mice [100]. Amongst all the factors that influence MUC7 gene expression, TNF-alpha 
is an important cytokine that stimulate MUC7 transcription via NF-kappa B signaling 
pathway [101].  
MUC7 is a secreted, soluble, low-molecular-weight mucin. This monomeric 
molecule lacks the ability to oligomerize [95, 96] as they do not form linear multimers 
but polymerize to form a wheel-like structure [102]. MUC7 has a low-specificity but is 
a favorable bacteria binder and thus exhibits an anti-bacterial role in modulation of the 
microbial flora [93, 103, 104]. Salivary mucins have been found to interact with 
mutans streptococci, P. gingivalis, C. albicans and even with HSV-1 and HIV-1 
viruses [94]. 
MUC7 peptides 
MUC7 is a single polypeptide chain composed of 357 amino acid residues, 
divided into five distinct domains: (1) an N-terminal basic, histatin-like domain which 
has a leucine-zipper segment, (2) a moderately glycosylated domain, (3) six heavily 
glycosylated tandem repeats each consisting of 23 amino acids residues, (4) another 
heavily glycosylated MUC1- and MUC2-like domain and (5) a C-terminal 
leucine-zipper segment [105]. 
The peptides derived from the N-terminal region (domain 1) of MUC7 can kill 
fungi and bacteria in vitro, making MUC7 a multifaceted, critical component of the oral 
defense mechanism [106, 107]. Since this region is free of glycosylation and is 
therefore susceptible to proteolysis, there is a possibility that these peptides can be 
generated by the action of proteolytic enzymes in the oral cavity and can thus exert 
antimicriobial function in vivo. 
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Figure1. Schematic diagram of the structural features of MUC7 and derivation of MUC7 peptides. MUC7 is a 
single polypeptide chain composed of 5 domains (from D-1 to D-5) with 357 amino-acid residues. Domain 1 (D-1) 
is truncated from the N-terminal region of MUC7 giving MUC7 51-mer (span1-51), a MUC7 peptide containing 51 
amino acid residues. MUC7 51-mer is further truncated from its C-terminal at number 31 amino acid (L), giving a 
peptide comprised of 20 amino acid residues (span 31-51), named MUC7 20-mer, and at number 39 amino acid 
(K), giving a peptide comprised of 12 amino acid residues (span 39-51), named MUC7 12-mer. This figure is 
modified based on Dr. Libuse Bobek’s presentation slides [108]. 
 
It was found that MUC7 N-terminal region (domain 1) consists of 51 amino acid 
residues and contains a histatin-like sequence. As shown in figure 1(in brown), the 
sequence near the N terminus spans 15 amino acid residues (R3 to Q17) and 
exhibits 53% sequence similarity with histatin 5 [105]. It has been demonstrated that 
intact MUC7 did not show any candidacidal activity. However, chemically synthesized 
15-aa histatin-like domain showed candidacidal activity but less than natural histatin 
5 [109]. Further study showed that the entirely synthesized 51-aa MUC7 D1, which 
includes the 15-aa histatin-like domain, was found to be as potent as histatin 5 in 
candidacidal activity [106]. Moreover, MUC7 D1 showed broad spectrum antifungal 
activities against clinically important fungal strains including C. albicans, C. glabrata 
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and their azole-resistant counterparts, as well as Cryptococcus neoformans and its 
amphotericin B-resistant counterpart. In addition, MUC7 D1 showed greater stability 
than histatin 5 in whole human saliva and human serum. Compared to amphotericin 
B, both MUC7 D1 and histatin 5 showed much lower cytotoxicity [110]. These 
findings suggested that MUC7 D1 could also act as an antimicrobial agent in the oral 
cavity and could be used as an antifungal therapeutic agent.  
Since the molecule is large in size and therefore not economical for synthesis 
and application in vivo, MUC7 51-mer was truncated into a 20-amino acid sequence 
with 7 positive charges at the C-terminal region. The peptide, named MUC7 20-mer 
had potent fungicidal and bactericidal activity [107]. In order to define the minimal 
length that retains antimicrobial activity, the peptide was further truncated and tested. 
MUC7 12-mer, spanning 12 amino acid residues with 6 positive charges at C terminal 
region of MUC7 20-mer (Figure 1), was found to be the minimal segment with 
antifungal activity comparable to MUC7 20-mer. The detailed results can be found in 
Chapter 2 of this thesis. 
The antifungal mechanism of MUC7 peptides is not clear. A study showed that 
the action mode of MUC7 peptide is different from that of histatin 5 [107]. MUC7 
20-mer was found to have the ability to bind to fungal cell membrane proteins in a 
non-specific manner, to move across the fungal cell membrane and to accumulate 
inside the cells. Mitochondria are not the targets of MUC7 20-mer for either C. 
albicans or C. neoformans. The fungicidal activity of MUC7 20-mer against C. 
albicans is independent of fungal cellular metabolic activity.  
In vivo studies on the antifungal activity of MUC7 peptides were performed on 
a murine model of vulvovaginal candidiasis [83] and oral candidiasis [111]. MUC7 
peptide was found to be ineffective to reduce the fungal burden of vulvovaginal 
candidiasis and its effect on oral candidiasis was not conclusive.  
D. Potential and limitations of CAMPs as therapeutic agents 
As discussed above, the unique features of CAMPs allow them to become attractive 
candidates that could potentially be developed into effective and safe therapeutic 
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agents. However, it should be noted that they also have some limitations [40], listed as 
follows: 
Sensitivity of many peptides to high ionic strength 
When being assayed in normal buffer or dilution media, CAMPs exhibited 
substantial antimicrobial activity. However, in the presence of divalent cations like 
Mg2+ and Ca2+ (at physiological concentrations of 1 – 2 mM) and monovalent cations 
such as Na+ and K+ (100 mM), the antimicrobial activity of CAMPs is reduced. It is 
important to be aware that the reaction mechanism in vivo as compared to in vitro is 
more complicated due to the presence of various in vivo factors, which may exert 
synergistic as well as antagonistic action. It is therefore important to study CAMPs 
under physiological conditions and with modifying factors to investigate their 
antimicrobial efficacy. 
Susceptibility to proteolysis 
Many microbes produce proteases that degrade foreign peptides as a part of their 
natural defense mechanism. The presence of these proteases can severely reduce 
the effectiveness of CAMPs. A possible solution to this problem is to use synthetic 
derivatives of the native peptide, where some of its natural L-amino acids are 
substituted with their D-configuration stereoisomers. Theoretically, such modification 
could confer protease resistance to the entire peptide molecule.  
Safety, toxicity and immunogenicity 
Most CAMPs have been considered safe as they normally have no or low toxicity 
to host cells. Although it has been suggested that CAMPs may potentially be toxic to 
their hosts when used systematically, as inferred from the moderate haemolytic effect 
that they exerted in vitro [112], they are still generally believed to be quite safe for 
topical or oral use. Also due to the weak mucosal antibody response to short peptides, 
these peptides are not likely to pose immunological problems. 
Cost 
Synthetic antimicrobial products usually have much greater manufacturing costs 
than those of conventional antibiotics. Although various efforts have been made to 
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produce such desired products utilizing recombinant DNA methods, their production 
remains to be a costly process. 
E. New strategies for antibiotic peptides 
Although the above mentioned limitations exist, effective therapeutic antimicrobial 
peptides can still be developed within certain boundaries. Currently, the application of 
developed antimicrobial peptides is limited to topical use and only in situations where 
no other alternatives are permissible. Examples of such situations include resistance 
to conventional antimicrobials demonstrated by the microorganism(s), as well as 
severe and harmful side effects of conventional drug treatments. Also the developed 
antimicrobial peptides can be applied in combination with conventional antimicrobial 
agents where prominent antimicrobial synergism has been observed [113-115]. 
Several new strategies for the development of peptide-based antibiotics can be 
further proposed. First, protease resistant peptides can be synthesized by 
incorporating amino acid analogs. Also, molecular template-based synthetic 
strategies can be further explored for more cost effective productions of antimicrobial 
peptides with novel features. 
III. HYPOTHESIS 
MUC7 peptides are attractive novel candidates for development into antimicrobial 
therapeutic agents. Particularly MUC7 12-mer peptide is a potential candidate for 
clinical development, since it shows little or no toxicity toward mammalian cells and as 
many other antimicrobial peptides, has a low tendency to elicit resistance. 
IV. AIM OF THE STUDY 
The development of effective antimicrobial agents from human salivary antimicrobial 
peptides is the ultimate goal of this thesis. It is expected that the new antimicrobial 
products can be used in vivo as compounds of artificial saliva, mouth rinse or other 
oral health products for therapeutic purposes. As a first step to meet this goal, more 
research is needed to obtain fundamental information on the potential of MUC7 
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peptide as a therapeutic agent. This thesis is focused on the in vitro antimicrobial 
activity of salivary mucins MUC7 derived peptides and deals with question such as: a) 
what are the effects of molecular and host physiological factors on the antimicrobial 
activity of MUC7 peptides? b) how to make MUC7 peptides work efficiently under 
physiological conditions? c) can the MUC7 peptides be used in the control of dental 
biofilm? d) what is the toxicity of the MUC7 peptides to the hosts?  
 More precisely, the specific objectives of this study are to determine: 
1. the minimum peptide chain length and its location within the MUC7 20-mer 
region that retains antifungal activity and to examine the effect of cysteine residues on 
the fungicidal activity of MUC7 derived peptides (Chapter 2); 
2. the antifungal activity of MUC7 peptides under physiological like conditions 
(Chapter 3); 
3. the microbial source of proteases that are released into saliva (Chapter 4); 
4. the effects of saliva on the stability of MUC7 peptides and to test the 
enhancement of antifungal activity of MUC7 peptides through protease inhibitors 
(Chapter 5); 
5. the synergic antifungal effect of MUC7 peptides in combination with other 
antifungal agents (Chapter 6); 
6. the inhibiting effect of MUC7 peptides on the growth of oral bacteria and on 
mutans streptococci biofilms (Chapter 7); 
7. the cytotoxicity of MUC7 peptides to normal human erythrocytes and oral 
keratinocytes (Chapter 5 and 6). 
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ABSTRACT 
We have previously shown that MUC7 (human salivary low-molecular-mass mucin) 
20-mer: LAHQKPFIRKSYKCLHKRCR (residues 32–51 of the parent MUC7, with a 
net positive charge of 7) possesses a broad-spectrum antimicrobial activity. [Bobek 
and Situ (2003) Antimicrob. Agents Chemother. 47, 645–652].  The aims of the 
present study were to determine the minimum peptide chain length and its location 
within the 20-mer region that retains potent antifungal activity against Candida 
albicans and Cryptococcus neoformans and to examine the effect of net charge of the 
peptide as well as the role of cysteine residues on the fungicidal activity. First, several 
C-terminal truncated MUC7 20-mer fragments (16-mer, 12-mer, 11-mer, 10-mer and 
8-mer) and one N-terminal fragment (8-mer-N) were synthesized and tested. The 
results showed that MUC7 12-mer, located at the C-terminal region of MUC7 20-mer, 
having a net charge of +6 and exhibiting an amphipathic helical conformation, not only 
retained but exceeded the antifungal activity of that of 20-mer. Secondly, several 
variants of the 12-mer peptide containing a lower or no net positive charge, or no 
cysteine residues were synthesized and tested. A clear correlation between the net 
positive charge of the 12-mer, its potency and initial interaction of peptide with fungal 
cells was found by killing assays, fluorescence microscopy and fungal cell-membrane 
potential measurements. Furthermore, cysteine residues, which play a critical role in 
bacterial binding, were found to be not important for the fungicidal activity of these 
peptides. These results identified MUC7 12-mer as a potential candidate for 
development into a novel antifungal therapeutic agent. 
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INTRODUCTION 
The occurrence of fungal infections has increased significantly in the past decade and 
is expected to continue to increase in the foreseeable future. Hosts for which there is 
evidence of increased risk of fungal infections are the classic immunocompromised 
patients (including HIV/AIDS patients, oncology patients with neutropenia, bone 
marrow and organ-transplant recipients) and non-immunocompromised critically ill 
patients[1]. The toxicity of some of the presently available antifungal agents and the 
emergence of drug-resistant fungal strains are the major disadvantages of the current 
antifungal therapies. Thus development of new antimicrobial agents with different 
mechanisms of action, low toxicity and low tendency to elicit resistance is urgently 
needed. 
In the past few years, CAMPs (cationic antimicrobial peptides) have received 
increasing attention as a promising source of novel antimicrobial compounds [2-5]. 
This is because unlike many currently used antimicrobials, CAMPs show little or no 
toxicity towards mammalian cells and low tendency to elicit resistance [6, 7]. Several 
hundred different natural (gene-encoded) CAMPs have been identified. They are 
produced by living organisms of all types, including humans and plants. They are 
mobilized shortly after infection as part of the innate immunity and act rapidly to 
neutralize a broad range of microbes, including Gram-negative and Gram-positive 
bacteria, antibiotic-resistant bacteria, fungi, viruses and parasites [8, 9]. In addition, 
thousands of synthetic CAMP variants have been synthesized [10]. The functional 
and structural properties and therapeutic potential of antimicrobial peptides have been 
recently reviewed [5, 11-15]. A low mass (molecular mass between 1 and 5 kDa), 
amphipathic structure (separate hydrophobic and hydrophilic domains) in non-polar 
solvent and net positive charge are the common features of most naturally occurring 
antimicrobial peptides. Most of these peptides exhibit a random structure in water and 
a well-defined structure (Į-helical, ȕ-sheet, extended structures and loops) in a 
simulated membrane-like environment [6, 14, 16]. Based on their secondary 
structures, antimicrobial peptides are commonly classified into four groups. Group I 
comprises linear peptides with Į-helical structure (examples include amphibian 
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buforin, insect and pig cecropins, frog magainins and human cathelidicin LL-37). 
Group II comprises linear peptides with an extended structure (examples include 
bovine and pig cathelicidins, proline-rich peptides produced by all classes of animals 
and human histatins). Group III comprises peptides containing loop structure and one 
disulphide (S–S) bond (examples are bovine bactenecin, bovine and human 
lactoferricin). Group IV consists of ȕ-strand peptides connected by intramolecular S–S 
bridges (examples are pig protegrins, human Į-defensins, human and other 
mammals' ȕ-defensins). With respect to structure and function, magainins, 
dermaseptins, cecropins, mammalian defensins, lactoferricin and histatins have been 
best characterized [14]. 
We have been encouraged and motivated to pursue further the antimicrobial 
activity of one such peptide based on our previous findings. We have shown 
previously that MUC7 (human salivary low-molecular-mass mucin) 20-mer (residues 
32–51 of the parent MUC7, with a net positive charge of 7) possesses a 
broad-spectrum antimicrobial activity in vitro [17]. It is effective against a variety of 
fungi (including Candida albicans and Cryptococcus neoformans), Gram-positive 
bacteria (including the cariogenic Streptococcus mutans) and Gram-negative bacteria 
(including the periodontopathic Porphyromonas gingivalis). The antifungal activity was 
inhibited by bivalent cations, but not inhibited by a low temperature. 
Secondary-structure prediction showed that MUC7 20-mer adopts an amphiphilic 
helical conformation with distinguished hydrophilic and hydrophobic faces; it thus falls 
into group I of antimicrobial peptides (described above). Fluorescence microscopy 
showed the ability of MUC7 20-mer to cross the fungal cell membrane and to 
accumulate inside the cells where it acts, quite probably, on a specific part of the 
subcellular machinery. The internalization of MUC7 20-mer was inhibited by bivalent 
cations [17]. Thus we hypothesized that amphipathicity and high net positive charge 
of MUC7 20-mer are the characteristics associated with its antifungal potency. 
Furthermore, the mechanism of antifungal action of a 20-mer involves initial 
electrostatic interactions between the positively charged residues of the peptide and 
the negatively charged lipid head groups of the fungal cell membrane (consisting of 
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phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and ergosterol). 
The bivalent cations would diminish the electronegative potential of the membrane, 
thus reducing and/or eliminating the cytotoxicity of the peptide. 
The present study was undertaken to: (1) determine the minimum peptide chain 
length and its location within the MUC7 20-mer region that retains antifungal activity 
comparable with that of 20-mer; (2) examine the effect of peptide charge on the 
fungicidal activity of MUC7-derived peptides; (3) examine the initial interaction of the 
peptides with fungal cells by fluorescent microscopy and transmembrane potential 
measurements; and (4) examine the effect of cysteine residues on the fungicidal 
activity of MUC7-derived peptides. The preliminary results on the antifungal activity of 
MUC7 20-mer truncated peptides were published in an abstract form [18]. 
EXPERIMENTAL 
Materials 
SAB (Sabouraud dextrose agar) was from Difco Laboratories (Detroit, MI, U.S.A.). 
Insulin chain A (21 amino acid residue peptide) and Magainin II (23 amino acid 
residue peptide) were purchased from Sigma (St. Louis, MO, U.S.A.). MUC7 20-mer 
(amino acid residues 32–51 of the parent MUC7) and its truncated and altered 
peptides (Tables 1 and 2), Hsn5 12-mer (amino acid residues 4–15 of a peptide 
derived from histatin 5 parent molecule; see Table 2) and FITC-labelled MUC7 20-mer 
and FITC-labelled MUC7 12-mer-3 (variants of MUC7 12-mer) peptides were all 
custom-synthesized by Bio-Synthesis (Lewisville, TX, U.S.A.). HPLC and MS assays 
were performed by the company to analyse the purity of the peptides. In general, the 
purity of the peptides was between 80 and 99%. The purity was taken into 
consideration in the preparation of the stock solution of each peptide for antifungal 
assays. DiSC3(5) (3,3´-dipropyl-2,2´-thiadicarbocyanine iodide) was purchased from 
Molecular Probes (Eugene, OR, U.S.A.). 
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Table 1. Amino acid sequences and ED50 of unaltered MUC7 20-mer and 
truncated peptides 
 
ED50 at 95% confidence limit (µM)Peptide Amino acid sequence* 
Net 
charge† C. albicans C. neoformans 
        +   ++   +    + +  +    
MUC7 20-mer L32AHQKPFIRKSYKCLHKRCR51 7+ 5.8 (4.2–8.7) 6.7 (6.1–7.4)‡ 
   16-mer KPFIRKSYKCLHKRCR 7+ 6.9 (4.8–9.5) 5.3 (4.1–6.7) 
   12-mer RKSYKCLHKRCR 6+ 2.1 (1.3–3.2) 2.1 (1.8–2.5) 
   11-mer KSYKCLHKRCR 5+ 3.3 (1.9–5.6) 4.5 (2.6–14.2) 
   10-mer SYKCLHKRCR 4+ 20.7 (17.7–24.6) 5.6 (2.3–19.4) 
   8-mer KCLHKRCR 4+ 23.2 (13.4–58.6) 5.8 (2.7–15.8) 
   8-mer-N LAHQKPFI 1+ No activity No activity 
     +       ++   +      -    
Magainin II G1IGKFLHSAKKFGKAFVGEIMNS23 3+ 5.7 (4.0–8.4) 4.4 (3.5–5.6) 
     -                 -    
Insulin chain A G1IVEQCCASVCSLYQLENYCN21 2- No activity No activity 
 
*Numbers in MUC7 20-mer sequence indicate residue numbers of the native MUC7. 
†Net charge of peptides at pH 7.0. 
‡Data on MUC7 20-mer are from our previously published study [17]. 
 
Strains and culture conditions 
A clinical isolate of C. albicans was a gift from Dr Theodore C. White (University of 
Washington and Seattle Biomedical Research Institute, Seattle, WA, U.S.A.). C. 
neoformans (CN2) strain was obtained from an AIDS patient with cryptococcal 
meningitis and was generously provided by Dr John H. Rex (University of Texas 
Medical School, Houston, TX, U.S.A.). Fungi were streaked and grown on SAB plates 
at 37 °C until large colonies were formed. One colony was then picked and 
resuspended in 10 mM sodium phosphate buffer (pH 7.4) and the concentration was 
adjusted to 1×105 cells/ml for the antifungal assay described below. 
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Table 2. Amino acid sequences and ED50 of MUC7 12-mer and its variants 
ED50 at 95% confidence limit (µM) Peptide Amino acid sequence* Net charge†
C. albicans C. neoformans 
 +  +  +    ++  +    
MUC7 12-mer R40KSYKCLHKRCR51 6+ 2.1 (1.3–3.2) 2.1 (1.8–2.5) 
   12-mer-2 AASYKCLHKRCR 4+ 4.9 (4.0–5.9) 4.5 (3.1–6.2) 
   12-mer-3 AASYACLHAACA 0 No activity No activity 
   12-mer-4 RKSYKALHKRAR 6+ 2.0 (0.8–3.7) 2.5 (1.6–3.9) 
   12-mer-5 RKSYKCLHKACA 4+ 5.1 (4.4–5.9) 4.9 (4.3–5.5) 
   ++      +++    
Hsn5 12-mer A4KRHHGYKRKFH15 5+ 3.7 (2.4–5.0) 2.6 (0.5–4.9) 
 
*Underlined residues indicate substitutions in the sequence. Numbers in the MUC7 12-mer and Hsn5 
12-mer sequences indicate residue numbers of the native MUC7 and Hsn 5 respectively. 
†Net charge of peptides at pH 7.0. 
 
Antifungal activity assays 
Two-fold serial dilutions of each peptide (ranging from 1.56 to 50 mM for C. albicans 
and 1.56 to 25 mM for C. neoformans) in 20 ml of 10 mM sodium phosphate buffer 
(pH 7.4) were incubated with an equal volume of C. albicans or C. neoformans (105 
cells/ml, also in 10 mM sodium phosphate buffer, pH 7.4) for 1.5 h at 37 °C. At the end 
of the incubation, the samples were diluted 20-fold with the same buffer and 50 ml of 
aliquots (approx. 150 cells) of each sample were plated on SAB plates. Plates were 
incubated for 1 or 2 days for C. albicans and C. neoformans respectively. Colonies 
were then counted and the loss of cell viability was plotted as a function of protein 
concentration. 
Statistical analysis 
ED50 values (molar concentrations of peptides required to kill half of the maximal 
number of cells) and 95% confidence limits of ED50 values were determined by the 
procedure PROBIT (SPSS software package 6.1.2 for Macintosh). 
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Secondary-structure prediction and CD spectral analysis 
For secondary-structure prediction, we utilized the PSI Pred graphical viewer by 
Brunel Bioinformatics Group of Brunel University (Uxbridge, Middx., U.K.). The helical 
wheel projections of the predicted helical region of each peptide were made using 
GCG Sequence Analysis software. 
CD spectra were acquired on a JASCO J715 spectropolarimeter, calibrated with 
d10 camphor sulphonic acid. Samples (15 mg/ml) were dissolved in 10 mM sodium 
phosphate buffer (pH 7.4) or 100% TFE (trifluoroethanol) and spectra were scanned 
in the range of 260–190 nm at 20 °C using a cell of 1.0 cm path length. All CD spectra 
are expressed in ellipticity in millidegrees. 
Fluorescence light microscopy 
The internalization of MUC7 20-mer and 12-mer-3 into fungi was visualized using 
FITC-labelled peptides. Cells (107) were treated with 50 mM FITC–MUC7 20-mer or 
12-mer-3 for 45 min in 100 ml of sodium phosphate buffer (10 mM, pH 7.4) at 37 °C. 
The cells were then extensively washed with the same phosphate buffer, 
concentrated by centrifugation and resuspended in the same buffer. The cell 
suspension was then quickly mounted on slides with sealed coverslips. Fluorescence 
light micrographs were obtained using a Nikon Optiphot microscope, with a 
fluorescent light source. 
Analysis of changes in fungal transmembrane potential 
Peptide-induced permeabilization of C. albicans and C. neoformans cell membranes 
was monitored by measuring changes in transmembrane potential. Measurements 
were taken using the transmembrane potential-sensitive fluorescent dye DiSC3(5). 
Experiments were performed using a PerkinElmer LS 50 B spectrofluorimeter kindly 
provided by Dr John M. Canty (School of Medicine, University at Buffalo, NY, U.S.A.) 
in a 700 ml fluorescence cuvette connected to a 37 °C water bath. Fungi were grown 
overnight on SAB plates and resuspended in 10 mM sodium phosphate buffer (pH 7.4) 
at a concentration of 1×105 cells/ml (same conditions as for fungicidal assays) and 
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placed into a cuvette. Dye (diluted in ethanol) was then added to the cells to achieve a 
final concentration of 714 nM. Ethanol in such a low dilution does not have any 
significant effect on the killing of the cells. Samples were monitored at excitation and 
emission wavelengths of 633 and 666 nm respectively. After internalization of the dye 
into cells (at approx. 10 min; shown by the lowest point in the fluorescence), the 
peptides were added at concentrations of 18 mM. Changes in fluorescence density 
were monitored further up to 1500 s (25 min). Results were graphically displayed as a 
function of fluorescence intensity in arbitrary units against time. 
RESULTS 
Effect of peptide size on fungicidal activity 
To determine the minimum peptide chain length and its location within the MUC7 
20-mer required for antifungal activity comparable with that of 20-mer, we first tested a 
series of truncated peptides. We decided to make the truncation at the N-terminus of 
the 20-mer (with the net positive charge of 7) since the N-terminus lacks positively 
charged residues. We began the analysis with five N-truncated peptides (see Table 1): 
16-mer, 12-mer, 11-mer, 10-mer and 8-mer, with net positive charges of 7, 6, 5, 4 and 
4 respectively. The fungicidal activities of these peptides (dose–response curves) 
against C. albicans and C. neoformans are shown in Figure 1. Since these peptides 
are more effective against C. neoformans than C. albicans, the peptide concentration 
axes for C. neoformans is scaled only up to 25 mM (rather than 50 mM) to see better 
the dose–response differences at lower peptide concentrations. The ED50 values for 
the MUC7 peptides in comparison with a well-characterized CAMP Magainin II (23 
amino acid residues) [19] and a negative control peptide insulin chain A (21 amino 
acid residues) are shown in Table 1. 
Our results indicate that 16-mer (with the net positive charge of 7, same as the 
20-mer) has an activity comparable with that of 20-mer against both the C. albicans 
(ED50 of 6.9 mM for 16-mer versus 5.8 mM for 20-mer) and C. neoformans (ED50 of 
5.3 mM for 16-mer versus 6.7 mM for 20-mer). The activities of both MUC7 20-mer 
and 16-mer are also comparable with that of Magainin II (95% confidence limits of all 
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ED50 values overlap). On the other hand, insulin chain A showed no activity. 
Interestingly, compared with 20-mer and 16-mer, 12-mer (with the net positive charge 
of 6) possesses increased activity against both fungi (showing ED50 of 2.1 mM for 
both). The activity of 11-mer (with the net positive charge of 5) slightly decreased 
compared with that of 12-mer. The activities of 10-mer and 8-mer (net positive charge 
of 4 for both) against C. albicans markedly decreased (ED50 of 20.7 and 23.2 mM 
respectively). On the other hand, the activity of 10-mer and 8-mer against C. 
neoformans remained comparable with that of 11-mer (95% confidence limit of the 
ED50 values for all three peptides overlap). This may be because the cell surface of C. 
neoformans is highly negatively charged (more so compared with C. albicans) owing 
to its polysaccharide capsule and melanin [20], which may favour an association with 
the MUC7 cationic peptides. Because even the 8-mer possessed considerable activity 
against both fungi, but in particular against C. neoformans, we wondered if a peptide 
of the same length from the N-terminus of 20-mer would also show antifungal activity. 
Thus the N-terminal 8-mer (with a net positive charge of 1) was custom-synthesized 
and tested. As shown in Figure 1 and Table 1, this 8-mer-N showed no antifungal 
activity. From the above experiments we concluded that the 12-mer, the C-terminal 
fragment of the 20-mer, which not only retained but also exceeded the antifungal 
activity of the 20-mer, is the optimal peptide fragment that possesses the strongest 
antifungal activity. 
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Figure 1. Fungicidal activity of MUC7 16-mer and other truncated peptides. Fungal cells (2×103 in 20 ml of 
10 mM sodium phosphate buffer) were incubated with 20 ml of peptide [concentrations ranging from 1.56 to 
25 mM (or 50 mM) in 10 mM sodium phosphate buffer] for 1.5 h at 37 °C. Cell viability was determined by 
plating on SAB plates. Results represent the mean for duplicate or triplicate experiments. 
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Figure 2. Fungicidal activity of unaltered MUC7 12-mer peptide and its variants. Details are the same as in the 
legend to Figure 1. 
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Effect of charge on MUC7 12-mer fungicidal activity 
Several modified peptides of the 12-mer were synthesized and tested to determine 
the importance of its structural features, in particular the net charge. The fungicidal 
activities (dose–response curves) of several MUC7 12-mer variants in comparison 
with the unaltered MUC7 12-mer are shown in Figure 2. The ED50 values of these 
peptides in comparison with the Hsn5 12-mer are shown in Table 2. Hsn5 12-mer 
(P113) is a 12 amino acid-residue fragment of Hsn5 (residues 4–15) that was 
previously shown to be the smallest fragment retaining the anticandidal activity 
comparable with that of full-length Hsn5 [21]. MUC7 12-mer has a net positive charge 
of 6 (versus 7 in the 20-mer). Its ED50 values against both fungi are 2.1 mM. In 
comparison with MUC7 12-mer, Hsn5 12-mer (net positive charge of 5) showed 
slightly lower activity against C. albicans but a comparable activity against C. 
neoformans (Table 2). 
In the first variant 12-mer-2, two positively charged amino acid residues (arginine 
and lysine) at the N-terminus were substituted with alanine, decreasing the net 
positive charge of the peptide from 6 to 4. In comparison with the unaltered 12-mer, 
the ED50 values of this variant against both C. albicans and C. neoformans 
approximately doubled (Table 2) and the values are comparable with that of 20-mer 
(the ED50 values overlap). To determine if the position of the positive charges in the 
peptide play a role in its activity, a peptide with an equivalent deletion of two positive 
charges at the C-terminus (12-mer-5) was synthesized and tested. This variant 
showed an activity comparable with the one at the N-terminus (12-mer-2; 95% 
confidence limit values of the two peptides overlap), indicating that the position of the 
positive charges does not play a role in the activity. Activities of both these variants 
against C. albicans are higher than that of 8-mer, which has the same net positive 
charge (+4), indicating that both the charge and size are important for the optimal 
activity. Replacement of all six positively charged amino acid residues of MUC7 
12-mer with alanine (12-mer-3), resulted in zero net charge and in a complete loss of 
antifungal activity (Table 2).  
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CD spectroscopy and secondary-structure predictions of MUC7 peptides 
The CD spectra of several MUC7 12-mer peptides obtained in TFE (a membrane 
mimetic environment), in comparison with those of MUC7 20-mer and Hsn5 12-mer 
are shown in Figure 3(A). Similar approaches (CD spectroscopy and helical wheel 
projection) have been used in related studies using Hsn5 peptide fragments [21, 22]. 
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Figure 3. CD spectra and helical wheel projections of MUC7 12-mer peptides.CD spectra (A) were obtained in 
100% TFE as described in the Experimental section. Helical wheel projections (B) were made using GCG 
Sequence Analysis software. They were based on the 20-mer (LAHQKPFIRKSYKCLHKRCR) Į-helical prediction, 
where 12 amino acid residues (FIRKSYKCLHKR) were predicted to be Į-helical [17]. The 12-mer (RKSYKCLHKR 
CR), depicted on the left side, is the C-terminal region of the 20-mer, where 10 amino acid residues are in Į-helical 
conformation. In the 12-mer-2, depicted on the right side, the first two amino acid residues, RK, were substituted 
with AA (indicated by arrows). Basic amino acid residues are displayed in black letters in open circles. 
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We have determined previously [17] and confirmed in the present study that 
MUC7 20-mer adopts an Į-helical conformation in TFE. Similarly, all MUC7 12-mer 
peptides show a tendency to adopt the helical conformation. This is exhibited by a CD 
spectrum with a positive band below 200 nm and negative bands at 206–208 nm and 
approx. 220 nm (on the other hand, in aqueous buffer, MUC7 20-mer and 12-mer 
exhibited spectra characteristic of polypeptide random coils; results not shown). To 
compare the tendency of MUC7 20-mer and of the other peptides investigated in the 
present study to adopt helical structures, we used R values (R=qn-p*/qp-p*), the ratio 
of the two negative bands (220/206–208). This is because using absolute ellipticity 
values to estimate the helical content of peptides of low molecular mass has been 
reported to underestimate the helical content [23, 24]. An R value of approx. 1.00 has 
been assigned to Į-helical peptides. The R value for MUC7 20-mer is 0.86, indicating 
a strong tendency to adopt Į-helical conformation; R values for MUC7 12-mer and 
Hsn5 12-mer are 0.56 and 0.55 respectively, also indicating populations of Į-helical 
conformation in each of these peptides. 
Previously, we also showed by a secondary-structure prediction and helical wheel 
projection that MUC7 20-mer adopts an amphiphilic helical conformation with 
distinguished hydrophobic and hydrophilic faces, thought to be important for 
antimicrobial activity [17]. A secondary-structure prediction (based on the 20-mer) 
indicated that the ten N-terminal residues of the 12-mer are in a helical conformation. 
A helical wheel projection of MUC7 12-mer depicted in Figure 3(B) (left side) shows 
that this peptide, similar to MUC7 20-mer [17], also adopts an amphiphilic helical 
conformation with a distinguished hydrophobic and a hydrophilic face. This prediction 
was confirmed by CD spectroscopy in TFE, as shown in Figure 3(A). 
MUC7 12-mer-2 has a similar tendency to adopt Į-helical conformation to that of 
unaltered 12-mer with an R value of 0.6. However, this substitution adds more 
hydrophobic residues and somewhat disrupts the hydrophilic phase of the helix 
(Figure 3B, right side). The CD spectrum of 12-mer-3 (all positively charged residues 
substituted by alanine) indicated that this peptide exhibits even stronger tendency to 
adopt Į-helical conformation than the unaltered 12-mer (R value of 0.79). Even 
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though these amino acid substitutions completely disrupted the amphipathicity, they 
increased the hydrophobicity and thus the tendency to adopt an helical structure. 
These results indicate that the amphipathic nature of the peptide and higher net 
positive charge are important for the antifungal activity. 
Effect of cysteine residues on fungicidal activity of MUC 12-mer 
It was previously reported that rNMUC7 (recombinant protein consisting of the 
N-terminal 144 residues of MUC7) bound to S. mutans [25]. Reductive methylation 
(RM) of rNMUC7 (lysine residues were converted into mono- or dimethyl lysine, as 
confirmed by the amino acid analysis) had little or no effect on S. mutans binding. 
When RM sample was reduced further and alkylated (RM/RA; alkylation performed by 
iodoacetic acid; cysteine residues were quantitatively converted into carboxymethyl 
cysteine residues, as confirmed by amino acid analysis), no binding was detected. 
When the rNMUC7 was just reduced and alkylated (RA), again, no binding was 
detected. The authors concluded that alkylation of the two cysteine residues (Cys45 
and Cys50) resulted in the complete loss of bacterial binding [25]. To examine if the 
two cysteine residues play a role in the fungicidal activity of MUC7 12-mer, 12-mer-4 
with the two cysteine residues substituted with alanine was designed and 
custom-synthesized. Interestingly, this substitution did not alter the 12-mer antifungal 
activity (Figure 2 and Table 2), indicating that the cysteine residues are not important 
for fungicidal activity against both C. albicans and C. neoformans. By CD 
spectroscopy, this peptide shows a tendency to adopt an Į-helical structure similar to 
that of unaltered peptide, with the R value of 0.55. 
Visualization of binding of MUC7 peptides and internalization 
We hypothesized that the initial mechanism of antifungal action of the MUC7 20-mer 
involves initial electrostatic interactions between the positively charged residues of the 
peptide and the negatively charged head groups of the fungal cell membrane. 
Therefore with no positively charged residues, the interaction of 12-mer-3 with fungal 
cells would be completely abolished. Our fluorescence light microscopy study 
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confirmed our hypothesis (Figure 4). After incubating the fungal cells (C. albicans and 
C. neoformans) with FITC–12-mer-3, this peptide was not visible either on the cell 
membrane or inside of both the Candida (Figure 4B) and Cryptococcus cells (Figure 
4E), whereas the FITC–20-mer was visible (Figures 4A and 4D). These results 
showed that MUC7 12-mer-3, with zero net positive charge, is not able to interact with 
the fungal cell membrane and subsequently be taken up by the cells. The 
transmission microscopy (bright field) of cells treated with FITC–12-mer-3 assured the 
presence of fungal cells (Figures 4C and 4F). 
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Figure 4. Fluorescence light microscopy of internalization of MUC7 peptides by C. albicans and C. neoformans. 
Cells (107) were treated with 50 mM of FITC–MUC7 20-mer (A, D) or 50 mM of FITC–MUC7 12-mer-3 (B, C, E, F) 
for 45–90 min in 100 ml of sodium phosphate buffer (10 mM, pH 7.4) at 37 °C. After extensive washing, cells were 
examined by light microscopy using a Nikon Optiphot microscope, with a fluorescent light source. Cells treated 
with FITC–12-mer-3 were also examined by transmission microscopy (C, F, bright field). 
Effects of MUC7 peptides on fungal cell-membrane depolarization 
Relative changes in transmembrane potentials of C. albicans and C. neoformans 
were monitored as MUC7 peptides, Hsn5-12-mer and insulin chain A were added to 
the cells preloaded with a membrane potential-sensitive fluorescent dye, DiSC3(5), as 
described in the Experimental section. Similar approach was used by other 
investigators using Hsn5 and Hsn5 variants [22] [26]. This dye distributes between 
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cells and suspension medium depending on the membrane potential gradient. It is 
fluorescent in solution but when taken up by the cells, it aggregates and 
self-quenches [27]. On permeabilization of the membrane by peptides, the 
transmembrane potential changes due to the flux of ions, triggering release of 
DiSC3(5) dye from the cells into the medium. The released dye regains its fluorescent 
properties outside the cells and is detected by an increase in fluorescence reading 
monitored by spectrofluorimeter. 
280
160
200
80
40
0
240
120
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (A
U
)
MUC7 20-mer
Hsn5 12-mer
Insulin
MUC7 12-mer
Time (seconds x 100 )
MUC7 12-mer-3
2 4 60 8 1210 14 15
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (A
U
)
 
Figure 5. Effects of MUC7 peptides on transmembrane potential of C. albicans. Alterations in transmembrane 
potential were measured by release of DiSC3(5) dye from fungal cells on the addition of peptides to a final 
concentration of 18 mM. Traces were recorded by an LS 50 B PerkinElmer spectrofluorimeter at 37 °C. To a 
suspension of cells (690 ml of 105 cells/ml in 10 mM sodium phosphate buffer, pH 7.4) in a 700 ml cuvette, 10 ml of 
dye was added to final concentration of 714 nM (shown by an initial peak of fluorescence). Internalization of the 
dye by the cells is shown by a decrease in fluorescence. When a constant fluorescence was achieved (at approx. 
600 s, shown by the lowest fluorescence), peptides were added. Release of the dye, shown by an increase in 
fluorescence, was monitored up to 1500 s. Relative fluorescence intensity is depicted in arbitrary units. 
To observe the dissipation of membrane potential immediately after the addition 
of peptides, relatively high doses of peptides (18 mM or 3–8-fold of their ED50 values) 
were used for this experiment. The results, depicted in Figure 5, showed that MUC7 
20-mer and 12-mer possess membrane-perturbation activity. This is evidenced by the 
release of DiSC3(5) probe on addition of these peptides to the cells, measured by an 
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increase in the fluorescence signal (only the results obtained with C. albicans are 
shown; however, similar patterns were observed with C. neoformans). Experiments 
involving Hsn5-12-mer peptide also showed a notable increase in the fluorescence 
signal, indicating release of the dye into the medium. On the other hand, MUC7 
12-mer-3 (with zero net positive charge), which has no antifungal activity, showed little 
or no release to DiSC3(5) dye (indicated by a solid line in Figure 5) and thus had no 
effect on the cell-membrane potential. This result correlates well with the result 
obtained for the FITC-labelled MUC7 12-mer-3, showing no internalization of this 
peptide in the fungal cells (Figure 4). The control peptide, insulin chain A, which had 
no antifungal activity, also showed no effect on the fungal cell-membrane potential 
(Figure 5). 
DISCUSSION 
Salivary mucins are important components of the non-immune innate host–defence 
system. They contribute to the formation of a protective film on both soft and hard 
tissues of the oral cavity and play a role in the modulation of microbial flora [28-30]. 
They do not directly kill micro-organisms, but have been found to interact with 
respiratory (e.g. P. aeruginosa), cariogenic (e.g. S. mutans) and periodontal 
pathogens (e.g. P. gingivalis), the opportunistic yeast C. albicans and even with 
HSV-1 and HIV-1 viruses [31]. Recombinant full-length MUC7 apo-protein (357 amino 
acid residues) did not show any appreciable candidacidal activity (ED50 of 280 mM; 
see [32]). However, the peptides derived from its N-terminal region have a significant 
and a broad-spectrum fungicidal and bactericidal activity in vitro [17, 18, 25, 32, 33]. 
There is also a possibility that MUC7 peptides from the N-terminal end can be 
generated in vivo by degradation of the parent MUC7 molecule by proteolytic 
enzymes present in human saliva, since the N-terminal region is free of glycosylation, 
and thus susceptible to proteolysis. Free in saliva, these peptides could serve as a 
part of the innate defence system against pathogens. In fact, a recent study [34] 
revealed a 20 kDa MUC7 fragment present in total saliva that contained a portion of 
an N-terminal region of MUC7, suggesting that cleavage of MUC7 in vivo might yield 
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fragments with microbicidal properties. A previous study [32] had analysed whether 
whole saliva or C. albicans cells are capable of degrading the MUC7 parent molecule 
to smaller fragments. A radiolabelled MUC7 was used and its degradation was 
monitored by SDS/PAGE. The exposure of MUC7 to saliva resulted in its considerable 
degradation (after 12 h, almost a complete loss of the intact MUC7 band was 
observed); a lower rate of degradation of MUC7 was noted in the presence of C. 
albicans, indicating that saliva contains a higher level of proteolytic enzymes than C. 
albicans, and hence is also capable of degrading MUC7. At present in our laboratory, 
we are actively pursuing the identification of the generated fragments. In the present 
study, however, we stress the point of considering the MUC7 peptides as candidates 
for development into novel antimicrobial agents to be used for therapeutic purposes in 
vivo, including their use as salivary substitutes. In that regard, MUC7 12-mer is an 
optimal candidate. 
For a better definition of the factors affecting the specific antifungal activity of 
MUC7 peptides, in the present study, we investigated the relationship between factors, 
such as peptide chain length, net positive charge, amphipathicity and its fungi-killing 
ability. We first determined the minimum peptide chain length and its location within 
the MUC7 20-mer required to retain the antifungal activity comparable with that of the 
20-mer. A series of truncated peptides derived from 20-mer were designed and 
prepared. The antifungal activity of MUC7 20-mer appears to be in the C-terminal half, 
and in fact, discarding the N-terminal region increased the activity. Since the 8-mer-N 
contains a net positive charge of +1, whereas the 8-mer from the C-terminus contains 
+4 this indicates that the ratio of basic residues to total residues is also important and 
a high ratio is favourable. Also, because the anticandidal activity of 8-mer, compared 
with 20-mer and 12-mer, was reduced, larger peptide(s) are required for considerable 
antifungal activity, and the 12-mer appears to be of the optimal length. 
It is interesting to correlate and contrast our study with similar studies performed 
with bovine lactoferricin-derived and Hsn5-derived peptides. The study on the bovine 
lactoferricin B, a 25 amino acid residue peptide (FKCRRWQWRMKKLGAPSITCVRR 
AF) [35] showed that peptide 2, a 10 amino acid residue peptide from the N-terminus 
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of lactoferricin B (FKCRRWQWRM), where four of the 10 residues are positively 
charged, possesses the strongest anticandidal activity. In fact, discarding the 
C-terminal region (15 amino acid residues, where four of the 15 residues are 
positively charged) increased the activity. The superior activity of peptide 2 thus 
appeared to be (at least in part) due to the high ratio of basic residues. In addition, this 
peptide up-regulated the polymorphonuclear function in cells and showed additive 
activity with other antifungal drugs (amphotericin B and miconazole). 
Analysis of peptide fragments of Hsn-5 identified a 12 amino acid fragment of 
Hsn5 (amino acids 4–15 with net positive charge of 5), designated as P-113, as the 
smallest fragment that retained (but did not increase) anticandidal activity comparable 
with that of the parent compound [21]. P-113, designated here as Hsn5 12-mer, was 
selected to be used as a control peptide in the present study because of the same 
length as the MUC7 12-mer and containing a similar net positive charge (5 versus 6 
respectively). Hsn5 12-mer (P-113) was shown in the original study [21] (and 
confirmed here) to retain the ability to form Į-helical conformation in TFE solution, and 
by the helical wheel projection to form an amphipathic a helix. Additional study with 
the P-113-modifed peptides indicated that the replacement of two or more of the basic 
residues of P-113 to uncharged residues resulted in a substantial loss of anticandidal 
activity. These results correlate well with our results obtained with the MUC7 12-mer 
variants. 
Many structural parameters such as appropriate chain length, amino acid 
composition, peptide secondary structure, net positive charge and amphiphilicity were 
reported to have an influence on the activity and selectivity of antimicrobial peptides 
[13, 36-39]. However, net positive charge and amphiphilicity were reported to be the 
most important factors governing the activity [13, 37, 40, 41]. As pointed out 
previously [42], the positive charge of a peptide is consistent with its affinity for 
microbial membranes bearing negative charge, and amphipathy of a peptide is 
consistent with its capacity to intercalate into a membrane. MUC7 12-mer has a net 
positive charge of 6. Moreover, the helical-wheel projection of this peptide showed a 
good amphiphilic nature with well-defined and separate polar and hydrophobic faces. 
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Decrease of the net positive charge by 2 lowered the cidal activity of the 12-mer. 
However, replacement of all six positively charged residues of the MUC7 12-mer 
(12-mer-3) resulted in a complete loss of activity against both fungi. Further 
experiments with the 12-mer-3 using fluorescence microscopy and membrane 
potential measurements indicated that the lack of activity is due to the loss of initial 
interaction of the peptide with the cell membrane and its subsequent uptake by the 
cells. Cysteine residues were all dispensable for the activity of the MUC7 12-mer. 
Although they seemed to be important for binding of MUC7 peptide to bacteria [25], 
their substitution by alanine did not affect the fungicidal activity of MUC7 12-mer. 
Overall, the antifungal assays, fluorescent studies and membrane potential 
measurements suggest that both amphiphilic nature and high net positive charge of 
the MUC7 peptides are important determinants for the fungicidal activity, more 
specifically, for the initial interaction of the peptide with the fungal cells. 
In summary, the results of the present study suggest that MUC7 12-mer peptide, a 
fragment of a naturally occurring human salivary mucin glycoprotein MUC7, may be 
an excellent candidate for development into a novel antifungal therapeutic agent. To 
lower the cost of antimicrobial peptides, it is of significance to minimize fragment 
length to the length that preserves or even exceeds the antimicrobial activity of the 
parent molecule. In that regard, the cost of chemical synthesis of the 12-mer peptide 
would be much reduced compared with that of MUC7 20-mer. 
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ABSTRACT 
Background: MUC7 12-mer (RKSYKCLHKRCR), a cationic antimicrobial peptide 
derived from the human salivary mucin MUC7, possesses potent antimicrobial activity 
in vitro. In order to evaluate the potential therapeutic application of the MUC7 12-mer, 
we examined the effects of mono- and divalent cations, EDTA, pH, and temperature 
on its antimicrobial activity.  
Methods: Minimal inhibitory concentrations (MICs) were determined by using 
microdilution Method. To examine the effect of salts or EDTA, a checkerboard 
microdilution technique was used. Fractional inhibitory concentration index (FICi) was 
calculated. The viability of microbial cells treated with MUC7 12-mer in the presence 
of Na+ or K+ was also determined by killing assay or flow cytometry.  
Results: The MICs of MUC7 12-mer against organisms tested ranged from 6.25-50 
µM. For C. albicans, antagonism (FICi 4.5) was observed for the combination of 
MUC7 12-mer and Ca2+; however, there was synergism (FICi 0.22) between MUC7 
12-mer and EDTA, and the synergism was retained in the presence of Ca2+ at its 
physiological concentration (1-2 mM). No antagonism but additivity or indifference 
(FICi 0.55-2.5) was observed for the combination of MUC7 12-mer and each K+, Na+, 
Mg2+, or Zn2+. MUC7 12-mer peptide (at 25 µM) also exerted killing activity in the 
presence of NaCl, (up to 25 mM for C. albicans and up to 150 mM for E. coli, a 
physiological concentration of sodium in the oral cavity and serum, respectively) and 
retained candidacidal activity in the presence of K+ (up to 40 mM). The peptide 
exhibited higher inhibitory activity against C. albicans at pH 7, 8, and 9 than at pH 5 
and 6, and temperature up to 60ºC did not affect the activity. 
Conlusions: MUC7 12-mer peptide is effective anticandidal agent at physiological 
concentrations of variety of ions in the oral cavity. These results suggest that, 
especially in combination with EDTA, it could potentially be applied as an alternative 
therapeutic agent for the treatment of human oral candidiasis. 
INTRODUCTION 
Cationic antimicrobial peptides (CAMPs) are one of the body's host defenses against 
invading microorganisms. These peptides have broad-spectrum antimicrobial activity, 
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including antibacterial, antiviral, and antifungal activity. They have a rapid onset of 
killing, cidal activity, and concomitant broad anti-inflammatory activities [1]. CAMPs 
show little or no toxicity towards mammalian cells, and have a low tendency to elicit 
resistance, and have thus become a promising novel group of antibiotics [2]. 
MUC7 peptides are the CAMPs derived from the human low molecular weight 
salivary mucin MUC7, a component of innate immunity (the first-line of the host 
defense system against pathogens). MUC7, the low molecular weight human salivary 
mucin glycoprotein (357 aa residues), protects the oral cavity from microbial infections 
through more general protective mechanisms rather than the direct killing of 
microorganisms. The peptides derived from the N-terminal region of MUC7 have a 
significant fungicidal activity in vitro [3] [4] [5] [6]. The representative MUC7 peptide, 
MUC7 12-mer (RKSYKCLHKRCR), a cationic peptide spanning residues 40-51 of the 
MUC7, possesses potent antimicrobial activity in low-ionic-strength buffers and in low 
salt RPMI 1640 medium. This peptide exhibits synergistic antifungal effects with 
histatin 5 12-mer (Hsn5 12-mer) and with miconazole [7]. 
In effort to establish a transition from in vitro activity of MUC7 12-mer into clinical 
efficacy, it is necessary to investigate the factors affecting antimicrobial activity of 
MUC7 peptides. Our previous study showed that the peptides face the challenge of 
the degradation by proteases in saliva. We have demonstrated that antifungal activity 
of MUC7 12-mer-L in human whole saliva was enhanced in the presence of protease 
inhibitors and EDTA, and MUC7 12-mer-D isomer exerted higher antifungal activity 
compared to MUC7 12-mer-L in human whole saliva [8]. Beside proteases, salt 
sensitivity of antimicrobial peptides poses a major obstacle in their development as 
novel antibiotics. In addition, other factors such as pH value and temperature may 
also affect the antimicrobial activity of the peptides.  
In this study we examined the effects of monovalent (Na+ and K+) and divalent 
(Ca2+, Mg2+, and Zn2+) cations, EDTA (a chelator of divalent cations), pH, and 
temperature on the antimicrobial activity of the MUC7-12-mer, with a special 
emphasis on the activity against C. albicans. 
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MATERIALS AND METHODS 
Peptides and chemicals 
MUC7 12-mer (RKSYKCLHKRCR, amino acids 40-51 of the parent human salivary 
mucin, MUC7) and Hsn5 12-mer (AKRHHGYKRKFH, amino acids 4-15 of the parent 
human salivary histatin 5) were custom-synthesized by Bio-Synthesis (Lewisville, 
Texas). The company analyzed the prepared peptide by high-performance liquid 
chromatography and mass spectrometry. The purity (>70%) was taken into 
consideration in preparing the stock solution of each peptide for antifungal assays. 
The peptide was dissolved in sterile de-mineralized water at 10 mg/mL; aliquots were 
freeze-dried and stored at -20°C. For each experiment, the freeze-dried peptides were 
re-dissolved at 1 mg/mL in sterile dd-water. The stock solutions of 1 M each EDTA, 
NaCl, KCl, CaCl2, MgCl2, and Zn2 SO4 were prepared in de-mineralized water. The 
working solutions were obtained by diluting the stock and filter-sterilization.  
Microbial strains and growth media 
C. albicans DIS (clinical isolate from denture induced stomatitis), Escherichia coli 
HB101 and Streptococcus mutans UA159 were stock strains from our lab.  The 
strains were stored at -80°C in glycerol.  For each experiment, C. albicans cells were 
cultured freshly from frozen stock on Sabouraud dextrose agar (SDA, Difco) for 24 
hours at 37°C. To prepare fungal cell suspension for antifungal activity assays, 
colonies were picked from the plate and resuspended in 10 mM sodium phosphate 
buffer (pH 7.4) for killing assay, and in 12.5 % Sabouraud dextrose broth (SDB) for 
MIC assay. A 25 % Brain Heart Infusion (BHI) was used for bacterial susceptibility test 
(MIC test). To prepare E. coli cell suspension for killing assays, the overnight culture 
was harvested by centrifugation (3783 x g, 10 min), washed once with 10 mM sodium 
phosphate-buffered saline (PBS, pH 7.2) and resuspended in PBS. The 
concentrations of the microbial cells were adjusted to 1 x 105 cells/mL.  
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MIC susceptibility tests  
The effect of salt concentration on the antimicrobial activity of the peptides was tested 
by determining the MICs of the peptides at various cation concentrations. MICs of 
MUC7 12-mer were determined by the microdilution method as described previously 
with some modifications [7]. Briefly, two-fold serial dilutions of test agents were 
prepared, with 12.5% SDB at a volume of 200 µl per well, in 96-well flat-bottom 
microtiter plates (Costar, Cambridge, MA). The final concentration of the antifungal 
agents ranged from 3.13 to 50 µM for MUC7 12-mer, and 2.5 to 160 µM for cations or 
EDTA. The microtiter plate was inoculated with cell suspension (final concentration 
1x104 cells per mL) and incubated at 37°C for 48 h. Afterwards, the absorbance was 
measured at 595 nm by using a microplate reader (Model AD 340, Beckman Coulter) 
to assess the cell growth. Minimal inhibitory concentrations (MIC) were determined at 
three endpoints: MIC-0, MIC-1 and MIC-2, indicating the lowest agent concentration 
showing no more than 10%, 25% and 50% growth respectively, in comparison to that 
of the agent-free control. For each set of conditions, the MIC tests were carried out 
independently two or three times, using duplicate samples each time. The MICs were 
reported as the geometric means and the 95% confidence intervals for the means. 
The effect of pH on the antimicrobial activity of MUC7 12-mer was tested by 
determining the MIC of the peptide at a variety of pH values. This was achieved by 
altering the pH of the media with 5 M HCl or NaOH. The peptide was tested in pH 
conditions from pH 5 to 9. 
The effect of temperature on the antimicrobial activity of MUC7 12-mer was tested 
by determining the MICs of the peptides after incubation at temperatures 60 and 90°C 
for 30 min followed by cooling to room temperature. 
Synergy tests  
Checkerboard titrations were used to test the interaction of MUC7 12-mer peptide 
separately with each divalent cation, EDTA, and EDTA in the presence of divalent 
cations. The tests were performed in 96-well microtiter plates. A two-dimensional 
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checkerboard (8 x 8) microdilution technique was selected to span from synergy to 
antagonism.  
The assay were performed in the 96-well microtiter plate in total volume of 200 µl 
per well. In one dimension, a two-fold serial dilution of CaCl2, MgCl2, or Zn2 SO4 in 
sterile water was prepared across the rows, giving the final concentrations from 2.5 to 
160 µM for divalent cations and EDTA, and 1-125 mM for monovalent cations. In the 
second dimension, a two-fold dilution series of MUC7 12-mer was prepared down the 
columns, giving a final concentration from 0.78 to 100 µM. Each well of the microtiter 
plate was inoculated with C. albicans DIS cells suspended in 25% SDB (2 x 12.5%) to 
a final cell concentration of 1x104 cells per mL. For bacteria, S. mutans or E. coli cells 
were suspended in 50% BHI (2 x 25%) to a final cell concentration of 1x105 cells per 
mL. After incubation at 37ºC for 48 h, the absorbance of the culture was measured at 
595 nm by using a microplate reader. MIC was determined at endpoint MIC-0 and the 
values were used for calculating the fractional inhibitory concentration (FIC), defined 
as the ratio of the MIC of a drug used in combination to the MIC of the drug tested 
alone. 
Synergy tests interpretation  
The FIC index (FICI, the sum of the FICs) was calculated as described by Meletiadis 
et al. 2005 [9]. Briefly, for each checkerboard assay there were several ȈFICs, 
ranging from the ȈFICmin (the lowest ȈFIC) to ȈFICmax (the highest ȈFIC). The 
reported FIC index (FICi) was the ȈFICmin when the ȈFICmax was lower than 4; when 
ȈFICmax was higher than 4, the ȈFICmax was reported as FICi. The ȈFICmax was also 
reported as the FIC index for data sets where the ȈFICmax was lower than 4 but the 
ȈFICmin was higher than 1. If for a data set the ȈFICmin was lower than 0.5 and the 
ȈFICmax was higher than 4, both ȈFIC were reported. The off-scale MIC was 
converted to the next highest or lowest two fold concentration. The data represents 
three independent experiments. As the FICi are not normally distributed, the median 
and the range of FICi among the replicates were calculated. FICi values  0.5 have 
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been considered to indicate synergism; 0.5-1.0, additivity; 1-4, indifference; and > 4, 
antagonism. 
Killing assay  
The assays were performed in a final volume of 40 µl. Two-fold serial dilutions of NaCl 
(final concentrations ranging from 6.25 to 150 mM) and MUC7 12-mer or Hsn5 12-mer 
(at a final concentration of 25 µM in each reaction) were prepared in 10 mM sodium 
phosphate buffer (PB), pH 7.4, in a volume of 20 µl.  An equal volume (20 µl) of C. 
albicans DIS or E. coli HB101 suspended in the same buffer was then added (to a 
final concentration of 5 x 104 cells/ml). After incubation at 37 °C for 1.5 hours, the 
samples were diluted 20-fold with the same buffer and 50 µl aliquots (approximately 
120 cells) of each sample were plated on tryptic soy agar for E. coli and SDA for C. 
albicans.  The plates were incubated at 37°C for 24 h aerobically. The number of 
colony-forming units (CFUs) was counted. Loss of cell viability (percentage of killing 
compared to agent free control) was calculated as (1- amount of viable cells in the test 
group) / (amount of viable cells in the control group) x 100.  
Flow cytometric assay  
Flow cytometric assays were based on detection of increased permeability of fungal 
cells to propidium iodide (PI), a membrane impermeant DNA-intercalating dye, 
following treatment with MUC7 12-mer peptide in the presence of KCl.  Analyses 
were performed on a Becton Dickinson FACScalibur system equipped with an 
argon-cooled argon laser (488 nm, 5 mW) and standard system configuration for 
orange-filtered light detection (620 nm) using CELLQuest software (Becton Dickinson, 
Heidelberg, Germany). For these analyses, two-fold serial dilutions of KCl ranged 
from 5 to 80 mM were prepared in 10 mM sodium phosphate buffer (Na-PB), pH 7.4, 
containing 2% glucose (PBG). MUC7 12-mer was added to each tube, giving a final 
concentration of 25 µM in (0.2 mL). C. albicans cells subcultured on SDA were 
suspended in PBG to give 3 x 106 cells/mL, and aliquots (0.1 mL) of the fungal 
suspension were then added to the solution containing the peptide and KCl. After 
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incubation at 37°C for 1.5 h, a 1 mM-filtered solution of PI (Sigma-Aldrich) was then 
added to the peptide-treated fungi at a final concentration of 3 mg/L. The cell 
suspension without K+ and peptide was used as the agent free control. The samples 
were analyzed after 4 min of incubation at 37°C.  The cell scattergram and the 
intensity of fluorescence at FL3 (red fluorescence, 620 nm) were recorded by using a 
logarithmic scale. The results are expressed as the percentage of positive cells 
showing high fluorescence at FL3. To obtain a positive control for permeabilization, 
fungal suspensions were pelleted and resuspended in cold absolute ethanol for 30 
min at –20°C. Ethanol was removed by aspiration following centrifugation at 1000 g for 
10 min, and the pellet resuspended in PBG solution. Data analysis was performed 
with the FCS Express version 3 (De Nova Software, Thornhill, Ontario, Canada).  
RESULTS  
Growth inhibitory activity by MUC7 12-mer in the presence of salts or EDTA 
The effect of salts or EDTA on the antimicrobial activity of MUC7 12-mer was 
examined by determining the FICi values of each combination pair in the 
checkerboard. As shown in Table 1 for C. albicans, the MICs of MUC7 12-mer were 
from 6.25 to 50 µM; when combined with the other test agent, the MICs either 
increased or decreased. The MICs of MUC7 12-mer increased 4 fold when combined 
with Ca2+. After analysis of the data with FIC index model, FICi value of 4.5 was 
obtained, indicating antagonisms between MUC7 12-mer and Ca2+. In contrast, the 
MICs of MUC7 12-mer decreased 8 fold when combined with EDTA; FICi of 0.22 was 
obtained in this case, indicating a synergism between MUC7 12-mer and EDTA.  In 
addition, Na+, Mg2+, and Zn2+ decreased the MIC of MUC7 12-mer by 2 fold, while K+ 
increased the MIC by 2 fold. However, instead of antagonism, an additivity or 
indifference (FICi 0.55 to 2.5) was observed in the combination of MUC7 12-mer and 
each K+, Na+, Mg2+, or Zn2+. Interestingly, for growth inhibition of S. mutans and E. coli 
(data not shown), synergism (FICi 0.38) between MUC7 12-mer and EDTA, or 
additivity (0.56) between MUC7 12-mer and Zn2+ was also observed. Instead of 
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antagonism, the combination of MUC7 12-mer and Ca2+ exhibited indifference (FICi 
2.5) for the inhibition of S. mutans growth. 
 
Table 1 Interaction of MUC7 12-mer in the combination with salts or EDTA against 
C. albicans 
MIC (µM)a 
Combination pairs 
Alone Combined 
FICb FICic 
     
MUC7 12-mer 50 25 0.5  
Na+ >250 31 0.062 0.562 (ADD)d 
     
MUC7 12-mer 50 100 2  
K+ >250 250 0.5 2.5 (IND) 
     
MUC7 12-mer 12.50 50.00 4.00  
Ca2+ >160 80.00 0.50 4.50 (ANT) 
     
MUC7 12-mer 12.50 25.00 1.00  
Mg2+ >160 80.00 0.25 1.25 (IND) 
     
MUC7 12-mer 6.25 3.13 0.50  
Zn2+ 160.00 7.50 0.05 0.55 (ADD) 
     
MUC7 12-mer 18.75 2.35 0.13  
EDTA 75.00 6.25 0.09 0.22 (SYN) 
     
a Minimal inhibitory concentrations (MIC) was determined at the endpoint of MIC-0, which is defined as the 
lowest agent concentration showing  no more than 10% growth in comparison to that of the growth control. 
The data represents the median obtained from three independent experiments.  
b FIC is a fraction inhibitory concentration that was calculated by dividing the MIC value of agent in 
combination by the MIC value of the agent alone.  
c FICi is a FIC index, indicating the sum of the FICs of the two agents in the pairs. 
d Interactions: SYN, synergism (FICi <0.5);  ADD, additivity (FICi 0.5-1.0); IND, indifference (FICi 1.0 - 4.0); 
ANT, antagonism (FICi >4). 
 
The physiological concentration of Ca2+ in human whole saliva is 1-2 mM [10]. 
Ca+2 may be the main inhibitory factor on the activity of MUC7 12-mer in vivo.  In fact, 
as shown in Table 2, MIC of MUC7 12-mer against C. albicans increased from 18 to 
200 µM as the concentration of Ca2+ increased. Therefore, the effect of EDTA on the 
anticandidal activity of MUC7 12-mer in the presence of Ca2+ was also determined. As 
pointed out above, the combination of MUC7 12-mer and EDTA exhibited a 
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synergistic effect on the anticandidal activity. In the presence of Ca+2 and EDTA 
(Table 2), MUC7 12-mer still showed strong activity, with the MIC decrease from 4 to 
16 fold compared to the MICs in the presence of Ca+2  without the EDTA. Synergism 
was still observed with FICi 0.22 to 0.31.  
 
Table 2 Interaction of MUC7 12-mer in the combination with EDTA 
against C. albicans in the presence of Ca2+ 
MIC (µM) 
Ca2+ (mM) Combination pairs 
alone combined
FIC FICi 
      
0 MUC7 12-mer 18.75 2.35 0.13  
 EDTA 75.00 6.25 0.09 0.22 
      
0.01 MUC7 12-mer 25 6.25 0.25  
 EDTA 50 3.13 0.0626 0.3126 
      
1 MUC7 12-mer 100 6.25 0.0625  
 EDTA 100 25 0.25 0.3125 
      
2 MUC7 12-mer 200 6.25 0.03125  
 EDTA 200 50 0.25 0.28125 
      
 
All parameters (MIC, FIC, FICi) are defined in table 1 footnote. 
 
Killing activity of MUC7 12-mer peptide in the presence of sodium and 
potassium  
The effect of peptides on cell viability of C. albicans in the presence of NaCl is shown 
in Figure 1. MUC7 12-mer exhibits 100% killing activity in the presence of NaCl up to 
25 mM, a physiological concentration of Na+ in human saliva. Some decrease in the 
activity of the MUC7 12-mer was observed in the presence of 50 mM NaCl or higher. 
However, MUC7 12-mer still exhibited more resistance to NaCl than Hsn5 12-mer. In 
the presence of 50 mM NaCl, MUC7 retained 90% killing activity, while Hsn5 12-mer 
40%. Additionally, MUC7 12-mer peptide was effective against E. coli in the presence 
of NaCl up to 150 mM (data not shown), a physiological concentration of Na+ in 
plasma.  
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Figure 1. Effect of sodium chloride on 
candidacidal activity of MUC7 12-mer and Hsn5 
12-mer, determined by killing assay. MUC7 12-mer 
or Hsn5 12-mer (25 µM) were incubated with C. 
albicans (105 cells/ml) in 10 mM Na-PB containing 
NaCl. The killing activities were determined by 
comparing the number of colonies at each salt 
concentration to those of the agent-free control. 
Data represents two independent experiments, 
each performed in duplicate.  
 
Figures 2 and 3 show the effect of K+ on the anticandidal activity of MUC7 12-mer, 
which was determined with flow cytometry. Untreated cells stained with PI showed a 
very low intensity of fluorescence, expressed as negative (viable cells, Figure 2a) for 
PI. In contrast, MUC7 12-mer or ethanol (data not show) treated cells showed a high 
red fluorescence, expressed as positive (dead cells, Figure 2b) for PI. Candida cells 
treated with MUC7 12-mer in the presence of 40 mM KCl still showed  PI 
fluorescence (Figure 2c) with  96% PI positive cells (Figure 3),  although the PI 
positive cells deceased to 47% in the presence of 80 mM KCl (Figure 2d and Figure 3). 
Similarly, when treated with a low concentration of MUC7 12-mer (5 µM), more than 
96% of Candida cells were killed in the presence of KCl at concentrations up to 20 mM, 
and 56% of cells were killed at 40 mM KCl. 
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Figure 2. Antimicrobial activity of MUC7 12-mer against C. albicans in the presence of K+, monitored by 
flow cytometry. Fluorescence distribution of the control (untreated) C. albicans cells (a); cells incubated for 
90 min at 37ºC with 25 µM MUC7 12-mer (b-d), in the absence of KCl (b), in the presence of 40 mM KCl (c), 
in the presence of 80 mM KCl (d). The cells were stained with propidium iodide (3 µg/mL). Susceptibility to 
MUC7 12-mer is shown as percentage of C. albicans with increasing fluorescence; 10,000 events were 
analyzed. 
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Figure 3. Effect of potassium on anticandidal 
activity of MUC7 12-mer. C.abicans DIS (106 
cells/ml) was treated with 5 and 25 µM MUC7 
12-mer in Na-PB containing KCl (5 - 80 mM) and 
PI fluorescence was analyzed by flow cytometry 
as described in Materials and Methods. 
 
 
 
 
 
 
 
Effect of pH 
The effect of pH on the activity of the peptide was established by determining the MIC 
of MUC7 12-mer against C. albicans DIS at pH values varying from 5 to 9 (Figure 4). 
There are no significant differences among the MIC-0, MIC-1, and MIC-2 (95% 
confidence intervals overlap). However, MICs of MUC7 12-mer were higher in acidic 
conditions than in neutral and basic conditions, and its antimicrobial activity was 
optimum at pH 8 (95% confidence intervals do not overlap). 
Effect of temperature 
The effect of temperature on the activity of MUC7 12-mer was determined by heating 
MUC7 12-mer for 30 min prior to determining the MIC values (Figure 5). MIC values of 
MUC7 12-mer did not significantly change after the peptide was pre-treated at 60ºC; 
when pre-heated at 90ºC, the peptide was still active although its MIC values slightly 
increased (MIC-0 = 25 µM, one dilution level). Temperature up to 60ºC does not affect 
the activity of the peptide. 
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Figure 4. Effect of pH on MIC of MUC7 12-mer 
against C. albicans. MIC-0, MIC-1 and MIC-2 
indicate the lowest concentration showing less 
than 10%, 25% and 50% growth of the agent-free 
control, respectively. The bars indicate the 
geometric means of two independent tests each 
performed in duplicate. The error bars show the 
95% confidence intervals for the means.  
 
 
 
 
 
 
 
 
Figure 5. The effect of temperature on MIC of 
MUC7 12-mer against C.albicans. MUC7 12-mer 
was heated for 30 min prior to determining the MIC 
values. RT: Room temperature. The bars indicate 
the geometric means of two independent 
experiments, each performed in duplicate. The 
error bars represent the 95% confidence intervals 
for the means. 
 
 
 
DISCUSSION  
To have a therapeutic use against oral or systemic infections, antimicrobial peptides 
need to retain their activity in physiological conditions.  Some antimicrobial peptides 
have a broad activity against fungi, bacteria and viruses. However, a major obstacle in 
their development as novel antibiotics is the antagonism between the peptides and 
ionic strength in their environment. As a result, the practical therapeutic use of 
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antibiotic peptides is significantly impaired or attenuated. Many cationic antimicrobial 
peptides including ȕ-defensins and the Į-defensin HD-5 [11] [12] [13] [14] [15] [16], 
lactoferricin B [17], histain 5 [18] [19] [20], human cathelicidin LL-37 [21], protegrins 
[22], and pleurocidin [23] are salt sensitive and reduce or lose their antimicrobial 
activity at elevated concentrations of  mono- or divalent cations. The persistence of P. 
aeruginosa infections in the lungs of patients with cystic fibrosis is attributed to the 
susceptibility of epithelial antimicrobial peptides to salt antagonism [14]. The 
antibacterial effectiveness of lactoferricin B was reduced in the presence of Na+, K+, 
Mg2+ or Ca2+ ions, or in the presence of various buffer salts [17]. Hypertonic salt 
concentrations and heat-inactivated serum were found to be inhibitory to the 
bactericidal activity of protegrin (PG-1), a broad spectrum antibiotic peptide isolated 
from porcine leukocytes [22]. Human ȕ-defensin-2 and cathelicidin LL-37 inhibit the 
growth of P. aeruginosa in vitro, but this activity is markedly reduced in the presence 
of tears [24]. In saliva, histatin 5, a human basic salivary peptide with strong fungicidal 
properties in vitro, is salt sensitive and exerts low activity at high salt conditions [25]. 
The activity resumed after removing the salts by dialysis [19]. 
 
 
Table 3. Normal values of cations and pH in human 
whole saliva and plasma  
 Saliva (mM) Plasma (mM) 
   
Ca 2+ 1-2 2.5 
Mg 2+ 0.2-0.5 0.5-1.0 
Na+ 6-26 140 
K+ 14-32 4 
NH4+ 1-7 0.03 
pH 6.7  
pH range 6.2-7.6  
   
 
Reference: [10] 
 
Saliva is vitally important for the normal functioning of healthy human beings. 
Saliva is hypotonic in relation to serum; the average concentration of Na in saliva is 
6-26 mM, versus 140 mM in plasma. Ca2+ and K+ are the major salivary 
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complex-forming ions [26]. The normal values of major cations and pH in mixed 
human saliva and plasma is summarized in Table 3. Since NaCl is the most 
predominant salt in vivo, the ability to resist this salt is significant for antimicrobial 
peptides to function under physiological conditions. Oral candidiasis is a superficial 
mucosal infection caused by C. albicans that is frequently associated with 
chemotherapy, organ transplantation, immunodeficiency virus infections, underlying 
disease states or medications that reduce salivary flow. A NaCl concentration of 6-26 
mM has been reported to be present in the environment of the epithelial cells of the 
oral cavity (Table 3). In this study, the antagonism in terms of growth inhibition 
between Na+ and MUC7 12-mer was not observed by the checkerboard test (Table 1). 
More importantly, MUC7 12-mer still exhibited anticandidal activity at the human 
salivary Na+ concentration (less than 26 mM; Figure 1). This suggests that MUC7 
12-mer peptide is active for oral candidiasis in oral physiological conditions. This is 
consistent with the observation of our previous study using mouse model of oral 
candidiasis in vivo [27]. The other reported NaCl-resistant peptides include clavanins 
(histidine-rich, amidated alpha-helical antimicrobial peptides) [28], CP26, CP29, 
CEME, CEMA (the analogues based on the insect cecropin-bee melittin hybrid 
peptide) [29], P18 (KWKLFKKIPKFLHLAKKF, an alpha-helical antimicrobial peptide) 
[30], cathelicidin CAP18, SMAP29 [31], and modified forms of LL-37, such as 
pentamide-37 [32]. Ponti, et al. reported that the cyclic and linear analogues of 
esculentin-1, an antimicrobial peptide from amphibian skin, have a strong killing 
activity against gram-negative bacteria, and the activity is not affected by salts [33]. 
Nuding, et al.  reported that the antibacterial effect of the isolated cationic 
extracts from human intestinal biopsies was diminished towards E. coli with 150 mM 
NaCl [34]. Our study (data not shown) demonstrated that MUC7 12-mer exerted 
strong activity towards E. coli HB101 up to 150 mM NaCl. This suggests a potential for 
MUC7 12-mer as a chemotherapeutic agent for the systematic infection with E. coli 
without being affected at physiological salt concentrations.  
KCl is one of the salts affecting the antimicrobial activity. However, to our 
knowledge, the reported information regarding the effect of KCl on the antimicrobial 
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peptide activity is limited. KCl is not a principal salt in plasma, but is predominant in 
saliva (14-32 mM) [26]. Thus, the role of KCl should not be neglected for the 
anticandidial activity of peptides. Previously, it has been observed that extended 
indolicidins, ȕ-sheet gramicidins, and looped and linear bactenecins are all quite 
sensitive to KCl [35]. In this study, the antagonistic effects of KCl was not observed on 
MUC7 12-mer, which still showed high anticandidal activity in the presence of 40 mM 
KCl,  the concentration higher than its physiological concentration in saliva.  
Ca2+ is a major divalent cation in saliva, a potent inhibitor of histatin 5 candidacidal 
activity at physiological concentrations, and may be the primary ion responsible for 
the masking effect of saliva [36]. Our previous study showed that Ca2+ exhibited 
inhibitory effect on the fungicidal activity of MUC7 20-mer (a peptide extended by 8 aa 
residues at the N-terminus of the MUC7 12-mer) [3]. In this study, we found that Ca2+ 
is the only ion that exhibited an antagonistic effect on MUC7 12-mer against C. 
albicans.  
It has been reported that Mg2+ also inhibits the activity of antimicrobial peptides, 
but the inhibition potency is lower that that of Ca2+.  For example, Mg2+ at the 
physiological concentration (less than 1 mM) does not change the antibacterial activity 
of the Sphe-2, a ȕ-defensin from the king penguin stomach, against S. aureus, and  
the growth of E. coli was altered by 2 fold in the presence of 1 mM MgCl2 [37]. We 
have demonstrated (in the previous study) that more than 5 mM MgCl2 exhibited 
inhibitory effect on the candidacidal activity of MUC7 20-mer. The activity, however, 
was not altered in the presence of 1 mM MgCl2 [3]. In this study, we demonstrated that 
Mg2+, unlike Ca2+, did not show an antagonistic effect on MUC7 12-mer against C. 
albicans. 
Zn2+ does not exist in saliva, but Zn2+ can enhance the antimicrobial activity of 
peptides. It has been reported that poly (arginyl-histidine) peptide, which shows 
activity against a broad range of bacteria and fungi, lost its activity under conditions of 
high ionic strength. Zn2+ can specifically change the circular dichroism spectra of this 
peptide and restore its antimicrobial activity under high ionic strength conditions [38]. 
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Melino et al. reported that Zn2+ ions selectively induce salivary histatin-5 to fuse 
negatively charged vesicles through a zinc-binding motif present in its functional 
domain, and stated that the action of this antimicrobial peptide is likely mediated by 
the presence of zinc ions [39]. Our results are consistent with the above studies in that 
Zn2+ exhibits an additive effect on the antimicrobial activity of MUC7 12-mer. However, 
the mechanism of this effect in not known.  
EDTA (ethylenediamine tetraacetic acid), which chelates divalent cations, is 
approved by the FDA as a preservative in packaged foods, vitamins, and baby food.  
EDTA has been widely used in many areas.  In medicine, EDTA is used in chelation 
therapy for acute hypercalcemia and for treating mercury or lead poisoning. EDTA is 
also used as an anticoagulant for blood samples, and as an anticollagenase to 
prevent the worsening of corneal ulcers in animals. In dentistry, EDTA is used as a 
root canal irrigant to remove organic and inorganic debris (smear layer) [40] [41]. Sen 
et al. demonstrated that EDTA exhibited the highest antifungal activity against C. 
albicans, compared with those of routine antifungal drugs [42]. Our previous study 
showed that that EDTA enhanced the antifungal activity of MUC7 peptides in human 
saliva mainly by chelating the divalent cations (such as Ca+2) [8]. In support of this 
discovery, the results of this study indicated that EDTA has a synergistic effect on the 
antimicrobial activity of MUC7 12-mer (Table 1), and abrogates the activity that was 
inhibited by Ca2+ (Table 2).  These findings suggest that concurrent therapies with 
EDTA and MUC7 12-mer may be of value in patients with oral fungal or bacterial 
infections, although further studies in vivo are needed to examine the safety, 
tolerance, and optimal dosing of EDTA in the treatment of these infections. The 
mechanism for the EDTA action is likely that it competes with microorganism for any 
of the trace iron and Ca2+ ions that are essential to the maintenance of their life cycle 
[43] or it disturbs the integrity of bacterial outer membrane [44]. It may be also due to 
the fact that EDTA prevents the peptide degradation by the metalloprotease [45].  
In addition to salt sensitivity, antimicrobial peptides are also pH-dependent.  Lee 
et al. [28] demonstrated that the activities of histidine-rich, amidated alpha-helical 
antimicrobial peptides were substantially greater at pH 5.5 than at pH 7.4. In another 
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study, Minahk et al. also showed that the antilisterial activity of enterocin CRL35 was 
higher at acidic than neutral or basic conditions [46].  In contrast, our study showed 
that the antimicrobial power of MUC7 12-mer peptide was enhanced in neutral or 
slightly alkali media, although the peptide acted in a broad range of pH. Therefore, 
saliva with pH range 6.2-7.6 appears to be the suitable environment for the action of 
MUC7 12-mer. Similar observations have been reported for other antimicrobial 
peptides [47] [48]. 
Temperature is also one of the important factors for the therapeutic application of 
the peptide. Some antimicrobial peptides retained their activity when pre-heated [47]. 
MUC7 12-mer is also thermo-stable. It retained significant antimicrobial activity after 
incubation at 60ºC for 30 min. This thermal stability is probably due to this peptide’s 
very simple secondary structure that cannot be denatured. 
CONCLUSIONS  
At oral physiological concentrations, the antimicrobial activity of MUC7 12-mer is not 
affected by Na+, K+, or Mg2+, but is inhibited by Ca+2, which has an antagonistic effect 
on MUC7 12-mer. However, this inhibition can be reversed in the presence of EDTA, 
as EDTA exhibited a synergistic effect when combined with MUC7 12-mer. This 
peptide exerts optimum anticandidal activity at neutral or slightly basic conditions. 
MUC7 12-mer peptide is stable, and temperature up to 60ºC has not affected its 
activity. These findings suggest that MUC7 12-mer peptide, especially in combination 
with EDTA, could be potentially applied as an alternative therapeutic agent for the 
treatment of human oral candidiasis. 
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ABSTRACT 
Subgingival dental plaque consists mainly of microorganisms that derive their energy 
from amino acid fermentation. Their nutrient requirements are met by the subgingival 
proteolytic system, which includes proteases from microorganism and inflammatory 
cells, and substrate proteins from sulcus exudate, including albumin. To determine the 
selective effect of individual proteins on microbiota, we used albumin as the main 
substrate for growth. Eight subgingval plaque samples from untreated periodontal 
pockets of patients with adult periodontitis were inoculated in peptone yeast medium 
with bovine albumin (9 g/l). After three subculture steps, cell yields of the enrichment 
cultures at the medium with 0, 1.25, 2.5, 5, 10, and 20 g/L albumin were determined. 
Proteolytic activity (U/absorbance at 550 nm) of the enrichment cultures and different 
isolates derived from the cultures was estimated by the degradation of 
resorufin-labeled casein. It was observed that the yield of the mixed culture was 
albumin limited, and the proteolytic activities of the cultures in albumin broth were 
higher than in control (peptone broth). Among the isolates from the enrichment 
cultures, Peptostreptococcus micros, Prevotella melaninogenica, Prevotella buccae 
and Prevotella bivia demonstrated proteolysis. The frequent occurrence of 
Streptococcus gordonii and Streptococcus anginosus in the albumin cultures is 
explained by their ability to utilize arginine as an energy source for growth. Albumin in 
the medium was partly degraded by pure cultures but completely consumed in 
enrichment cultures, indicating synergy of bacterial proteinases. It is concluded that 
the subgingival microbiota possesses proteolytic activity and may use albumin as a 
substrate for their growth. Enrichment cultures on albumin may serve as a relatively 
simple in vitro model to evaluate the effects of proteinase inhibitors.  
 
 
 

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INTRODUCTION 
Predominant microorganisms of subgingival plaque, including Prevotella, 
Porphyromonas, Fusobacterium, Peptostreptococcus and Treponema species, derive 
their energy mainly from fermentation of amino acids. These nutrient requirements are 
met by crevicular fluid that is rich in serum-derived proteins [2, 5, 19]. As bacteria only 
take up free amino acids, and peptides, proteins must first be split. For the liberation 
of small peptides and amino acids, the subgingival microflora disposes of a proteolytic 
system consisting of proteinases and peptidases. Proteinases cleave natural proteins 
into polypeptides, which are further degraded by aminopeptidases and 
endopeptidases [1]. Other protein-degrading enzymes in the subgingival ecosystem 
include metalloproteases and elastase released by phagocytic cells. While the 
individual contributions of bacterial or cellular proteinases are difficult to separate, the 
combined proteinase activities are supposed to play a major role in the causation of 
periodontal tissue damage. The degradation of protein in the periodontal pocket is 
probably very similar to that in other anaerobic environments including the rumen and 
the large intestine, where the principal proteolytic bacteria are also gram-negative [15]. 
The main proteinase-producing subgingival bacteria include Porphyromonas and 
Prevotella species. They have cysteine proteinases that hydrolyze various serum 
proteins [4, 9, 11, 13]. The present experiment was set up to get more insight in the 
role of protein, as a substrate, for the growth and the composition of the periodontal 
microbiota. Previous experiments have shown that human serum supports growth of 
highly complex mixed cultures of periodontal microbiota in vitro [17, 18]. The high 
species diversity in these cultures is likely due mainly to the presence of different 
proteins in serum.  
To determine the selective effect of individual proteins on microbiota, we used 
albumin, quantitatively the principal protein in human serum and crevicular fluid [19], 
as the main substrate for growth. Samples of subgingival plaque were repeatedly 
subcultured (enriched) in medium with albumin, and the cell yields and composition of 
the cultures were estimated.  
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MATERIAL AND METHODS 
Enrichment cultures of subgingival plaque 
Eight plaque samples were obtained from untreated pockets in as many periodontitis 
patients. The pockets were at least 8 mm deep and showed bleeding on probing. After 
removal of supragingival plaque, a sample of the pocket contents was taken with a 
dental scaler. The samples were immediately immersed in 5 ml of pre-reduced 
albumin medium. The medium contained per liter: 9 g of bovine albumin (Sigma 
Chemical Co., St. Louis, MO), 0.5 g proteose peptone (Difco Laboratories, Detroit, MI), 
and 0.5 g of trypticase peptone (BBL Microbiology Systems, Cockeysville, MD). The 
samples were transported into an anerobic isolator (Coy, Ann Arbor, MI) with an 
atmosphere of 91% N2, 5% CO2 and 4% H2 that was kept at 37°C. All further 
procedures were carried out in the isolator. Plaque was suspended by vortexing for 1 
min. In order to select for protein-degrading microbiota, enrichment cultures were 
started by inoculating 0.1 ml of the plaque suspension into 8-ml amounts of albumin 
medium of the above composition, and peptone medium. The peptone medium 
contained per liter 5 g proteose peptone (Difco Laboratories) and 5 g of trypticase 
peptone (BBL Microbiology Systems), but no albumin. After incubation for 7 days, 
0.1-ml amounts of the enrichment cultures were transferred into the same volume of 
fresh medium. The proteolytic activities, pH values, optical densities at 550 nm and 
species composition of the cultures were determined after 3 enrichment steps.  
Microbiological analysis 
The samples from the mixed cultures were plated onto enriched-blood agar [18]. The 
plates were incubated for 7 days in the isolator. From a radial segment of the plate all 
colonies, but at least 25, were picked and subcultured for identification. Gram stain 
and cellular morphology were determined microscopically. Further identifications were 
done using API RapID 32A, API 32E, API 32STREP (all BioMerieux, Marcy l'Etoile, 
France).  
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Cell yields at varying concentrations of albumin 
To estimate the effects of albumin on the cell production in the enrichment cultures, 
media with 0, 1.25, 2.5, 5, 10, and 20 g/l albumin were tested. Growth assays were 
performed in triplicate using 96-well microtiter plates (Flow Laboratories, McLean, VA). 
To each well, 200 µl of medium and 50 µl of a 24-h preculture of subgingival plaque 
were added. After growth for 3 days, absorbance values at 540 nm (A540 nm) were 
recorded using a Titertek Multiskan MC (Flow Laboratories). Residual albumin in the 
cultures was examined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE).  
Proteolytic activity 
For determination of proteolytic activities, the cultures were centrifuged at 20,000 × g 
for 5 min, washed and resuspended in saline to a A550 nm value of 1.0. Using well 
plates, the reaction mixture consisted of 50 µl of cell suspension, 25 µl of 0.4% 
resorufin-labelled casein (Boehringer, Mannheim) in water and 25 µl of 0.2 mol/L 
Tris-HCl buffer pH 7.8. After incubation for 4 h, the reaction was stopped by addition 
of 250 µl of 5% trichloroacetic acid, and the reaction mixture was centrifuged. Finally, 
200 µl of the supernatant was added to 0.3 ml of 0.5 mol/l Tris-HCl pH 8.8, and 
absorbancies were read at 574 nm. Proteolytic activity was expressed as unit of A574 
nm per unit of cell density (unit A550 nm).  
The ability of individual strains to degrade albumin was measured after 7 days of 
incubation at 37°C in medium containing 1 g/l albumin. 
Albumin assay 
To determine the proteolytic activities of strains, albumin was assayed in the 
incubation mixtures using SDS-PAGE [14, 16]. Samples of the bacterial cultures were 
diluted in water, and boiled for 5 min with an equal volume of sample application 
buffer containing 1% SDS, 2 moles/l urea and 50 mmol/l dithiothreitol, in addition to 
the normal constituents. A nominal amount of approximately 4 g of albumin was 
loaded on the gel. The samples were electrophoresed with 3% stack gel at 40 mA. 
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Gels were stained with coomassie blue, and destained in 7% acetic acid and 5% 
methanol. Densitometry was performed directly on the wet gels by a laser 
densitometer (Pharmacia-LKB GSXL, Bromma, Sweden). The amount of degraded 
albumin was determined by comparison with the internal albumin standard on each 
gel.  
Residual albumin in cultures was assayed by capillary electrophoresis (P/ACE 
System 2210, Beckman, Fullerton, CA) on a 27-cm coated glass column with an 
internal diameter of 50 µm (Applied Biosystems, Foster, CA). The system was 
provided with a an ultraviolet detector (214 nm). Separations were carried out at 10 kV 
in 0.1 mol/l phosphate buffer pH 2.5. 
RESULTS 
Enrichment cultures 
The mean cell yield (A550 nm) of eight enrichment cultures originating from subgingival 
plaque samples in medium with 10 g/l albumin was 0.88 (SD 0.40; Table 1). Assuming 
a mean molecular weight of 100 for amino acids, the cell yield is 0.0088 A550 nm 
units/mol amino acid. The pH values of the enrichments in albumin ranged from pH 
7.3 to pH 7.9. No residual albumin was found in the cultures, indicating that albumin 
was limiting the growth of the cultures. Some samples were also enriched in medium 
with 10 g/l peptone (Difco Labs) instead of albumin. The cell yields in the hydrolyzed 
protein, peptone, were found to be equally high as in albumin medium ( Table 1).  
 
Table 1. Cell yield and proteinase activities of mixed culures of periodontal bacteria. 
Means and standard deviations in brackets 
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Table 2. Isolates from enrichment cultures of subgingival plaque in albumin medium 
and their proteinase activities  
 
 
Microorganisms in enrichment cultures and proteolytic activities 
Microorganisms isolated from eight enrichments of individual subgingival plaque 
samples are listed in Table 2. Peptostreptococcus micros, Prevotella buccae, 
Fusobacterium nucleatum, Streptococcus gordonii and Streptococcus anginosus 
frequently occurred in the eight enrichment cultures. The microbial composition of a 
representative enrichment culture, enrichment culture no. 3 (see Fig. 1, at 10 g/l 
albumin), was as follows: P. micros, 9%; P. buccae, 60%; F. nucleatum, 10 %; 
Actinomyces meyeri, 3%; S. gordonii, 9%; and S. anginosus, 9%. Proteinase activities, 
measured with resorufin casein and by degradation of albumin, was found in some 
species but not in others.  
The proteolytic activities of the cellular and supernatant fractions of mixed cultures 
are shown in Table 1. The activities in the albumin cultures were noticeably higher 
than those in the peptone cultures. In both media, most of the proteolytic activity that 
occurred was cell associated.  
Albumin as a growth-limiting substrate 
A linear relationship was found between the cell mass (units A550 nm) in plaque 
enrichment cultures and the concentration of albumin in the medium. A typical 
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example is given in Fig. 1. No residual albumin was found in the cultures, up to the 
highest concentration (20 g/l) tested. Individual isolates from the same plaque 
enrichment culture were grown in the albumin medium. Fig. 1 indicated that the pure 
cultures of the isolates grew poorly, in contrast to their mixture.  
 
Figure. 1. Cell mass of enrichment culture (E. culture number 3) and cell masses of pure cultures of its isolates in 
media with increasing concentration of albumin. The microbial composition of the enrichment culture number 3 is 
detailed in the text. 
DISCUSSION 
Proteins from crevicular fluid seem to be the major energy source for growth of the 
periodontal microflora. This focuses the attention on the role of proteolytic enzymes in 
the acquisition of substrate. Because of its predominance in crevicular fluid, albumin 
was selected as substrate for enrichments of subgingival plaque. Using a single 
protein instead of serum [18], it was anticipated that relatively simple mixed cultures 
would be obtained.  
This appeared to be the case, and albumin supported growth of 5–8 membered 
mixed cultures originating from subgingival plaque samples. The complete utilization 
of albumin in the cultures suggested that albumin acted as growth-limiting substrate. 
This was confirmed by the linear relationship between cell yield and albumin 
concentration. Assuming a mean molecular weight of amino acid of 100, the cell yield 
of the mixed cultures was approximately 0.09 A550 nm units/mol amino acid. Growth of 
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oral streptococci and actinomyces species on hexose gives yields of approximately 
0.1 A550 nm units/mol hexose [8, 21]. The higher efficiency of hexose than amino acid 
as energy substrate for mixed growth of oral bacteria corraborates findings in other 
ecosystems [3, 10] . The reasons are that only some amino acids can be fermented, 
and that the molar ATP yield of amino acid fermentation is generally lower than that of 
hexose.  
That most of the proteinase activity occurred cell-associated is a common 
observation for periodontal microflora [6, 11]. Most of the proteolytic activity in the 
rumen and the large intestine also resides in the bacterial fraction [15, 22]. The 
stimulation of proteinase activities by albumin in the medium suggested that 
proteinase was induced.  
All eight albumin enrichment cultures had some crucial characteristics in common. 
Each contained one or more proteinase-producing bacteria, including Prevotella spp. 
and A. meyeri. Peptostreptococcus and Fusobacterium occurred in most cultures. 
Their presence is thought to be due to the availability of polypeptides generated by 
the proteinase-producing strains. The degradation of albumin by P. micros, as found 
here, seems in contrast with other observations indicating the absence of proteinase 
activity [12] in this species. Instead, albumin breakdown by P. micros may have 
resulted from endopeptidase activity and the long incubation (1 week) in the test that 
was used here.  
Since the carbohydrate content of the albumin medium was low, the frequent 
occurrence of typical carbohydrate fermenters as S. anginosus and S. gordonii is 
interesting. In fact, these streptococcal species are versatile and, in addition to the 
fermentation of different sugars, they have the ability to ferment arginine [7, 20]. This 
may explain their common appearance in various sites in the mouth. Other species, 
such as Gemella, do not seem to ferment amino acid, and their presence may be due 
to the small amount of carbohydrate in the medium.  
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The mixed culture grew much better than would be expected from growth of the 
individual strains. This strongly suggested that microorganisms synergistically 
degrade albumin by overlapping proteolytic (proteinase and peptidase) activities. 
Overall, the albumin enrichment cultures have some basal characteristics in 
common with natural subgingival plaque. Disease-associated microorganisms such 
as Prevotella, Porphyromonas, Peptostreptococcus, Fusobacterium and Treponema 
use amino acids as energy source and rely on proteolytic activities to fulfil their amino 
acid requirements. This would make it interesting to estimate the effect of proteinase 
inhibitors on the subgingival microflora. The albumin enrichment cultures may serve 
as a relatively simple in vitro model to evaluate the effects of proteinase inhibitors.  
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Human salivary mucin MUC7 12-mer-L and 
12-mer-D peptides: antifungal activity in 
saliva, enhancement of activity with 
protease inhibitor cocktail or EDTA, and 
cytotoxicity to human cells 
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ABSTRACT 
MUC7 12-mer-L exhibits potent in vitro antifungal activity in low-ionic-strength buffers. 
In this study, we investigated the anticandidal activity and stability of MUC7 12-mer-L 
and its all-D-amino-acid isomer, along with Hsn5 12-mer (P113) and magainin-II, in 
human clarified and unclarified saliva in the absence or presence of protease inhibitor 
cocktail (PIC, which includes EDTA) or EDTA alone. In the absence of PIC or EDTA in 
saliva, only MUC7 peptides showed significant candidacidal activity. At a 100 µM 
concentration in clarified saliva and unclarified saliva, MUC7 12-mer-D demonstrated 
94 versus 64% killing, respectively; MUC7 12-mer-L showed 57 versus 32% killing; 
Hsn5 12-mer showed 16 versus 0% killing; and magainin-II showed no killing. 
Addition of PIC or EDTA to either saliva caused the enhancement of antifungal 
activities of all peptides, although to different degrees. Taken together, the results 
suggest that EDTA (a metal-dependent protease inhibitor and/or divalent cation 
chelator) enhanced the antifungal activity of all four peptides mainly by chelation of 
divalent cations present in saliva (known to inhibit peptide antifungal activity), and PIC 
enhanced the activity of the three L-peptides above that achievable by EDTA alone 
through inhibition of all classes of proteases. Peptide stability in saliva monitored by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed no degradation of 
MUC7 12-mer-D and 23, 60, and 75% degradation of MUC7 12-mer-L, Hsn5 12-mer, 
and magainin-II, respectively. Cytotoxicity assays determined that, at 100 µM peptide 
concentrations, MUC7 12-mer-D and 12-mer-L caused 3.5 and 4.3% hemolysis in 
phosphate-buffered saline and no toxicity to the HOK-16B cell line (derived from 
normal human oral keratinocytes). In summary, MUC7 12-mer peptides appear to be 
excellent candidates for investigation of antifungal activity in in vivo models of oral 
candidiasis. 
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INTRODUCTION 
Candidiasis is the most common oral fungal infection diagnosed in humans. Due to 
the emergence of pathogens resistant to conventional antifungals and the toxicity of 
some antimycotics, intense efforts have been made to develop more effective 
antifungal agents for clinical use [1-3]. Cationic antimicrobial peptides (CAMPs) have 
become attractive as novel candidates for this purpose. The native CAMPs contribute 
to innate host defense against a number of bacterial and fungal pathogens. They have 
been discovered from various natural sources, including humans, mammals, plants, 
insects, and bacteria [12, 13, 31]. Among these, the well-characterized human 
salivary histatins and frog skin magainins show activity against a variety of 
microorganisms [18, 31, 32]. 
MUC7, the low-molecular-mass human salivary mucin (comprised of 357 amino 
acid residues), exerts antimicrobial activity by binding to and clearing microorganisms 
from the oral cavity [25]. While the full-length MUC7 has no appreciable candidacidal 
activity [11], we have shown that peptides derived from its N-terminal region have 
significant and broad-spectrum fungicidal and bactericidal activities in vitro in 
low-ionic-strength buffers [6, 24, 27]. MUC7 12-mer (amino acids 40 to 51 of the 
parent MUC7, with a net charge of +6) is a peptide of the optimal size that possesses 
potent activity against Candida albicans and Cryptococcus neoformans [28]. MUC7 
12-mer also exhibits synergistic antifungal effects in vitro with histatin 5 12-mer (Hsn5 
12-mer) or miconazole [29]. 
It has been demonstrated in vitro that antimicrobial peptides can be degraded by 
proteases, resulting in a decrease or loss of their biological activity [7, 22, 26, 27]. It is 
well known that protease inhibitors can prevent the degradation of peptides. Since 
proteases recognize only L amino acids, the peptide degradation can also be 
decreased or prevented by modifying the peptide's molecular structure by substitution 
of the natural L amino acids with their D forms. For example, an all-D-amino-acid 
magainin-II was highly resistant to proteolysis, exhibited antibacterial potency nearly 
identical to that of the all L enantiomer, and showed no hemolytic activity [5]. Similarly, 
the all-D-amino-acid isomer of Hsn5 12-mer (P113-D) was as active against 
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C.albicans as the natural L form. In addition, P113-D but not the L peptide was active 
against respiratory bacteria in the presence of sputum from cystic fibrosis patients[23]. 
Despite the wealth of information on the antimicrobial activity of the CAMPs in 
vitro, in vivo studies are limited. Our own study showed that neither MUC7 16-mer nor 
full-length Hsn5 was effective in the treatment of a murine model of vaginal 
candidiasis [15]. Based on the results of studies with the other D-isomer peptides, we 
obtained the D-amino-acid isomer of MUC7 12-mer and initiated investigation of this 
peptide's potential for therapeutic use against oral candidiasis. As the first step, in this 
study we tested the antifungal activity and stability of MUC7 12-mer-D along with that 
of MUC7 12-mer-L and two other well-known antimicrobial peptides, salivary Hsn5 
12-mer (P113) [20] and magainin-II [32], in human saliva. Because salivary 
components, in particular proteases and divalent cations, may affect peptide activity, 
the tests were performed in the absence or presence of protease inhibitors or EDTA. 
Furthermore, we determined the cytotoxicity of these peptides to human erythrocytes 
and the cell lines of human oral epithelial origin HOK-16B (normal human oral 
keratinocytes) and KB (human oral epithelial carcinoma). 
MATERIALS AND METHODS  
Fungal strains and growth media 
C. albicans DIS was provided by M. Edgerton, University at Buffalo. C. albicans ATCC 
96112 and Candida glabrata ATCC 90030 were purchased from the American Type 
Culture Collection. An azole-resistant clinical isolate of C. glabrata 65°C was provided 
by John E. Bennett, National Institute of Allergy and Infectious Diseases, Bethesda, 
MD. A clinical isolate of Candida krusei was obtained from the Erie County Medical 
Center, Buffalo, NY. For each experiment, cells were cultured (from í80°C frozen 
stocks) on Sabouraud dextrose agar (SDA; Difco) for 24 h at 37°C. One colony was 
picked and resuspended in 10 mM sodium phosphate buffer (PB; pH 7.4), and the cell 
concentration was adjusted to 1 × 105/ml. 
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Peptides 
MUC7 12-mer-L (RKSYKCLHKRCR, residues 40 to 51 of the parent human salivary 
mucin, MUC7), MUC7 12-mer-D (with all 12 l-form amino acids replaced by the d 
form), Hsn5 12-mer (AKRHHGYKRKFH, also known as P113 [20], residues 4 to 15 of 
the human salivary histatin 5), and magainin-II (GIGKFLHSAKKFGKAFVGEIMNS, a 
23-residue peptide isolated from frog skin) were custom synthesized by Bio-Synthesis 
(Lewisville, Texas). The company analyzed the peptide preparations by high 
performance liquid chromatography and mass spectrometry. The peptide purity 
ranged from 70 to 100% (the “impurities” consisted of the shorter peptides). The 
peptides were dissolved in sterile double-distilled (dd) water at 10 mg/ml; aliquots (0.1 
ml) were freeze-dried and stored at í20°C. For each experiment, the freeze-dried 
peptides were redissolved at 1 mg/ml in sterile dd water. 
Protease inhibitors 
Protease inhibitor cocktail (PIC) P-2714 was purchased from Sigma Chemical Co. (St. 
Louis, MO). It was prepared as a 10× solution by dissolving the powder in 10 ml of 
sterile dd water and stored at í20°C [1× PIC contains 2 mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride, 1 mM EDTA, 130 µM bestatin, 14 µM E-64, 1 µM leupeptin, 
and 0.3 µM aprotinin]. EDTA was from J.T. Baker Chemical Co. (Philipsburg, NJ); a 
0.2 M solution was prepared in sterile dd water. 
Saliva 
The collection and use of saliva samples were approved by the Institutional Review 
Board of the University at Buffalo. Unclarified saliva (unstimulated whole saliva) was 
collected from five healthy individuals after fasting. Clarified saliva (filter sterilized) 
was obtained by passing unclarified saliva through the 0.2-µm-pore-size sterile 
syringe filter (VWR Scientific Products, West Chester, PA). The subjects were asked 
to salivate into a sterile 50-ml container. Immediately after collection, each specimen 
was divided into three equal aliquots, which were processed as follows: (i) for 
saliva-PIC preparation, the aliquot was mixed 10:1 with 10× PIC; (ii) for saliva-EDTA, 
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the second aliquot was mixed with EDTA to give a final concentration of 1 mM; and (iii) 
for plain saliva, the third aliquot was stored at 4°C. Afterwards, all samples were 
placed in a í20°C freezer and stored for approximately 1 week before the analyses. 
Killing assays in saliva 
Candidacidal activity assays were performed as described previously [28], except the 
phosphate buffer was replaced by saliva. To determine the optimal concentration of 
peptide for candidacidal activity in saliva, 20 µl of twofold serial dilutions of peptides in 
saliva (to give final peptide concentrations of 25, 50, and 100 µM), saliva containing 
1× PIC, or saliva containing 1 mM EDTA was incubated in duplicate with an equal 
volume (20 µl) of fungal cell suspension (105 cells/ml) in PB. Saliva without the 
addition of any compound served as a control. After incubation at 37°C for 1.5 h, the 
reactions were diluted 20-fold in PB, and aliquots (50 µl, ~120 cells) of each sample 
were plated on SDA. The plates were incubated at 37°C for 1 day aerobically, and the 
number of CFU was counted. The percentage of killing was calculated as (1 í amount 
of viable cells in the test group/amount of viable cells in the control group) × 100%. 
Statistics  
Each value was determined from two independent experiments performed in 
duplicate. The Wilcoxon signed-rank test was performed by using SPSS software to 
compare the mean difference between PIC and non-PIC groups. The peptides are 
considered to have a statistically significant difference in candidacidal activity if P was 
<0.05. 
Stability of peptides in saliva and susceptibility of peptides to trypsin 
Three micrograms (in 3 µl) of each peptide in 0.2 M Tris-HCl buffer (pH 7.5) was 
incubated with 11 µl of 0.2-µg/ml trypsin or saliva. The reactions, without PIC or with 
1× PIC, were incubated for 0.5 h with trypsin or for 1 h with saliva at 37°C. For controls, 
each compound was incubated with Tris-HCl buffer in parallel. The samples were 
analyzed by sodium dodecyl sulfate-13% polyacrylamide gel electrophoresis 
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(SDS-13% PAGE). Gels were stained with Coomassie brilliant blue R-250 and further 
analyzed for peptide degradation with a GS-700 imaging densitometer (Bio-Rad). The 
degradation was estimated by the following equation: [1 í (density of test 
band/density of control band)] × 100%. 
Hemolytic assay 
Hemolysis of MUC7 12-mer-D and PIC was examined as described previously [29]. 
Amphotericin B and MUC7 12-mer-L were used as controls. 
Cell culture 
The HOK-16B cell line (originated from primary normal human keratinocytes) was 
kindly provided by No-Hee Park, UCLA School of Dentistry. The KB cell line was 
obtained from the American Type Culture Collection (CLL-17). Cells were maintained 
in keratinocyte growth medium (KGM; Clonetics, Cambrex, MD), which consists of 
keratinocyte basal medium (KBM-2) supplemented with KGM-2 SingleQuots. The 
cells were grown in an incubator at 37°C in an atmosphere of 5% CO2 and 95% air. 
MTS cell viability assay 
The toxic effect of the compounds on the cells was determined by calorimetric assay 
using a CellTiter 96 AQueous One Solution cell proliferation assay (MTS) kit (Promega, 
WI). MTS tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy- 
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] reduction is an indication of cell 
viability. Approximately 80% confluent cells were detached by treating with cell 
dissociate buffer and trypsin-EDTA solution. The cells were washed twice with trypsin 
neutralization solution (Clonetics) and resuspended in KGM at 2.5 × 105 cells/ml. An 
aliquot (50 µl) of the cell solution was incubated with an equal volume of peptides or 
agent (12.5 to 200 µM) in a 96-well plate at 37°C in a 5% CO2 atmosphere. After a 
1.5-h exposure, 20 µl of MTS agent was added to each well, and the cells were further 
incubated at 37°C in a 5% CO2 atmosphere for 4 h. Absorbance at 490 nm was then 
measured using a microplate reader. Wells without drugs were used for cell viability, 
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and wells without cells were used for blanking the spectrophotometer. Fifty percent 
inhibitory concentrations (IC50s) for each cell line were evaluated at a dose of drug 
causing 50% absorbance reduction in comparison to the untreated control cells. 
RESULTS 
Candidacidal activity of MUC7 and other peptides in saliva 
First we determined the candidacidal activities (using the C. albicans DIS isolate) of 
MUC7 12-mer-L and 12-mer-D and compared them to those of Hsn5 12-mer and 
magainin-II at three different concentrations (25, 50, and 100 µM) in clarified or 
unclarified whole human saliva. Saliva without peptides was used as a control. In a 
pilot experiment, neither Candida nor candidacidal activity was detected in saliva 
(data not shown). The results are shown in Fig. 1 (hatched bars in each panel). Higher 
peptide concentrations were required for killing activity in unclarified saliva (Fig. 1, 
right panels) than in clarified saliva (Fig. 1, left panels). Nevertheless, MUC7 peptides 
and in particular the d isomer showed significant anticandidal activity in saliva. More 
specifically, at a 100 µM concentration in clarified saliva, MUC7 12-mer-D exhibited 
94% activity (Fig. 1C), compared to 57% exhibited by MUC7 12-mer-L (Fig. 1A), 16% 
by Hsn5 12-mer (Fig. 1E), and 0% by magainin-II (Fig. 1G). In unclarified saliva, 
MUC7 12-mer-D and -L exhibited 64 and 32% activity, respectively, while Hsn5 
12-mer and magainin-II showed no activity (Fig. 1D, B, F, and H). Thus, MUC7 
12-mer-D was the most active peptide in both salivas. 
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Figure 1. Candidacidal activity of MUC7 12-mer-L, MUC7 12-mer-D, Hsn5 12-mer, and magainin-II in human 
whole saliva and saliva supplemented with PIC or EDTA.  Panels A, C, E, and G show results for clarified 
saliva (filter-sterilized saliva), while panels B, D, F, and H show results for unclarified saliva. Each peptide, at 
a final concentration of 25, 50, or 100 µM, was incubated with 20 µl of C. albicans (DIS isolate at 1 × 105 
cells/ml) and 20 µl of clarified or unclarified saliva (SL; hatched bars), saliva containing PIC (SL+PIC; filled 
bars), or saliva containing EDTA (SL+EDTA; clear bars) at 37°C for 1.5 h. At the end of incubation, the 
samples were diluted 20-fold and aliquots plated on SDA. The CFU were counted after 24 h of incubation. 
The loss of C. albicans viability was determined by the equation (1 í CFU of the test group/CFU of the control 
group) × 100%. The data represent three individual trials, and in each trial the sample was duplicated; the 
error bars represent standard deviation. 
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Candidacidal activity of peptides in saliva supplemented with PIC or EDTA 
First, the amount of PIC added to saliva was optimized so that the PIC alone had very 
little to no effect on C. albicans cell viability (data not shown). In the presence of PIC, 
the activities of peptides in saliva increased at each concentration compared to those 
without PIC (Fig. 1, filled bars). In terms of the PIC enhancement level, magainin-II 
activity was most enhanced, followed by Hsn5 12-mer and MUC7 12-mer-L. 
Surprisingly, MUC7 12-mer-D, a peptide theoretically not susceptible to protease 
degradation, also showed enhanced activity (Fig. 1C and D). A closer look at the 
composition of PIC revealed that it contains 1 mM EDTA, a metal-dependent protease 
inhibitor and/or divalent cation chelator. Since saliva contains divalent cations known 
to inhibit peptide antifungal activity [6], we postulated that EDTA alone might play an 
important role in the enhancement of peptide activity in saliva by chelating divalent 
cations. Experimental results demonstrated that addition of 1 mM EDTA to clarified 
saliva achieved, in most instances, enhancement of peptide activity similar to the 
addition of PIC (Fig. 1A, C, E, and G). In unclarified saliva, the activity of peptides in 
the presence of EDTA, with the exception of MUC7 12-mer-D, was lower than in the 
presence of PIC (Fig. 1B, D, F, and H). 
Peptide stability 
Stability was determined in trypsin and unclarified and clarified saliva, and 
degradation was monitored by SDS-PAGE (Fig. 2). As shown in Fig. 2A, MUC7 
12-mer-D was resistant to degradation by trypsin. The other three peptides, MUC7 
12-mer-L, Hsn5 12-mer, and magainin-II, were degraded by trypsin. Similarly, MUC7 
12-mer-D was resistant to degradation by unclarified saliva (Fig. 2B), and the other 
peptides were degraded by saliva, although to different degrees. Figure 2B is a 
representative of several gels using whole unclarified saliva from different donors 
(similar patterns of peptide degradation were seen). Degradation was determined 
quantitatively with a GS-700 imaging densitometer. The percentage of peptide 
remaining was then calculated, and the values are indicated at the bottom of each 
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lane (Fig. 2). In clarified saliva (results not shown), a much longer incubation time was 
needed to produce a similar but much less dramatic pattern of l-peptide degradation. 
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Figure 2. Stability of MUC7 12-mer-D (M7-D), MUC7 12-mer-L (M7-L), Hsn5 12-mer (H5), and magainin-II (M-II) in 
(A) trypsin and (B) unclarified saliva. Peptides were incubated with trypsin containing PIC or no PIC for 0.5 h or 
saliva (10 µl) for 1 h. The samples were analyzed by SDS-13% PAGE. After staining, the gel was analyzed for 
peptide degradation with a GS-700 imaging densitometer. The degradation was estimated by the equation [1 í 
(density of test band/density of control band)] × 100%. C, each peptide alone as a control; T, trypsin plus peptide; 
T+PIC, trypsin containing PIC plus peptide; S, saliva plus peptide; S+PIC, saliva containing PIC plus peptide. The 
most intense bands (the highest molecular mass) in the control (C) lanes represent full-length peptides, and the 
other bands (less intense) represent truncated peptides; for more detail, see the text. Densitometry data of control 
peptides and peptides remaining after incubation with trypsin or saliva are indicated at the bottom of each lane in 
each panel. 
Candidacidal activity of peptides in saliva from different subjects 
Figure 3 shows the outcome of killing assays performed in clarified whole human 
saliva samples from five subjects, using the peptides at a concentration of 50 µM. 
From 60 to 100% killing of C. albicans was observed in saliva containing PIC, while 
only 6 to 60% was observed in saliva without PIC. The difference is statistically 
significant (P < 0.05). 
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Figure 3. Candidacidal activity of peptides in saliva from different subjects and enhancement of activity by PIC. 
Whole human saliva from five healthy subjects was collected and clarified (filter sterilized). Peptides (at 50 µM) in 
20 µl of each individual saliva or saliva containing PIC were incubated with an equal volume of C. albicans cells 
(105 cells/ml in 10 mM sodium phosphate buffer, pH 7.4) at 37°C for 1.5 h. At the end of the incubation, the 
samples were diluted 20-fold and aliquots plated on SDA. Loss of cell viability was determined as described in the 
legend to Figure 1. Values represent the mean ± standard deviation (n = 5). P < 0.05 compared to those without 
PIC (Saliva). 
Activity of peptides in saliva against different Candida strains 
Candidacidal activities of the four peptides against four Candida strains in clarified 
saliva are shown in Table 1. The data are presented as the percent loss of cell viability 
compared to a control. With the exception of MUC7 12-mer-L against both strains of C. 
albicans, the L peptides exhibited low activity against all strains in saliva without PIC. 
MUC7 12-mer-D showed high activity against all strains, even in saliva without PIC 
(between 47 and 100%) and was very effective against both strains of C. glabrata 
(~100% killing). Hsn5 12-mer and magainin-II showed basically no activity against 
C.glabrata and C. krusei. 
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Table 1.  Loss of cell viability by exposure of Candida spp. to four individual peptides 
(50 µM) in clarified (filter-sterilized) saliva  
% Loss of cell viability 
MUC7 12-mer-D MUC7 12-mer-L Hsn5 12-mer Magainin-II Strain 
*PIC + *PIC - PIC + PIC - PIC + PIC - PIC + PIC - 
    
C.albicans 
ATCC96112 
100.0 
±0.0 
74.2 
±35.7
98.9 
±1.3 
79.9 
±31.2 
97.2 
±2.3 
19.1 
±29.9 
97.9 
±0.8 
7.2 
±5.3 
         
C.albicans 
DIS 
99.9 
±0.2 
73.8 
±10.5
91.0 
±13.7 
44.8 
±13.0 
64.6 
±10.7 
18.7 
±14.0 
94.4 
±3.8 
0.0 
±0.0 
         
C.glabrata 
ATCC90030 
99.8 
±0.3 
100.0 
±0.0 
94.2 
±0.3 
20.6 
±1.7 
30.6 
±15.6 
1.7 
±1.5 
99.1 
±0.8 
0.0 
±0.0 
         
C.glabrata 
65C 
100.0 
±0.0 
99.8 
±0.2 
96.4 
±1.3 
21.6 
±4.1 
40.6 
±12.4 
0.0 
±0.0 
99.8 
±0.3 
0.0 
±0.0 
         
C. krusei 
 
98.9 
±0.0 
47.2 
±8.8 
99.5 
±0.0 
17.6 
±13.5 
74.4 
±29.5 
0.0 
±0.0 
100 
±0.0 
0.0 
±0.0 
     
*PIC+ or PIC- indicates in the presence or absence of protease inhibitor cocktails. 
 
Peptide toxicity studies 
(i) Hemolytic activity. Hemolysis assays were performed in phosphate-buffered 
saline (PBS) (high-salt buffer, where the antifungal activity of peptides is masked by 
high ionic strength) and in isotonic glucose phosphate (IGP) buffer (a low-salt buffer 
supplemented with glucose for osmolarity, where the peptides are active). As 
indicated in Fig. 4, at the highest concentration tested (100 µM), MUC7 12-mer-D 
exhibited 3.5% hemolysis in PBS (Fig. 4A) and 36% hemolysis in IGP (Fig. 4B). These 
values are lower than those for MUC7 12-mer-L, which were 4.3% in PBS and 56% in 
IGP (29). Amphotericin B showed 100% hemolysis in both buffers. 
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Figure 4. Hemolysis caused by the antifungal agents 
amphotericin B (AMB, ), MUC7 12-mer-L (×), MUC7 
12-mer-D ( ), and PIC ( ). Human erythrocytes (final 
concentration, 0.5%) were incubated for 1 h at 37°C 
with a twofold dilution series of peptides in PBS or 
IGP buffer [29]. Hemolysis was determined by an 
absorbance reading of the supernatant at 450 nm and 
compared to hemolysis achieved with 1% Triton 
X-100 (reference for 100% hemolysis). Values 
represent the mean of results from two independent 
experiments, each of which was done in duplicate. 
 
 
 
 
 
(ii) Cytotoxic activity against oral epithelial cells. HOK-16B and KB cells were 
used for the toxicity studies of the four peptides. The results depicted in Figure 5 
indicate that all peptides showed very low toxicity or no toxicity to these cell lines at all 
concentrations tested. Specifically, at the 100 µM concentration (the highest 
concentration used for candidacidal killing assays), the peptides showed no toxicity to 
either cell line. At the highest concentration tested (200 µM), none of these peptides 
caused 50% cytotoxic effect (IC50) against either cell line, but magainin-II caused 
about 30% loss of HOK-16B cell viability and MUC7 12-mer-D caused about 10%. 
Amphotericin B exhibited a dose-dependent toxic activity against HOK-16B, and the 
IC50 was 100 µM (Figure 5A). 
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
Figure 5. Effect of peptides on viability of (A) 
HOK-16B cells and (B) KB cells. The toxic effect of 
the compounds on the cells was determined by 
calorimetric assay using a CellTiter 96 AQueous One 
Solution cell proliferation assay (MTS) kit, as 
described in the text. Briefly, the cells were grown to 
about 80% confluence, harvested, washed, 
resuspended in KGM, and dispensed into a 96-well 
microtiter plate. They were then exposed to different 
concentrations of peptides or amphotericin B at 37°C 
and 5% CO2 for 1.5 h. MTS agent was then added to 
each well, and the cells were further incubated for 4 h. 
Absorbance at 490 nm was then measured using a 
microplate reader. MTS reduction is an indication of 
cell viability. The viability is expressed as relative 
absorbance (percentage of no-agent control). Data 
represent the average and standard deviation of 
results from two independent experiments. 
 
DISCUSSION 
Previously, we determined the 50% effective doses (ED50s) for MUC7 12-mer-L, Hsn5 
12-mer, and magainin-II in 10 mM PB to be 2.1, 3.7, and 5.7 µM, respectively [28]. In 
this study, an ED50 of 2.6 µM was determined for MUC7 12-mer-D in PB (a value 
comparable to the L-isomer) (results not shown). Other studies also showed that L 
peptides exert remarkable antifungal activity in low-ionic-strength buffers or media [4, 
10, 20, 21, 27-29]. However, as shown by our results, the antifungal activities of the 
tested peptides were substantially decreased in saliva. In unclarified saliva, 25 µM 
concentrations of MUC7 12-mer-L and 12-mer-D were needed to achieve mean 
activities of 14 and 23%, respectively, and Hsn5 12-mer and magainin-II showed no 
activity even at 100 µM concentrations. Salivary proteases and ionic strength are at 
least two factors that may account for this decrease. Human whole saliva contains a 
number of proteolytic enzymes, mostly derived from white blood cells and microflora 
but some which are produced by the salivary glands [9, 16]. 
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PIC, which includes EDTA and has specificity for the inhibition of serine, cysteine, 
aspartic, and metalloproteases, enhanced antifungal activities of peptides in saliva 
and surprisingly also that of MUC7 12-mer-D, the peptide theoretically not susceptible 
to protease degradation. The use of EDTA alone facilitated determination of the roles 
of PIC and EDTA in this enhancement. The results suggest that in clarified saliva it is 
the EDTA content in the PIC that is responsible for the enhancement of MUC7 
12-mer-D activity by PIC (as well as that of L-peptides). EDTA serves a dual function; 
it not only inhibits metal-dependent proteases but also chelates divalent cations 
present in saliva known to inhibit peptide antifungal activity (see below). In unclarified 
saliva, the PIC plays a role in the L-peptide antifungal activity enhancement above 
that achievable by EDTA alone, through inhibition of all classes of proteases. 
Previous studies showed magainin-II [5] and histatins [22, 30] to be susceptible to 
degradation by proteolytic enzymes and histatins to be degraded by saliva; the latter 
is mediated mainly by trypsin-like enzyme activity. MUC7 12-mer, Hsn5 12-mer, and 
magainin-II contain large and almost equal numbers of lysine and arginine residues 
(targets of trypsin). Yet, compared to MUC7 12-mer-L, Hsn5 12-mer and magainin-II 
appear to be more sensitive to saliva degradation (Figure 2), which is consistent with 
their lower activity in saliva (Figure 1). These results indicate that other factors, such 
as other classes of proteases, may play a role in the degradation of different peptides 
by saliva. 
Ionic strength has also been demonstrated to be one of the important factors that 
affect the efficiency of antimicrobial peptides in the medium [17] and in saliva [14]. 
Both mono- and divalent ions exert inhibitory effects on some antimicrobial peptides. 
For example, increased amounts of Ca2+ and Mg2+ decreased the activity of MUC7 
20-mer [6] and histatin 5 [8]. K+, Na+, and Li+ exerted an inhibitory effect on peptide 
enterocin CRL35 [17]. A recent study [19] determined the mean concentration of total 
magnesium in saliva to be 0.22 mmol/liter and that of calcium to be 1.39 mmol/liter. 
EDTA added to saliva was apparently able to chelate these inhibitory ions. Regarding 
the effect of NaCl concentration on peptide antifungal activity, we have preliminary 
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evidence showing that MUC7 peptides are much less sensitive to NaCl than Hsn5 
12-mer and magainin-II. 
In conclusion, MUC7 12-mer-D exhibited activity comparable to MUC7 12-mer-L 
in PB, showed high candidacidal activity in clarified or unclarified saliva, and was 
resistant to salivary degradation. Meanwhile, the hemolysis and toxicity to oral 
epithelial cells caused by MUC7 12-mer-D was very low. The present study suggests 
that d amino acid substitution is a useful technique to improve the antifungal activity of 
MUC7 12-mer without increasing its toxicity. EDTA was very effective in the 
enhancement of antifungal activity of MUC7 12-mer-D in human saliva, suggesting 
that this combination may have a therapeutic potential for the treatment of oral 
candidal infections. For the L-peptides, the combination with PIC might be more 
effective because PIC contains inhibitors for all classes of proteases. 
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ABSTRACT 
Objectives: MUC7 12-mer (RKSYKCLHKRCR), a cationic peptide derived from 
human salivary MUC7 mucin, exhibits potent in vitro antifungal activity, as determined 
by killing assays in phosphate buffer. In this study we examined the MUC7 12-mer 
antifungal activity alone or in combination with other antifungal agents in LYM medium 
(modified RPMI 1640).  
Methods: Antifungal activities of MUC7 12-mer and other compounds against several 
fungal strains were first measured by MIC and minimum fungicidal concentration 
(MFC) tests using broth microdilution assay. The viability of Candida albicans and 
Cryptococcus neoformans were also determined by killing assays and time kinetics of 
peptide-mediated killing. Antifungal activities of MUC7 12-mer in combination with 
other compounds [histatin-5 (Hsn5) 12-mer: AKRHHGYKRKFH, amphotericin B or 
miconazole] against C. albicans and C. neoformans were determined by 
chequerboard assays and confirmed by killing assays. Toxicities of individual 
compounds were determined by haemolytic assays.  
Results: MICs and MFCs of MUC7 12-mer ranged from 3.13 to 6.25 mg/L for most of 
the strains tested, and were, in most cases, comparable to those of amphotericin B 
and miconazole (0.78–6.25 mg/L). ED50 values of MUC7 12-mer and Hsn5 12-mer 
were 7.1 and 7.4 µM (or 11.2 and 11.6 mg/L), respectively, for C. albicans; and 1.2 
and 1.1 µM (or 1.9 and 1.7 mg/L), respectively, for C. neoformans. The killing of C. 
albicans and C. neoformans was achieved after 30 and 10 min exposure to the 
peptides, respectively. Combinations of MUC7 12-mer and Hsn5 12-mer, and of 
MUC7 12-mer and miconazole have a synergic antifungal effect on C. neoformans, 
with a fractional inhibitory concentration index (FICI) of 0.37 and 0.25, respectively; 
and a slightly lower than synergic effect on C. albicans, with a FICI of 0.63 and 0.56, 
respectively. In addition, using human erythrocytes, the two salivary peptides showed 
low levels of haemolytic activity.  
Conclusions: This study suggests that MUC7 12-mer and Hsn5 12-mer peptides may 
be suitable candidates for use in combination antifungal therapy.  
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INTRODUCTION 
The incidence of fungal infection has escalated significantly and is expected to 
continue to increase for the foreseeable future because of the increase in the number 
of people whose immune system is compromised by AIDS, aging, organ 
transplantation, or cancer therapy [1-3]. The antifungal drugs for the treatment of 
fungal infections are limited and their application has become an increasing medical 
problem. Most of the current antifungal drugs, such as miconazole, simply reduce the 
growth of fungi. Amphotericin B, on the other hand, is a potent fungicidal agent, but its 
acute or chronic toxicities [4]  limit its clinical use. Reports of in situ or in bloodstream 
antifungal resistance are also becoming more common [5] . Thus, there is an urgent 
need to develop novel broad-spectrum antifungal agents with little or no toxicity [6]. 
Cationic antimicrobial peptides (CAMPs) have emerged as a promising new class of 
antibiotics [7]. However, there are some limitations of using CAMPs as therapeutic 
agents. These include sensitivity to high ionic strength, and susceptibility to proteolysis. 
Despite these shortcomings, several antimicrobial peptides with therapeutic potential 
have been developed [8]. Their application, due to their unique properties, has been, 
until recently, limited to a topical use. This may no longer necessarily be the case, 
since recent findings demonstrated that synthetic antimicrobial peptides can be 
designed to exert activities in complex biomatrices, including blood and blood 
fractionsy [9]. Also, it is important to keep in mind that the in vivo environment is rich in 
potentially synergic compounds. 
Histatins and mucins are two families of human salivary proteins that are 
important components of the innate host defence system. Ourselves and others have 
previously reported that histatins possess a significant in vitro antimicrobial activity, 
especially against fungi such as Candida, Cryptococcus neoformans and Aspergillus 
fumigatus [10-15]. The low molecular weight salivary mucin, MUC7, in its full-length 
form (357 amino acid residues) protects the oral cavity from microbial infections 
through more general protective mechanisms rather than the direct killing of 
microorganisms. However, recently, we have discovered that peptides derived from its 
N-terminal region have a significant and a broad-spectrum in vitro fungicidal and 
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bactericidal activity [16-18]. These properties, along with their low toxicity for human 
cells [19, 20], make these peptides promising candidates for the treatment of fungal 
infection as supplements to conventional antimycotics. 
The best antimicrobial treatment may involve drug combination therapy, using two 
or more drugs each of which has a separate mode of action and each of which results 
in a distinct mechanism of resistance. Antimicrobial agents in combination can, in 
certain cases, exhibit improved efficacy, reduce the development of resistant strains 
and side effects of some currently used antibiotics [21]. Achievement of synergy is 
one of the major theoretical justifications for combination therapy. Some in vitro 
studies show that antimicrobial peptides enhance the activity of antibiotics against 
bacteria [22] and of conventional antimycotics against fungi [23-26]. Recently, Lupetti 
et al. reported synergic activity of lactoferrin-derived peptide and fluconazole against 
Candida species [27], and van’t Hof et al. reported synergic activity of histatin-5 (Hsn5) 
and amphotericin B [23].  Yan & Hancock showed synergy between antimicrobial 
peptides [28]. However, to date, there has been no report on antifungal activity using 
combinations of salivary CAMPs. We have previously determined that MUC7 20-mer 
(amino acids 32–51 of the parent MUC7) is a potent agent against a broad range of 
microorganisms including fungi that are resistant to conventional antifungal drugs, and 
that it appears to work by a mechanism distinct from that of Hsn5 [18]. Further, we 
have shown that MUC7 12-mer, a 12-amino acid C-terminal fragment of MUC7 
20-mer (amino acids 40–51 of MUC7) not only retained but exceeded the antifungal 
activity of the 20-mer [29]. Its activity is also comparable to that of other CAMPs [14, 
30, 31]. Rothstein et al. reported that Hsn5 12-mer (P113), a 12 amino acid fragment 
of Hsn5, retains anticandidal activity comparable to that of the parent compound [14]. 
Based on the results of the above studies, we selected the MUC7 12-mer and Hsn5 
12-mer for this study where we aimed to examine the antifungal effect of combination 
of these two peptides, and of MUC7 12-mer with amphotericin B or miconazole 
against Candida albicans and C. neoformans.  
Chapter 6 
 123
MATERIALS AND METHODS  
Peptides and antimycotics  
Hsn5 12-mer (AKRHHGYKRKFH, amino acids 4–15 of the parent Hsn5) and MUC7 
12-mer (RKSYKCLHKRCR, amino acids 40–51 of the parent MUC7) were 
custom-synthesized by Bio-Synthesis (Lewisville, TX, USA). HPLC and mass 
spectrometry assays were carried out to analyse the purity of the peptides. The purity 
(80%) was taken into consideration in preparation of the stock solution of each peptide 
for antifungal assays. The peptides were dissolved in sterile double-distilled water at 1 
mg/mL; aliquots were freeze-dried and stored at –20°C. For each experiment, the 
freeze-dried peptides were re-dissolved at 1 mg/mL in sterile double-distilled water. 
Amphotericin B (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in dimethyl 
sulphoxide (DMSO) at 1 mg/mL. Miconazole (Sigma Chemical Co., St Louis, MO, 
USA) was dissolved in sterile double-distilled water at 0.1 mg/mL.  
Fungal strains and growth media  
C. albicans ATCC 96112, Candida glabrata ATCC 90030 and C. neoformans ATCC 
52817(capsular mutant), were purchased from ATCC. C. albicans DIS was kindly 
provided by M. Edgerton (Department of Oral Biology, State University of New York, 
Buffalo, NY, USA). C. albicans 12-99 was kindly provided by Theodore C. White 
(Department of Pathology, School of Public Health and Community Medicine, 
University of Washington, and Seattle Biomedical Research Institute, Seattle, WA, 
USA). C. albicans E81022 was kindly provided by K. Hata (Department of 
Microbiology and Infectious Disease, Tsukuba Research Laboratories, Eisai Co., Ltd., 
Tsukuba, Ibaraki 300–26, Japan). An azole-resistant clinical isolate of C. glabrata 65C 
was kindly provided by John E. Bennett, National Institute of Allergy and Infectious 
Diseases, Bethesda, MD, USA). A clinical isolate of Candida krusei was obtained from 
the Erie County Medical Center, Buffalo, NY, USA. Amphotericin B-sensitive (CN1, 
CN2 and CN3) and amphotericin B-resistant (CN2843 and CN2406) C. neoformans 
strains were obtained from AIDS patients with cryptococcal meningitis and were 
generously provided by John H. Rex (Division of Infectious Disease, Department of 
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Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, 
University of Texas Medical School, Houston, TX, USA). Saccharomyces cerevisiae 
strain S288C was kindly provided by D. Kosman (Department of Biochemistry, State 
University of New York, Buffalo, NY, USA). The fungal strains were stored at –80°C in 
glycerol. For each experiment, cells were cultured freshly from frozen stock on 
Sabouraud Dextrose Agar (SDA, Difco) for 24 h at 37°C, except for S. cerevisiae 
S288C, which was grown for 96 h at 30°C. To prepare fungal cell suspension 
(blastoconidia) for antifungal activity assays, one colony was picked from the plate 
and resuspended in LYM medium, and the concentration was adjusted to 1 x 105 
cells/mL.  
Antifungal susceptibility test  
MICs of MUC7 12-mer and other reference antifungal agents were determined by the 
broth microdilution method modified by Rothstein et al. [14] Briefly, two-fold serial 
dilutions of each peptide or antimycotics were prepared with modified RPMI 1640 
medium (LYM broth) [14], pH 7.0, at a volume of 200 µL per well in 96-well 
flat-bottomed microtitre plates (Costar, Cambridge, MA, USA). The final concentration 
of the antifungal agents ranged from 50 to 0.39 mg/L for MUC7 12-mer, Hsn5 12-mer, 
and amphotericin B, and 12.5 to 0.195 mg/L for miconazole. Each well of the microtitre 
plate was inoculated with fungal cell suspension to a final concentration of 1 x 104 
cells per mL and the plates were incubated at 37°C for 24–48 h. Afterwards, the 
absorbance was measured at 620 nm using a microplate reader (Model 3550, 
Bio-Rad, Japan) to assess the cell growth. The MIC endpoint was the lowest 
concentration of antifungal agent that completely inhibited growth or that produced at 
least 90% reduction in turbidity when compared with that of the drug-free control. The 
MIC value of two independent experiments was usually the same for a particular 
isolate; if not, a third test was required and the value from the majority of tests was 
reported. The minimal fungicidal concentration (MFC) was determined by the method 
used by Hong et al [25]. Briefly, an aliquot (100 µL) of cell suspension was taken from 
two wells above the MIC, centrifuged and washed three times with fresh LYM broth. 
Chapter 6 
 125
Then each cell suspension was plated on SDA plate, and the fungal cells were 
enumerated after incubation at 37°C for 48 h. The MFC was defined as the lowest 
concentration of the peptide in which no growth occurred.  
Chequerboard antifungal assay  
In one dimension of a 96-well microtitre plate, two-fold serial dilutions of amphotericin 
B, or miconazole, or Hsn5 12-mer in LYM were prepared in a volume of 100 µL per 
well, giving final concentrations from 3.13 to 0.03 mg/L, 10 to 0.16 mg/L, or 12.5 to 0.1 
mg/L, respectively. In the second dimension, a two-fold dilution series of MUC7 
12-mer in the same broth was added in a volume of 100 µL per well, giving a final 
concentration of MUC7 12-mer from 12.5 to 0.1 mg/L. Each well of the microtitre plate 
was inoculated with fungal cell suspension  [C. albicans (DIS) or C. neoformans 
(CN2)], to a final concentration of 1 x 104 cells per mL, and the plates were incubated 
at 37°C for 24–48 h. Afterwards, the absorbance was measured at 620 nm using a 
microplate reader. The lowest drug concentration that inhibited the growth of the 
fungal cells was used to determine the fractional inhibitory concentration (FIC), 
defined as the ratio of the MIC of a drug used in combination to the MIC of the drug 
tested lone. The FIC index (FICI, the sum of the FICs) was calculated for the most 
equally effective concentration of drugs [32]. According to the new policy of this 
journal, fractional inhibitory concentration index (FICI) values 0.5 are considered to 
indicate synergy; 0.5–4.0, no interaction; and >4, antagonism [33]. Each experiment 
was carried out in duplicate.  
Blastoconidia killing assay  
Killing assays were carried out essentially as described previously [18]. In brief, 20 µL 
of two-fold serial dilutions of peptides (50–1.56 µM in LYM) were incubated in 
duplicate with an equal volume (20 µL) of a C. albicans (DIS) or C. neoformans (CN2) 
suspension (1 x 105 cells/mL) in LYM medium. After incubation at 37°C for 1.5 h, the 
reactions were diluted 20-fold with 10 mM sodium phosphate buffer, pH 7.4, and 
aliquots (50 µL, or 120 cells) of each sample were plated on SDA. The plates were 
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incubated at 37°C for 1 or 2 days aerobically. The number of colony-forming units (cfu) 
was counted. Percentage of killing was calculated as:  [1 – (amount of viable cells in 
the test group/amount of viable cells in the control group)] x 100%.  
Killing activity in combination was carried out by exposure of the yeast cells to 
varying concentrations of MUC7 12-mer in LYM and a fixed concentration of the other 
agent. The concentrations of MUC7 12-mer used were based on ED50 and ED90 
values of the peptide; they were 6.26, 12.5 and 25 µM for C. albicans, and 0.78, 1.56 
and 3.13 µM for C. neoformans. Fixed concentrations of Hsn5 12-mer, amphotericin B 
or miconazole were: 7.5, 7.5 or 15 µM for C. albicans, and 0.78, 7.5 and 7.5 µM for C. 
neoformans, respectively. Untreated cells were used as control. Percentage of killing 
was calculated by the equation given above.  
Time–kill curves were determined by incubation of C. albicans (DIS) or C. 
neoformans (CN2) (20 µL of 1x105 cells/mL in LYM) with equal volumes of the 
peptides (in LYM) at three concentrations (10, 20 or 30 µM). At different time points (0, 
5, 15, 30, 45 and 90 min), samples were diluted 20-fold with 10 mM sodium phosphate 
buffer, pH 7.4, and cell viability was determined by plating on SDA.  
Haemolytic assay  
Human erythrocytes from healthy individuals were collected in vacuum tubes 
containing heparin (final concentration 20.4 U/mL) as anti-coagulant. The erythrocytes 
were harvested by centrifugation for 10 min at 2000 rpm at 20°C, and washed three 
times in PBS (10 mM sodium phosphate, pH 7.4, in 150 mM NaCl). To the pellet, PBS 
was added to yield a 10% (v/v) erythrocytes/PBS suspension. The 10% suspension 
was diluted 1:10 either in PBS or isotonic glucose phosphate buffer (IGP, 1 mM 
potassium phosphate buffer, pH 7.0, supplemented with 287 mM glucose as an 
osmoprotectant) [19], or LYM supplemented with 287 mM glucose as an 
osmoprotectant (LYMG). From each suspension, 100 µL was added in duplicate to 
100 µL of a two-fold dilution series of peptide in the same buffer in a 96-well 
V-bottomed microtitre plate (Dynatech Laboratories, Inc, Alexandria, VA, USA). Total 
haemolysis was achieved with 1% Triton X-100. The plates were incubated for 1 h at 
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37°C and then centrifuged for 10 min at 2000 r.p.m. at 20°C. From the supernatant 
fluid, 150 µL was transferred to a flat-bottomed low affinity microtitre plate (Corning, 
New York, USA), and the absorbance was measured at 450 nm using a microplate 
reader (Model 3550, Bio-Rad, Japan). The percentage of haemolysis was calculated 
by: [(A450 of the peptide-treated sample – A450 of buffer-treated sample)/(A450 of Triton 
X-100-treated sample – A450 of buffer-treated sample)] x 100%.  
Statistical analysis  
Each value was determined from at least two independent experiments carried out in 
duplicate. Statistical significance was evaluated by analysis of variance (ANOVA) 
followed by Tukey test. A P value of less than 0.05 was considered to be significant. 
Molar concentrations of peptides resulting in killing 50% or 90% of control cells (ED50 
or ED90) and corresponding 95% confidence limits were determined by PROBIT 
regression procedure in SPSS (SPSS software package 6.1.2 for Macintosh). 
RESULTS 
Fungal growth inhibitory activities of MUC7 12-mer and other compounds 
determined by broth microdilution assays  
Many antimicrobial peptides are sensitive to high ionic strength and thus their 
antimicrobial activity is usually determined by killing assays in low ionic strength 
buffers rather than by broth dilution assay commonly used for conventional 
antimicrobials [8, 14]. In order to measure the activity of Hsn5 and Hsn5-derived 
peptides in terms of MIC, Rothstein et al [14] developed a modified broth dilution 
susceptibility test. This broth, designated LYM, is a modified RPMI 1640 medium, 
which excludes excess of divalent cations and monovalent salt and includes a 
chelating agent and trace elements. In this study, we used this low ionic strength LYM 
medium for all susceptibility tests, including the killing assays, to determine the 
antifungal activity of MUC7 12-mer.  
The in vitro susceptibilities of the fungal strains to MUC7 12-mer, Hsn5 12-mer, 
amphotericin B and miconazole are shown in Table 1. The data are presented as MIC 
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and MFC of the peptide or drug concentrations required to inhibit (MIC) or kill 90% or 
greater (MFC) of the fungal strain tested. MUC7 12-mer and Hsn5 12-mer were active 
against the majority of selected stains, with MIC and MFC values ranging from 3.13 to 
6.25 mg/L, with the exception of C. glabrata ATCC 90030. In comparison, the MIC and 
MFC values for amphotericin B, and miconazole ranged from 0.78 to 6.25 mg/L. 
Interestingly, for C. krusei and C. neoformans 2406, the MICs and MFCs of the two 
peptides were 2–5-fold lower than those of amphotericin B. In addition, MFCs of 
MUC7 12-mer and Hsn5 12-mer for C. albicans ATCC 96112 were two- and four-fold 
lower, respectively, than those of miconazole.  
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Table 1.  MIC and MFC of antifungal peptides and conventional antimycotics 
MUC7 12-mer Hsn5 12-mer AmpB Miconazole 
Strainb 
MICa MFC MIC MFC MIC MFC MIC MFC 
C. albicans ATCC 96112  6.25 6.25 3.13 3.13 1.56 1.56 6.25 12.5 
C. albicans DIS  6.25 6.25 6.25 6.25 1.56 1.56 3.13 6.25 
C. albicans E81022   6.25 6.25 6.25 6.25 3.13 6.25 3.13 6.25 
C. albicans (Azole-R) 6.25 6.25 3.13 3.13 3.6 5.78 6.25 >12.5
C. glabrata ATCC 90030  25.0 50.0 25.0 25.0 3.13 6.25 3.13 6.25 
C. glabrata 65C (Azole-R) 6.25 6.25 6.25 6.25 6.25 6.25 1.25 12.5 
C. krusei 6.25 6.25 3.13 6.25 12.5 31.3 3.13 3.13 
C. neoformans CN1(AmpB-S)  6.25 6.25 3.13 3.13 1.56 3.13 0.78 3.13 
C. neoformans CN2(AmpB-S) 3.13 3.13 3.13 3.13 0.78 1.56 0.78 1.56 
C. neoformans CN3(AmpB-S)  6.25 6.25 3.13 6.25 6.25 6.25 1.56 3.13 
C. neoformans CSF(AmpB-S)  3.13 3.13 3.13 3.13 3.13 6.25 1.56 1.56 
C. neoformans 2406 (AmpB-R)  3.13 3.13 3.13 3.13 15.6 15.6 0.78 1.56 
C. neoformans 2483 (AmpB-R) 3.13 3.13 3.13 3.13 3.13 12.5 1.56 1.56 
C. neoformans ATCC 52817 6.25 6.25 6.25 6.25 1.56 1.56 1.56 1.56 
S. cerevisiae S288C   6.25 6.25 3.13 6.25 6.25 12.5 3.13 3.13 
a MIC and MFC (mg/L) were determined in accordance with the standard broth microdilution assay using 
modified RPMI 1640 broth.14  The values represent the majority of three independent tests. 
b Azole-R and AmpB-R: azole and amphotericin B resistant strains; AmpB-S: amphotericin B susceptible strains. 
Growth inhibitory activities of MUC7 12-mer and Hsn5 12-mer using killing 
assay  
Because MUC7 12-mer showed antifungal activity in LYM medium using broth 
microdilution assay, next we determined how MUC7 12-mer (and Hsn5 12-mer) 
fungicidal activities in LYM media compared to those in phosphate buffer. Table 2 
shows the ED50 and ED90 values (and their 95% confidence limits) of these peptides 
against C. albicans and C. neoformans. In order to compare these values with the MIC 
values shown in Table 1, they are expressed in both µM and mg/L. The results 
indicate that killing activities of both peptides in LYM are retained, but in comparison to 
those in 10 mM sodium phosphate buffer, pH 7.4 (determined previously) [29] they are 
somewhat lower for C. albicans but comparable for C. neoformans. In general, the 
fungicidal assays showed that the ED50 or ED90 values for C. neoformans were lower 
than those for C. albicans in LYM. For comparison, in the phosphate buffer, ED50 
values for C. albicans were: MUC7 12-mer, 2.68 (2.04–3.35) µM, Hsn5 12-mer, 3.68 
Synergic antifungal effect of MUC7 12-mer 
 130 
(2.66–4.84) µM; and for C. neoformans: MUC7 12-mer, 1.75 (0.46–2.68) µM, and 
Hsn5 12-mer, 2.55 (0.48–4.45) µM.  
 
Table 2.  ED50 and ED90 of two antimicrobial peptides against two fungal strains 
ED50  
(95% confidence limit) 
ED90 
(95% confidence limit) 
Strain Agent 
(mg/L) (µM) (mg/L) (µM) 
C. albicans DIS: 
 MUC7 12-mer 11.2 (9.1-13.6) 7.1 (5.8-8.6) 45.5 (34.2-67.5) 28.8 (21.7-42.8) 
 Hsn5 12-mer 11.6 (7.9-17.0) 7.4 (5.0-10.8) 70.8 (41.1-192.6) 45.2 (26.2-122.8) 
C. neoformans CN2: 
 MUC7 12-mer 1.9 (0.2-3.6) 1.2 (0.2-2.3) 4.5 (2.5-156) 2.9 (1.6-99.2) 
 Hsn5 12-mer 1.7 (1.1-2.1) 1.1 (0.7-1.4) 4.7 (3.4-8.8) 3.0 (2.2-5.6) 
 
The fungicidal assay of two peptides was performed in LYM, a modified RPMI 1640 broth.14  ED50 or ED90 is the 
minimum Effective Dose required to kill 50% or 90% of the test fungal cells for a given sample.  ED50 or ED90 and 
95% confidence limit were calculated from three independent experiments, each of which was done in duplicated 
as described in Materials and Methods.  
Time killing assays  
Time–kill experiments, carried out with three different concentrations of peptides (10, 
20 and 30 µM), indicated differences in killing rate between Hsn5 12-mer and MUC7 
12-mer, as well as between C. albicans and C. neoformans (Figure 1). At a 
concentration of 30 µM, 90 min of incubation with Hsn5 12-mer was needed to reach 
more than 90% killing of C. albicans, whereas MUC7 12-mer achieved 95% killing 
within 45 min at this concentration. Both MUC7 12-mer and Hsn5 12-mer killed C. 
neoformans much faster than C. albicans. At concentrations of 30 µM, both peptides 
needed only 5 min to achieve complete killing for C. neoformans, whereas for C. 
albicans this was only accomplished after 45 min. However, at equally potent 
concentrations of the two peptides, MUC7 12-mer and Hsn5 12-mer showed similar 
rates of killing for both fungi (Figure 2).  
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Figure 1. Time kinetics of MUC7 12-mer and Hsn5 12-mer mediated killing at equal molar concentrations. C. 
albicans or C. neoformans cells (20 µL of 1 x 105 cells/mL in LYM) were incubated with an equal volume (20 µL) of 
peptide dilutions; 10 µM (filled diamonds), 20 µM (open squares), and 30 µM (open triangles) in LYM at 37°C. At 
indicated time points (0, 5, 15, 30, 45 and 90 min), samples were diluted 20-fold with phosphate buffer and cell 
viability was determined by plating on SDA. Values represent the mean of three independent experiments, each of 
which was done in duplicate. 
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Figure 2. Time kinetics of 
MUC7 12-mer (filled squares) 
and Hsn5 12-mer (open 
diamonds) mediated killing 
of C. albicans and C. 
neoformans at equally 
potent concentrations. ED90 
concentrations, or amount of 
peptide required for killing 
90% cells, were used. The 
assays were carried out as 
described in the legend to 
Figure 1. 
 
 
 
 
 
 
Growth inhibitory activities of the combination of compounds using 
chequerboard assay  
A two-dimensional chequerboard assay was used first to characterize interactions 
between MUC7 12-mer and other agents. In this method, one is looking for a 
reduction in the MIC of each compound in the presence of the other. The results are 
expressed in fractional inhibitory concentration index (FICI). Compared to the MICs 
obtained when each compound was used alone, MICs were substantially reduced, 
although to a variable extent, when the compounds were used in combinations. As 
shown in Table 3, the combination of MUC7 12-mer with Hsn5 12-mer appeared to 
have strong synergic effect on the growth of C. neoformans (FICI 0.37); MUC7 12-mer 
at 1/4 MIC promoted the activity of Hsn5 12-mer by decreasing the MIC of Hsn5 
12-mer by eight-fold. A strong synergic effect on the growth of C. neoformans (FICI 
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0.25) was also found when MUC7 12-mer was combined with miconazole; the MICs of 
the two agents in combination were eight-fold lower than the MICs of each agent alone. 
‘No interaction’ (according to the new standard of this journal) on growth of either 
fungus was found when MUC7 12-mer was combined with amphotericin B (FICI 0.75). 
In general, C. albicans showed lower susceptibility to the tested compounds than C. 
neoformans. ‘No interaction’ was found when MUC7 12-mer was used in combination 
with Hsn5 12-mer, amphotericin B, or miconazole (FICI 0.63, 0.75 or 0.56, 
respectively). Yet, the addition of MUC7 12-mer at 1/2 MIC led to a decrease in the 
MIC of amphotericin B by four-fold, of Hsn5 12-mer by eight-fold, and of miconazole 
by 16-fold. No antagonism was found with any combination of compounds used.  
 
Table 3. Interaction of MUC7 12-mer in combination with Hsn5 12-mer, 
amphotericin B, and miconazole against two fungal strains determined by 
chequerboard assay 
MIC (mg/L) Strain Combo 
Alone Combined 
FIC a  FICI b 
      
C. albicans DIS MUC7 12-mer 6.25 3.13 0.50  
 Hsn5 12-mer 6.25 0.78 0.12 0.63 
      
 MUC7 12-mer 6.25 3.13 0.50  
 Amphotericin B 1.56 0.39 0.25 0.75 
      
 MUC7 12-mer 6.25 3.13 0.50  
 Miconazole 2.5 0.16 0.06 0.56 
      
C. neoformans CN2 MUC7 12-mer 3.13 0.78 0.25  
 Hsn5 12-mer 3.13 0.39 0.12 0.37 
      
 MUC7 12-mer 3.13 1.56 0.50  
 Amphotericin B 0.78 0.20 0.25 0.75 
      
 MUC7 12-mer 3.13 0.39 0.13  
 Miconazole 1.25 0.16 0.13 0.25 
      
a FIC (Fractional Inhibitory Concentration) was defined as the ratio of the MIC of an agent used in combination 
to the MIC of the agent tested alone. The values represent the majority of three independent tests. 
b FICI (FIC index) was calculated from summing the FIC of each agent.  
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Growth inhibitory activities of MUC7 12-mer in combination with other 
antifungal agents using fungicidal assay  
Recently, there have been some concerns that the FIC values determined by 
chequerboard assay are inherently prone to inaccuracies due to the possibility of 
partial inhibitory effects of the antimicrobial agents used individually. Thus, it is 
important to strengthen the data by combination killing assay. The effects of the MUC7 
12-mer alone and in the combination with Hsn5 12-mer, amphotericin B, or 
miconazole on the killing of C. albicans or C. neoformans are shown in Figure 3. 
However, in this assay, the concentration of only one agent can be varied (by serial 
dilution), while the concentration of the other is fixed (in contrast to the chequerboard 
assay, where there are serial dilutions of both agents). Compared to MUC7 12-mer 
alone, an enhanced effect on the loss of C. albicans viability was observed when 
MUC7 12-mer (at 12.5, and 6.25 µM) was combined with Hsn5 12-mer at 7.5 µM, or 
miconazole at 15 µM. The addition of amphotericin B at 7.5 µM had only a slightly 
increased effect on the activity of MUC7 12-mer at 12.5 µM concentration. A 
significant enhancement (P < 0.05) of activity of MUC7 12-mer was also found in 
killing of C. neoformans when MUC7 12-mer at 0.78 µM was combined with 0.78 µM 
of Hsn5 12-mer or 7.5 µM of miconazole. MUC7 12-mer induced a significant increase 
(P < 0.05) in the activity of the second agent (Hsn5 12-mer, amphotericin B, or 
miconazole) against both C. albicans and C. neoformans, compared to those of each 
second agent alone. The enhancement of MUC7 12-mer appeared to be 
concentration-dependent. Overall, these results showed consistency with those 
obtained in chequerboard assay.  
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Figure 3. Effect of MUC7 12-mer alone 
and in combination (combo) with other 
antifungals on the viability of C. albicans 
and C. neoformans determined by killing 
assays in LYM medium. (a) Effect on 
C.albicans. Cells were incubated with 
two-fold serial dilutions of MUC7 12-mer 
(25–6.25 µM) or with the same serial 
dilutions of MUC7 peptide in combination 
with a fixed concentration of the other 
antifungal agents: Hsn5 12-mer at 7.5 µM, 
amphotericin B (AmpB) at 7.5 µM, 
miconazole (MCZ) at 15 µM. The same 
fixed concentrations of these three other 
agents were also used alone and their 
killing activities are shown in the left-most 
panels of columns with zero concentration 
of MUC7 12-mer.     (b) Effect on C. 
neoformans. Cells were incubated with 
two-fold serial dilutions of MUC7 12-mer 
(3.13–0.78 µM) or with the two-fold serial 
dilutions of MUC7 peptide in combination 
with a fixed concentration of the other 
antifungal: Hsn5 12-mer at 0.78 µM, 
AmpB at 7.5 µM or MCZ at 7.5 µM. The 
same concentrations of these three other 
agents were also used alone and their 
killing activities are shown in the left-most 
panels of columns with zero concentration 
of MUC7 12-mer. In both (a) and (b), 
values are expressed as mean ± S.D. of 
three independent experiments, each of 
which was done in duplicate. MUC7 
12-mer alone (open bar); Hsn5 12-mer 
alone or in combination with MUC7 
12-mer (solid bar), Amp B alone or in 
combination with MUC7 12-mer (dotted bar), MCZ alone or in combination with MUC7 12-mer (hatched bar). 
*Significant difference (P < 0.05) compared with results obtained in the absence of MUC7 12-mer. ¶Significant 
difference (P < 0.05) compared with results obtained with C. neoformans exposed to MUC7 12-mer alone at 0.78 
µM. 
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Haemolytic activity  
Since human erythrocytes are readily available, and their lysis is easy to monitor by 
measuring the release of haemoglobin, the haemolytic activity of antifungal agents is 
usually used as an indication for measuring their cytotoxicity. Effects of MUC7 12-mer, 
Hsn5 12-mer, magainin II, amphotericin B and miconazole on human red blood cells 
are shown in Figure 4. Haemolysis assays were carried out under the following 
conditions: PBS, where the peptide antifungal activity is decreased and haemolysis 
masked due to high salt concentration, in IGP buffer (isotonic glucose phosphate 
buffer containing 287 mM glucose) and LYMG medium (modified, low salt RPMI 1640 
medium, supplemented with 287 mM glucose). In IGP and LYMG, the peptide activity 
is retained and sugar provides osmotic stabilization in place of salt. Generally, the 
haemolysis of each test agent except amphotericin B was higher in IGP and LYMG 
than those in PBS (the test agents except amphotericin B did not exhibit remarkable 
haemolysis in PBS). At the highest concentration tested in this study (100 µM), 
conventional antifungal therapeutic agent amphotericin B exerted 100% haemolysis in 
all test media; and miconazole 98% and 44% in IGP and LYMG, respectively. MUC7 
12-mer caused 4.3%, 56% and 35% haemolysis in PBS, IGP and LYMG, respectively. 
Compared to MUC7 12-mer, Hsn5 12-mer exerted less haemolysis (1%, 41%, 16%, 
respectively), whereas magainin, a membrane-active antimicrobial peptide, caused 
more haemolysis than MUC7 12-mer (92% in IGP and 65% in LYMG). This indicates 
that the two salivary peptides tested in this study show low cytotoxic activity.  
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Figure 4. Haemolysis caused by different antifungal agents: MUC7 12-mer (filled squares), Hsn5 12-mer 
(diamonds), magainin II (crosses), miconazole (circles) and amphotericin B (open triangles). Human red blood 
cells (final concentration 0.5%) were incubated for 1 h at 37°C with a two-fold dilution series of peptides. 
Haemolysis was determined by an absorbance reading of the supernatant at 450 nm and compared to haemolysis 
achieved with 1% Triton X-100 (reference for 100% haemolysis). Values represent the mean of three independent 
experiments, each of which was done in duplicate. PBS, phosphate buffered saline; IGP, 1 mM potassium 
phosphate buffer, pH 7.0, supplemented with 287 mM glucose as an osmoprotectant; LYMG, LYM medium 
supplemented with 287 mM glucose as an osmoprotectant. 
DISCUSSION 
The search for novel antibacterial agents and the attempt to modify and improve the 
features of the currently available chemotherapeutic agents are in high demand as a 
consequence of the rapid spread of multidrug-resistant fungal pathogens. In this 
regard, naturally occurring antimicrobial peptides are an attractive option. In order to 
lower the cost of antimicrobial peptides, it is of significance to minimize fragment 
length to the length that preserves or even exceeds the antimicrobial activity of the 
parent molecule [34, 35]. The compact size of MUC7 12-mer reduces the cost of 
chemical synthesis. The activity of MUC7 12-mer is comparable to Hsn5 12-mer and 
conventional antimycotics used in this study, in both MIC tests (Table 1) and killing 
assays (Table 2). MUC7 12-mer has a very favourable spectrum of activity against the 
pathogens responsible for oral candidiasis and cryptococcal meningitis, including 
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strains resistant to amphotericin B and miconazole (Table 1). Unlike fungistatic 
antimycotics, MUC7 12-mer is a fungicidal peptide since MIC values were equal to the 
MFC. C. glabrata ATCC 90030 was not as sensitive to either peptide as the other 
tested strains, but was as sensitive to antimycotics amphotericin B and miconazole as 
the other strains (Table 1), suggesting that the peptide mode of action is different from 
that of conventional antimycotics.  
In vitro time–kill assays demonstrated that, similar to the assays carried out in 
phosphate buffer, in LYM medium both MUC7 12-mer and Hsn5 12-mer exhibit 
concentration-dependent fungicidal activity. This is also consistent with the activity of 
other antifungal peptides [31, 36, 37]. The killing rate of Hsn5 12-mer in this study 
agreed with that of full-length Hsn5 molecule (24-mer) [38]. However, to date no 
comparison of the killing rate of the two peptides at equal potent concentrations has 
been reported. This study showed that at the same molar concentrations the killing 
rate of MUC7 12-mer appeared to be faster than that of Hsn5 12-mer. However, when 
compared at equally potent concentrations, the killing rate was almost the same.  
In this study, we also found both MUC7 12-mer and Hsn5 12-mer to kill C. 
neoformans faster than C. albicans. This, in agreement with previous studies, 
suggests that C. neoformans is more susceptible than C. albicans to these peptides. 
Electrostatic interactions between the CAMP and anionic microbial surface has been 
proposed as one of the important processes in the mode of CAMP action [39, 40]. C. 
neoformans is an encapsulated yeast with a highly negatively charged surface due to 
its polysaccharide capsule and melanin [41]; this may favour the association with 
MUC7 12-mer or Hsn5 12-mer, of cationic peptides with the net positive charge of 6 
and 5, respectively.  
Combination regimens exhibiting synergy could provide additional options for 
treating fungal infections. As pointed out in the Introduction, a combination of 
antimicrobial peptides with conventional antimycotics has been investigated by other 
researchers [23-27, 42]. Antifungal activity of amphotericin B was enhanced by Hsn5 
[23] and pneumocandin (a cyclic hexapeptide) derivatives [24]. A promoted antifungal 
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activity was found in the combination of a membrane-active peptide (MP 11-mer) with 
fluconazole [25] and the combination of lactoferrin peptide (LF 9-mer) with miconazole. 
[26], In agreement with these reports, MUC7 12-mer also showed enhancement of 
antifungal activity when combined with amphotericin B, or miconazole. Significantly, 
the combination of MUC7 12-mer with miconazole showed a synergic effect (FICI 0.25) 
against C. neoformans (Table 3), and promoted antifungal activity (FICI 0.56) against 
C. albicans (however, no synergic effect was found). Moreover, in this study, we 
showed for the first time that the combination of two salivary antimicrobial peptides, 
MUC7 12-mer and Hsn5 12-mer, exhibits synergic activity against C. neoformans. 
These findings may have substantial significance for combination therapy. Beneficial 
effects of combination therapy may be slowing down the development of 
drug-resistant subpopulations of pathogenic organism [32] and a reduction in the 
adverse effects.  
Generally, the synergic effects of two agents can result from the combination of 
two different mechanisms of action. We found synergy between miconazole and 
MUC7 12-mer. Miconazole is one of the azole-based antifungal therapeutic agents. 
Azole antifungals inhibit the formation of ergosterol (the major component of fungal 
cell membrane) via inhibition of enzyme(s) involved in ergosterol biosynthesis. The 
peptides exert their effect through different mechanisms of action. Our recent study 
demonstrated that even two salivary molecule-derived peptides, MUC7 20-mer and 
full-length Hsn5 appear to work by distinct mechanisms. MUC7 20-mer fungicidal 
activity, unlike that of Hsn5 [43], does not require an active cell metabolic state [18]. 
MUC7 20-mer was able to cross the fungal cell membrane and to accumulate inside 
the cells but unlike Hsn5 and C. albicans [43], mitochondria are not the targets of 
MUC7 20-mer for both C. albicans and C. neoformans [18].  The internalization of 
MUC7 20-mer, unlike Hsn5, was not inhibited by low temperature, sodium azide or 
carbonyl cyanide m-chlorophenylhydrazone (CCCP), an uncoupler of cellular 
respiration [18].  Based on the above studies on the mechanism of action of the 
full-length Hsn-5 and MUC7 20-mer [18, 20, 44], we speculate that the synergic effect 
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between MUC7 12-mer and Hsn5 12-mer may be the result of two different 
mechanisms of action by these two peptides.  
Haemolytic effect is believed to be one of the adverse effects of some cationic 
antimicrobial peptides such as magainin, protegrin, mellitin, defensin and cecropin[45]. 
Most cationic antimicrobial peptides (CAMPs) do not show haemolysis in PBS 
(physiological conditions) partly because of the protection by high ionic strength [19]. 
Some CAMPs, however, still show haemolysis when examined under physiological 
conditions [46]. Compared with amphotericin B, MUC7 12-mer and Hsn5 12-mer 
showed almost no haemolytic activity against human erythrocytes in PBS (at peptide 
concentrations up to 100 µM; Figure 4). In the assays conducted in low ionic strength 
isotonic glucose phosphate buffer (IGP) or a low ionic strength broth (LYM, 
supplemented with glucose), the haemolysis caused by the peptides increased. 
However, MUC7 12-mer and Hsn5 12-mer still showed lower haemolysis than 
magainin and the two classical antifungal therapeutic agents. These results indicate 
that these peptides are not toxic to mammalian cells under physiological conditions.  
In summary, this study shows that MUC7 12-mer and Hsn5 12-mer have many 
potential advantages as candidates for antifungal agents. First, MUC7 12-mer and 
Hsn5 12-mer show fungicidal activity against pathogenic and resistant fungi and a fast 
killing rate but low cytotoxicity for mammalian cells (based on haemolytic assays 
carried out both in PBS, and low ionic strength buffer and medium). Second, the 
combination of MUC7 12-mer with miconazole shows a synergic effect (FICI 0.25) 
against C. neoformans and an enhanced antifungal activity (FICI 0.56) against C. 
albicans. Finally, combination of MUC7 12-mer and Hsn5 12-mer exhibits synergic 
activity against C. neoformans. On the basis of these results, we suggest that these 
peptides can be attractive and novel candidates for development into effective and 
safe antimicrobial therapeutic agents for topical and possibly systemic applications.  
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ABSTRACT 
Objectives: To investigate the susceptibility of selected bacteria as well as 
Streptococcus mutans biofilm to MUC7 peptides and compare the activities with those 
of other known antimicrobial peptides.  
Methods: MIC and MBC of peptides for S. mutans, Escherichia coli, Streptococcus 
gordonii, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis and 
Pseudomonas aeruginosa were determined using the microdilution method. For S. 
mutans, the effects of the peptides on the kinetics of growth inhibition, time-killing, and 
on biofilm formation and reduction were also examined. For biofilm studies, 
polystyrene microtitre plates, Calgary Biofilm Device (CBD) and hydroxylapatite (HA) 
discs, along with Crystal Violet and Alamar Blue dyes, and/or EM observations, were 
employed.  
Results: S. mutans was the most susceptible to all peptides tested (MICs of 9.4–25.0 
µM), compared with the other species (MICs of 3.1–>100 µM). MUC7 peptides (except 
MUC7-12-mer-L4) exerted 2-fold higher activity against S. mutans than Hsn5-12-mer 
and magainin-II, and faster killing of S. mutans than Hsn5-12-mer. The MUC7 
peptides also had an effect on S. mutans biofilm. On the polystyrene plates, they 
suppressed the biofilm formation, with MBIC50 of 6.25–12.5 µM, and reduced the 1 
day developed biofilm in a batch culture, with MBRC50 of 25–50 µM. On the CBD pegs, 
the viabilities of the biofilm were suppressed by >95% in the presence of MUC7 
peptides at 4x MIC (50 µM). One day developed biofilm viabilities were inhibited by 
49–75%. On HA, the formation of biofilm (as observed by EM) was also considerably 
reduced.  
Conclusions: MUC7 peptides present somewhat preferential antimicrobial activity 
against S. mutans. They also have an effect on in vitro formation and reduction of the 
preformed S. mutans biofilm. 
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INTRODUCTION 
Dental caries and periodontitis are common oral diseases. Streptococcus mutans is 
the main pathogenic agent of dental caries, and Porphyromonas gingivalis and 
Actinobacillus actinomycetemcomitans are the bacteria associated with periodontitis. 
There is a great interest in the use of antimicrobial agents for the prevention and 
treatment of caries and periodontitis. The prevention of dental caries and periodontal 
disease requires the control of these pathogens that exist in an oral biofilm know as 
dental plaque. Chlorhexidine is a potent antiplaque chemical agent. However, its 
clinical application is limited because it has a bitter taste and can cause teeth to stain 
on frequent use. Thus, it is important to develop alternative antiplaque agents from 
natural sources that exhibit few or no side-effects. Cationic antimicrobial peptides 
(CAMPs) have appeared as a promising novel group of antibiotics[1].  
Histatins and mucins are two families of human salivary proteins that are the 
components of the innate immunity, a first-line of the host defence system against 
pathogens. Histatins and histatin-derived peptides have been shown to possess a 
significant in vitro antimicrobial activity against fungi[2-6], bacteria[7-11] and bacterial 
biofilms[12]. MUC7, the low molecular mass human salivary mucin (357 amino acid 
residues), protects the oral cavity from microbial infections through more general 
protective mechanisms (such as binding to and clearance of various 
microorganisms)[13] rather than the direct killing of microorganisms. Our previous 
studies showed that the peptides derived from the N-terminal region of MUC7, 
including MUC7 51-mer, MUC7 20-mer and MUC7 12-mer, cationic peptides with a 
positive charge of 8, 7 and 6 respectively, have a significant fungicidal activity in 
vitro.[14-17] MUC7 12-mer possesses antifungal activity in low salt RPMI 1640 
medium and also exhibits synergic antifungal effects in vitro with histatin-5 12-mer 
(Hsn5 12-mer) or with miconazole[18]. Our most recent study showed that the 
antifungal activity of MUC7 12-mer-L in human whole saliva was enhanced in the 
presence of protease inhibitors and EDTA, and MUC7 12-mer-D isomer exerted 
higher antifungal activity than MUC7 12-mer-L in human whole saliva[19]. 
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To date, however, information on antibacterial activity of the MUC7 peptides is 
limited. In one of our earlier studies we demonstrated, by an in vitro killing assay, that 
MUC7 20-mer exerts antibacterial activity[14]. In the present study, we have further 
investigated the susceptibility of selected bacteria to MUC7 12-mer-L, MUC7 
12-mer-D and MUC7 20-mer, using a broth microdilution assay method. To examine 
the potential of MUC7 and other antimicrobial peptides as therapeutic agents to 
control the oral biofilm in vivo, we also examined the effect of these peptides on the 
formation and reduction of S. mutans biofilm. For these experiments we employed 
polystyrene microtitre plates as a primary substratum and Calgary Biofilm Device 
(CBD) and hydroxylapatite (HA) discs as supplementary substrata.  
MATERIALS AND METHODS  
Peptides and chemicals  
MUC7 12-mer-L (RKSYKCLHKRCR, amino acids 40–51 of the parent human salivary 
mucin, MUC7), MUC7 12-mer-L4 (RKSYKALHKRAR, the two C residues substituted 
with A), MUC7-12-mer-D (D-amino-acid-isomer), MUC7-20-mer (LAHQKPFIRKSYKC 
LHKRCR, amino acids 32–51 of the parent human salivary mucin, MUC7), Hsn5 
12-mer (AKRHHGYKRKFH, amino acids 4–15 of the parent Hsn5, also known as 
P113)[20] and magainin-II (GIGKFLHSAKKFGKAFVGEIMNS, a 24 amino acid 
peptide from frog skin) were custom-synthesized by Bio-Synthesis (Lewisville, Texas). 
The company analysed the prepared peptides by HPLC and mass spectrometry. The 
purity (>70%) was taken into consideration in preparing the stock solution of each 
peptide for antibacterial assays. The peptides were dissolved in sterile de-mineralized 
water at 1 mg/mL; aliquots were freeze-dried and stored at –20°C. For each 
experiment, the freeze-dried peptides were re-dissolved at 1 mg/mL in sterile dd-water. 
Chlorhexidine digluconate solution (Sigma Chemical Co., St Louis, MO, USA) was 
diluted to 0.04 mg/mL with sterile dd-water.  
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Bacterial strains and growth media  
The bacteria used in this study included S. mutans ATCC10449, S. mutans AU 159, S. 
mutans GS-5, S. mutans GS-5 mutant (ǻgtf BCD), Streptococcus gordonii Challis, P. 
gingivalis W50, P. gingivalis 381, A. actinomycetemcomitans NCTC 9710, 
Pseudomonas aeruginosa ATCC 17648 and Escherichia coli HB101. The strains were 
kindly provided by Kuramitsu's lab, the Department of Oral Biology, University at 
Buffalo. One-quarter strength (25%) of brain–heart infusion broth (BHI; DIFCO 
Laboratories, Detroit, MI, USA) was used for the growth of S. mutans, S. gordonii, A. 
actinomycetemcomitans, P. aeruginosa and E. coli. BHIS (25% BHI supplemented 
with 2% sucrose) was used for the growth of S. mutans biofilm. For the growth of P. 
gingivalis, tryptic soy broth-yeast extract medium (TSBY; DIFCO Laboratories) 
supplemented with cysteine hydrochloride (0.05%), menadione (0.02 µg/mL), haemin 
(5 µg/mL) and potassium nitrate (0.02%) was used. All bacteria were cultured at 37°C; 
P. aeruginosa and E. coli were grown aerobically and the other bacteria anaerobically. 
To prepare bacterial cell suspension for antibacterial activity assays, each overnight 
culture was harvested by centrifugation (3783 g, 10 min), washed once with 10 mM 
sodium phosphate-buffered saline (PBS, pH 7.2), resuspended in PBS and adjusted 
to a concentration of 1 x 106 cells/mL.  
Bacterial susceptibility assay  
MICs of the peptides were determined using the broth microdilution method as 
described previously[18]. Briefly, 2-fold serial dilutions of each peptide were prepared 
with 25% BHI medium at a volume of 200 µL per well in 96-well flat-bottom microtitre 
plates (Costar, Cambridge, MA, USA). The final concentrations of each peptide 
ranged from 0.78 to 100 µM, and that of chlorhexidine, used as a positive control, from 
0.16 to 20 µM (0.078–10 mg/L). The microtitre plate wells were inoculated with 20 µL 
per well of bacterial cell suspension, at a final concentration of 5 x 106 cfu/mL for P. 
gingivalis and 5 x 105 cfu/mL for the other bacterial species. After incubation at 37°C 
for 48 h, the absorbance was measured at 595 nm using a microplate reader (Model 
3550, Bio-Rad) to assess the cell growth. The MIC endpoint was defined as the lowest 
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concentration of the test agent that completely inhibited growth or produced at least 
90% reduction in absorbance compared with that of the drug-free control. The MIC 
value represents the median of at least three independent experiments. To measure 
the MBC, an aliquot (100 µL) of the cell suspension was taken from two wells above 
the MIC, centrifuged and washed three times with PBS. Then each cell suspension 
was plated on a TSBY agar plate, and bacterial cells were enumerated after 
incubation at 37°C for 48 h. MBC was defined as the lowest concentration of the 
peptide at which more than 99.9% of the cells were killed compared with a non-treated 
control.  
Growth curve assay  
The effect of the peptides on the growth of S. mutans was examined as follows: a 
bacterial culture was grown in 25% BHI at 37°C to an OD of 0.1 at 600 nm and then 
equally allocated into 50 mL tubes (20 mL/tube). Each peptide was added to one 
culture tube to a final concentration of 25 µM. Chlorhexidine (1.25 mg/L, 2.5 µM) was 
used as a positive control, and the culture without the agents was used as a bacterial 
growth control. The cultures were grown for 10 h and the absorbance at 600 nm of 
1mL aliquots recorded at 1 h intervals.  
Time-kill assay  
The time-kill kinetic studies against S. mutans were performed using the broth 
macrodilution method[21]. S. mutans GS-5 (1 x 106 cfu/mL) and antibacterial agents 
(12.5 µM for MUC7 12-mer-L, MUC7 12-mer-D or MUC7 20-mer; 50.0 µM for MUC7 
12-mer-L4; 25.0 µM for Hsn5 12-mer or magainin-II; and 2 µM for chlorhexidine) were 
incubated in 25% BHI at 37°C. At 0, 1, 2, 4, 8 and 24 h, samples were taken and 
viable counts determined as follows: the samples were serially diluted in sterile 10 mM 
PBS (pH 7.2) and 50 µL aliquots were plated onto TSBY agar. The plates were 
incubated anaerobically at 37°C for 48 h, followed by enumeration of the cfu. Killing 
curves were constructed by plotting the log10 cfu/mL versus time over 24 h. All assays 
were performed in duplicate on at least two occasions.  
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Biofilm susceptibility assay  
The following three models were used:  
(1) Polystyrene tissue culture plate. The effect of the peptides on S. mutans 
biofilm formation was examined using the microdilution method. This method was 
similar to the MIC assay for planktonic cells. Two-fold serial dilutions of each peptide 
were prepared in the wells of a 96-well polystyrene tissue culture plate (Falcon 3072, 
Becton Dickinson and Company, NJ) containing BHIS at a volume of 200 µL per well. 
The final concentration of the peptide ranged from 0.78 to 100 µM for each peptide. 
Chlorhexidine (0.078–10 mg/L) was used as the positive control, the medium without 
the agents as the non-treated control and the medium alone as the blank control. The 
cell suspension of S. mutans GS-5 was prepared as described in the MIC assay, and 
20 µL aliquots (final concentration of cells 5 x 105 cfu/mL) were inoculated in the wells 
of the polystyrene tissue culture plate except in the wells with the medium alone as the 
blank control. After incubation at 37°C for 24 h, absorbance at 595 nm was recorded 
to assess the culture growth. The culture supernatants from each well were then 
decanted and planktonic cells were removed by washing with PBS, pH 7.2. The 
biofilm was fixed with methanol for 15 min and then air dried at room temperature. It 
was then stained with 0.1% (w/v) Crystal Violet (Sigma) for 5 min and rinsed 
thoroughly with water until the control wells appeared colourless. Biofilm formation 
was quantified by the addition of 200 µL of 95% ethanol to each Crystal Violet-stained 
well. The plate was rocked at room temperature for 30 min and the absorbance at 595 
nm (A595) was determined using a microplate reader (Bio-Rad Model 3550). The 
percentage of inhibition was calculated using the equation (1 – A595 of the test/A595 of 
non-treated control) x 100. The minimum biofilm inhibition concentration (MBIC50) was 
defined as the lowest agent concentration that showed 50% or more inhibition on the 
formation of biofilm.  
To examine the effects of the peptides on the 1 day developed biofilm, S. mutans 
GS-5 cells (20 µL aliquots of 5 x 105 cfu/mL) were inoculated into the wells of a 
polystyrene microtitre plate containing BHIS at a volume of 200 µL per well. After 
incubation at 37°C for 24 h, the culture supernatant from each well was decanted and 
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planktonic cells were removed by washing with PBS. BHIS containing 0.78–100 µM 
peptides, prepared in another microtitre plate, was then transferred to the 1 day 
biofilm plate, and the plates were further incubated at 37°C for 24 h. The cell growth 
was then assessed by measuring the absorbance at 595 nm, and the biofilm was fixed, 
stained and quantified as described above. Minimum biofilm reduction concentration 
(MBRC50) was defined as the lowest drug concentration that showed reduction of the 
biofilm by 50% or more.  
(2) Calgary biofilm device. To examine the effects of the peptides on the biofilm 
formed on the vertical surface, which is closer to natural oral conditions than on a 
(horizontal) polystyrene surface, CBD (MBEC Bioproducts, Calgary Canada) Assay 
System was used. CBD was described earlier[22], and has essentially 96 pegs 
mounted on the inside surface of the lid of a 96-well microtitre plate. When the CBD is 
placed over a microtitre plate, each peg is lowered into its corresponding well, but 
without contacting the well surface. The peg-studded lid fits over the 96-well microtitre 
plate to permit cells from the culture medium to colonize on the surface of the pegs.  
To examine the effect of the peptides on the formation of biofilm on the peg 
surface, S. mutans (200 µL of 106 cfu/mL), in BHIS, was inoculated to each well of a 
96-well microtitre plate. The plate was covered with the peg-studded lid and incubated 
at 37°C anaerobically for 24 h. Then, the lid with pegs, to which cells adhered, was 
transferred to a challenge plate, in which a series of 2-fold dilutions of each test agent 
was made in BHIS medium. For the control, no agent was added. After further 
incubation at 37°C anaerobically for 24 h, the culture medium was discarded and the 
pegs were washed twice by submerging the lid for 5 s in 200 µL of PBS in each well of 
a 96-well microtitre plate. The presence of a heavy- and light-formed biofilm on the 
non-treated control pegs and drug-treated pegs, respectively, was confirmed by 
scanning electron microscopy (SEM). The viability of the biofilm on the individual pegs 
was determined by an assay using the redox indicator Alamar Blue according to the 
manufacturer's instructions. Briefly, Alamar Blue (Biosource, Camarillo, CA, USA) was 
diluted to 5% in BHIS and 200 µL was then added to each well of a clean 96-well plate. 
Also included on each plate was a blank containing Alamar Blue in the medium and a 
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blank containing the medium alone. The lid with pegs with the attached biofilm was 
transferred to the Alamar Blue plate, and the plate was then protected from light and 
incubated at 37°C for 4 h. The plates were read in a microplate reader AD340 
(Beckman Coulter, CA, USA) at a wavelength of 570 nm and a wavelength of 595 nm. 
The relative absorbance for the samples was converted into the percentage increase 
over background absorbance, as determined by the blank sample on each plate.  
To test the reduction effects of peptides on the 1 day developed biofilm, the lid 
with pegs to which the cells adhered was transferred to a plate containing fresh BHIS 
and the plate was further incubated for 24 h. The preformed biofilm was then 
transferred to the challenge plate containing the test agents for the determination of 
biofilm reduction using Alamar Blue viability dye, as described above.  
(3) HA discs. To examine the pattern of the biofilm formed on the surface of HA 
discs by SEM, biofilms were grown in BHIS on the surface of HA discs that were 
deposited in the wells of a 48-well polystyrene tissue culture plate (Falcon 3047, 
Becton Dickinson, NJ, USA). S. mutans (106 cfu/mL) in 0.5 mL of BHIS in the 
presence or absence of MUC7 12-mer-L at a concentration of 4x MIC was inoculated 
to each well of the plate. After incubation at 37°C anaerobically for 24 h, the HA discs 
were removed for SEM analysis.  
SEM  
Biofilms grown on the surfaces of HA discs and CBD pegs for 24 h in the presence or 
absence of antimicrobial agents were rinsed once with distilled water, fixed using 10% 
buffered formaldehyde (VWR) at 20°C overnight. Fixed samples were then 
dehydrated through a graded series of ethanol concentrations, air dried, mounted and 
sputter coated with carbon. Samples were analysed by SEM (Hitachi S-4000; Hitachi 
Instruments Inc., San Jose, CA, USA) at several magnifications (x1000 to x10 000 for 
HA discs, x200 to x5000 for CBD pegs) in the EM laboratory, located in the School of 
Dental Medicine, University at Buffalo.  
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RESULTS 
MIC and MBC  
The concentrations of the peptides required to inhibit and to kill planktonic bacteria 
(MIC) are summarized in Table 1. Among the test bacterial species, S. mutans was 
the most susceptible to the peptides, followed by E. coli, S. gordonii, A. 
actinomycetemcomitans, P. gingivalis and P. aeruginosa. MUC7 12-mer-L, 12-mer-D 
and 20-mer exerted 2-fold higher antibacterial activities against S. mutans (median 
MICs of 9.4–12.5 µM) than Hsn5-12-mer and magainin-II (MICs of 25 µM) and 4-fold 
higher activities than MUC7 12-mer-L4 (Table 1, MICs of 50 µM). MBC values were 
also determined (not shown). They were equal to the corresponding MIC values 
except the following: 2-fold higher values were found for Hsn5 12-mer and magainin-II 
against S. mutans and for all tested agents against S. gordonii. This indicates that 
MUC7 peptides exert bactericidal rather than bacteriostatic activity against S. mutans.  
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Table 1.  MIC of cationic antimicrobial peptides against selected bacteriaa 
MIC 
Range (n b =6) Median Species Strain Test agent 
(µM) (mg/L) (µM) (mg/L) 
S. mutans GS-5 MUC7 12-mer-L 6.25-25 9.9-39.5 12.5 19.7 
 GS-5 ^gtfBCD MUC7 12-mer-L4 25-50 39.5-79 50 79.0 
 AU 159 MUC7 12-mer-D 6.25-12.5 9.9-19.7 12.5 19.7 
 ATCC10449 MUC7 20-mer 6.25-12.5 15.7-31.4 9.4 23.6 
  Hsn5 12-mer 12.5-50 19.7-79 25.0 39.5 
  Magainin II 25-50 61.7-123.5 25.0 61.7 
  Chlorhexidine 0.62-2.5 0.313-1.25 2.6 1.3 
S. gordonii  Challis MUC7 12-mer-L 12.5-50 19.7-79.0 25.0 39.5 
  MUC7 12-mer-L4 50-50 79-79 50.0 79.0 
  MUC7 12-mer-D 12.5-50 19.7-79 25.0 39.5 
  MUC7 20-mer 6.25-12.5 15.7-31.4 6.3 15.7 
  Hsn5 12-mer 12.5-100 19.7-158.0 100.0 158.0 
  Magainin II 6.25-100 15.4-246.9 25.0 61.7 
  Chlorhexidine 0.62-2.5 0.313-1.25 2.6 1.3 
A. actinomycetemcomitans  NCTC 9710 MUC7 12-mer-L 50->100 79->158 100.0 158.0 
  MUC7 12-mer-D 25-100 39.5-158 75.0 118.5 
  MUC7 20-mer 50-100 125.6-251.3 50.0 125.6 
  Hsn5 12-mer 50->100 79->158 >100 >158 
  Magainin II 1.56-40 3.9-98.8 3.1 7.7 
  Chlorhexidine 1.25-20 0.63-10 2.6 1.3 
P. gingivalis  W 50 MUC7 12-mer-L >100->100 >158->158 >100 >158 
 381 MUC7 12-mer-D 25-100 39.5-158.0 75.0 118.5 
  MUC7 20-mer >100->100 >251.3->251.3 >100 >251 
  Hsn5 12-mer >100->100 >158->158 >100 >158 
  Magainin II >100->100 >246.9->246.9 >100 >246.9 
  Chlorhexidine 1.25-2.5 0.63-1.25 2.6 1.3 
P. aeruginosa  ATCC 17648 MUC7 12-mer-L 25-100 39.5-158.0 100.0 >158 
  MUC7 12-mer-D 50-100 79.0-158.0 50.0 79.0 
  MUC7 20-mer 100->100 251.3->251.3 >100 >251 
  Hsn5 12-mer >100->100 >158->158 >100 >158 
  Magainin II 25-100 61.7-246.9 62.5 154.3 
  Chlorhexidine 2.5-9.9 1.25-5 9.9 5.0 
E. coli HB101 MUC7 12-mer-L 12.5-25 19.7-39.5 12.5 19.7 
  MUC7 12-mer-D 3.13-6.25 4.9-9.9 6.3 9.9 
  MUC7 20-mer 6.25-50 15.7-125.6 37.5 94.2 
  Hsn5 12-mer 12.5-50 19.7-79.0 50.0 79.0 
  Magainin II 1.56-6.25 3.9-15.4 4.7 11.6 
    Chlorhexidine 1.25-2.50 0.63-1.25 2.6 1.3 
aFour S. mutans strains and two P. gingivalis strains were tested.  
bn: the number of the observations.   
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Growth inhibition and time-killing  
As shown in Figure 1(a), upon addition of the peptides or chlorhexidine to the 
exponentially growing S. mutans cell cultures, all cultures continued to grow 
approximately at the same rate, which was comparable to the non-treated control 
culture growth, for approximately 1 h. A decrease in bacterial growth rate was 
observed only after a longer exposure to some agents. MUC7 12-mer, MUC7 
12-mer-D and MUC7 20-mer at equal molar concentrations (25 µM), all exhibited 
inhibitory effect on the S. mutans growth, similar to that achieved by chlorhexidine (2.5 
µM) (represented in Figure 1a by the lower four curves). On the other hand, low 
inhibition or no inhibition was found in the presence of MUC7 12-mer-L4, Hsn5 12-mer 
and magainin-II (represented in Figure 1a by the upper curves).  
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Figure 1. Effect of MUC7 peptides on the growth of S. mutans (a) and time-killing curves for S. mutans (b). For 
growth inhibition (a), the peptides were used at 25 µM and chlorhexidine at 2.5 µM concentration, a control had no 
agent added. For the time-killing test, each agent was used at its MIC. The assays were performed as described in 
the text. Values are the means of two experiments. MUC7 12-mer-L, open triangles; MUC7 12-mer-D, open 
squares; MUC7 20-mer, filled triangles; MUC7 12-mer-L4, open diamonds; Hsn5 12-mer, crosses; magainin-II, 
filled circles; chlorhexidine, open circles; and control, filled squares. 
 
The results of the time–kill kinetic studies are shown in Figure 1(b). The killing was 
time-dependent within 24 h of incubation. At the MIC (equal potent concentration), 
magainin-II (25 µM or 61.7 mg/L) and MUC7 20-mer (12.5 µM or 31.4 mg/L) showed 
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the fastest killing rate for S. mutans, followed by MUC7 12-L and MUC7 12-D (12.5 
µM or 19.7 mg/L). MUC7 12-mer-L4 (50 µM or 79.0 mg/L), Hsn5 12-mer (25 µM or 
39.5 mg/L) and the positive control agent chlorhexidine (2 µM or 1.3 mg/L) showed a 
slow killing rate compared with the other agents. After 4 h of incubation, magainin-II 
reduced the viable counts of S. mutans by 3 log10; MUC7 20-mer, MUC7 12-mer-L and 
MUC7 12-mer-D by 2 log10; and MUC7 12-mer-L4, Hsn5 12-mer and chlorhexidine by 
1 log10, respectively.  
Biofilm inhibition  
MUC7 peptides, with the exception of MUC7 12-mer-L4, exhibited an inhibitory effect 
on the formation of S. mutans biofilm, with MBIC50 from 6.25 to 12.5 µM, and reduced 
activity against 1 day developed S. mutans biofilm, with MBRC50 from 25 to 50 µM 
(Table 2). Consistent with the activity against planktonic bacterial cells, MUC7 12 mer- 
L, 12-mer-D and 20-mer showed 2- or 4-fold higher activities against S. mutans biofilm 
formation than Hsn 5 12-mer or magainin-II (Table 2 and Figure 2). MUC7 12-mer-L4 
exerted low activity against the biofilm formation, with MBIC50 of 50 µM (Table 2). 
Table 2. Effects of peptides on the formation (MBIC50a) and reduction (MBRC50b) of 
S. mutans biofilm (nc=6) 
MBIC50 MBRC50 
Range Median Range Median Test agent 
(µM) (mg/L) (µM) (mg/L) (µM) (mg/L) (µM) (mg/L) 
MUC7 12-mer-L 6.25-12.5 9.9-19.7 12.5 19.7 12.5->50 19.7->79.0 50 >79.5 
MUC7 12-mer-L4 25-50 39.5-79.0 50 79 50->50 79.0->79.0 >50 >79.5 
MUC7 12-mer-D 3.1-12.5 4.9-19.7 6.25 9.9 6.25-25 9.9-39.5 25 39.5 
MUC7 20-mer 3.1-12.5 7.9-31.4 6.25 15.7 6.25-25 15.7-62.8 25 62.8 
Hsn5 12-mer 25-25 39.5-39.5 25 39.5 12.5->50 19.7->79.0 >50 >79.5 
Magainin II 25-25 123.5-123.5 25 123.5 25->50 61.7->123.5 >50 >123.5 
Chlorhexidine 0.625-1.25 0.313-0.625 1.25 0.625 2.5->20 1.25->10 >20 >10 
aMBIC50: Minimum biofilm inhibition concentration was defined as the lowest drug concentration that 
showed 50% or more inhibition on the formation of biofilm. 
bMBRC50: Minimum biofilm reduction concentration was defined as the lowest drug concentration 
that showed 50% or more reduction of biofilm.  
cn: the number of the observations 
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Figure 2. Effect of peptides on S. mutans biofilm formation. The bacterial cells were inoculated in a 96-well 
microtitre plate containing 25% BHIS medium with different concentrations of each agent. Culture without the 
agents was used as the no-treatment control. After incubation at 37°C for 24 h, absorbance at 595 nm was 
recorded to assess the cell growth; the results are expressed as a percentage of the no-treatment control cell 
growth and depicted by the clear bars. The biofilm assay was performed by discarding the supernatants, washing 
with PBS, fixing with methanol and staining with CV. The absorbance at 595 nm was recorded to assess the 
amount of biofilm formed; the results are expressed as the percentage of the no-treatment control formed biofilm 
and depicted by the solid bars. Data represent the mean and SD of two independent tests with duplicates for each. 
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Generally, the inhibition of the S. mutans biofilm formation corresponds to the 
inhibition of bacterial growth. However, for the 1 day developed biofilm (Figure 3), the 
reduction of the biofilm was observed in the presence of MUC7 12-mer, MUC7 
12-mer-D or MUC7 20-mer at MBRC50, while the growth did not decrease in parallel. 
This indicates that MUC7 peptides exerted reduction activity on the 1 day developed 
biofilm. The reduction was not observed in the presence of MUC7 12-mer-L4, Hsn5 
12-mer or magainin-II.  
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Figure 3. Effect of peptides on S. mutans 1 day developed biofilm. One day biofilm was prepared as described in 
the Materials and methods section. BHIS medium with different concentrations of each agent, prepared in another 
microtitre plate, was then transferred to the biofilm plate. After further incubation at 37°C for 24 h, the biofilm was 
fixed, stained and quantified as described in the legend to Figure 2. Data represent the mean and SD of two 
independent tests performed in duplicate. The symbols for the growth and biofilm are the same as in Figure 2. 
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In addition, MUC7 peptides also exhibited inhibitory effects on the formation of the 
biofilm on the vertical surface of CBD pegs. As shown in Figure 4, compared with the 
no-drug growth control, the viabilities of the biofilm were suppressed by more than 
95% in the presence of MUC7 peptides at 4x MIC (50 µM). The other tested agents 
suppressed the viability of the biofilm to a similar extent. The 1 day developed biofilm 
was also inhibited by MUC7 12-mer-L, 12-mer-D and 20-mer peptides, as 
demonstrated by biofilm viability reduction by 49, 50 and 75%, respectively (Figure 4). 
On the other hand, the other two peptides showed much lower biofilm viability 
reduction. The positive control, chlorhexidine, showed 97% reduction in terms of 
viability.  
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Figure 4. Effect of peptides on the formation of and reduction of 1 day developed S. mutans biofilm on CBD pegs. 
The biofilms were grown on the surface of CBD pegs (a) and the biofilm viabilities (b) were determined by an assay 
using Alamar Blue as described in the text. Data represent the mean and SD of four tests. CHX, chlorhexidine; M-L, 
MUC7 12-mer-L; M-D, MUC7 12-mer-D; 20-mer, MUC7 20-mer; H-L, Hsn5 12-mer; and MII, magainin-II. The 
agent concentrations were 10 µM for CHX and 50 µM for all the peptides. Filled bars, biofilm formation; open bars, 
reduction of 1 day biofilm. 
 
SEM photographs of biofilms formed on the pegs or HA discs and the effect of 
MUC7 12-mer-L, a representative MUC7 peptide, on the biofilm formation are shown 
in Figure 5. For the non-treated controls, a biofilm formed on the HA discs consists of 
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nearly uniform, thick layer of cells (Figure 5j–l), while the biofilm formed on the pegs is 
much less dense, and individually formed colonies are seen (Figure 5d–f). The 
formation of the biofilm on both surfaces was prevented or greatly reduced in the 
presence of the MUC7 12-mer-L peptide. More specifically, on the pegs, the biofilm 
contained only a few cells, with bacterial cells or colonies being spread around the 
pegs (Figure 5a–c) or discs (Figure 5g–i), and large parts of the pegs or discs were 
uncolonized.  
 
 
 
Figure 5. SEM micrographs of S. mutans biofilm formation on CBD pegs and HA disc surfaces. Biofilms were 
grown in BHIS in the presence of or absence of MUC7 12-mer-L at 4x MIC (50 µM). All images shown were taken 
at magnifications (x1000 to x10 000 for HA discs, x200 to x5000 for CBD pegs). The selected images were chosen 
as the best representatives of the amount of biofilm on the surface of the HA disc and CBD peg. 
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DISCUSSION 
In this study, we investigated the susceptibility of selected bacteria and S. mutans 
biofilm to several MUC7 peptides, along with two other antimicrobial peptides Hsn5 
12-mer and magainin-II. The major findings of this study are that (i) MUC7 peptides 
exhibit antibacterial activity, and among the tested bacteria, S. mutans is the most 
susceptible to all peptides tested; (ii) MUC7 peptides exert higher antibacterial 
activities against S. mutans than the well-known antimicrobial peptides Hsn5-12-mer 
and magainin-II with lower MIC values and faster killing rate; (iii) MUC7 peptides 
inhibit formation of S. mutans biofilm and are also effective in reduction of the 1 day 
developed biofilm; and (iv) MUC7-12-mer-L4, a peptide lacking cysteine residues, 
exhibits low antibacterial activity against S. mutans.  
S. mutans is considered one of the primary causative agents of dental caries and 
can also be a source of infective endocarditis[23]. The main virulence factors 
associated with cariogenicity include adhesion, acidogenicity and acid tolerance 
inside the dental biofilm. The prevention of dental caries is targeted at the control of 
dental plaque[24]. Studies have shown that chlorhexidine, hexetidine, delmopinol, 
amine fluoride/stannous fluoride, triclosan, phenolic compounds, among others, may 
inhibit biofilm development and maturation as well as affect bacterial metabolism[24]. 
CAMPs exhibit killing activity against numerous oral bacteria [8-10, 25-28]. 
Synthetic histatin analogue dhvar4[29], human B-defensin-2 (hBD-2) [25], hBD-3 [28] 
and gaegurin 6[27] have been reported to have inhibitory effects against oral bacteria 
including S. mutans and Streptococcus sanguis. Our study showed that MUC7 
peptides exhibit a preferential antibacterial activity against S. mutans, compared with 
the other species tested.  
Mechanisms of the antimicrobial peptide activity include three pore-forming 
models, and several modes of intracellular killing, though their relevance to how 
peptides damage and kill microorganisms still needs to be clarified[30]. Regardless of 
the specific antimicrobial mechanism, three specific steps (attraction, attachment and 
peptide insertion) must occur to induce bacterial killing. Our previous study showed 
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that cysteine residues are not important for fungicidal activity against both Candida 
albicans and Candida neoformans.[17] In the present study, however, antibacterial 
activity of MUC7 12-mer lacking cysteine residues decreased remarkably (Table 1). It 
has been demonstrated that the cysteine residues located in the N-terminal region of 
MUC7 are important components of a domain that binds bacterial surface of S. 
mutans [31-33]. Our results suggest that cysteine residues may play an important role 
in bactericidal activity against S. mutans. MUC7 cationic peptides are likely to be 
attracted to S. mutans bacterial surfaces by the electrostatic bonding between their 
cationic charges and anionic structures (such as teichoic acid) on the S. mutans 
bacterial surface or by cysteine binding domain. The peptides then may traverse 
capsular polysaccharides, teichoic acids and lipoteichoic acids before interaction with 
the S. mutans cytoplasmic membrane. MUC7 20-mer has been shown to be able to 
cross the fungal cell membrane and accumulate inside the cells[14], suggesting that 
MUC7 peptides may also exert intracellular killing activity against S. mutans. 
Interestingly, A. actinomycetemcomitans, P. gingivalis and P. aeruginosa, which are 
all Gram-negative bacteria, exhibited low susceptibility to the test peptides.  
The oral bacteria are protected by the formation of biofilms. Bacteria in a biofilm 
are invariably less susceptible to antimicrobial agents than their planktonic 
counterparts[34]. For biofilm studies presented, we employed three different substrata, 
polystyrene microtitre plates with a horizontal surface, CBD with pegs that provided a 
vertical surface and HA discs, also a horizontal surface but more relevant to in vivo 
situation in terms of tooth surfaces. The effect of MUC7 peptides and of other agents 
on biofilm formation and reduction was studied in most detail on the polystyrene plates. 
Because the biofilm showed less susceptibility to the agent compared with planktonic 
cells, we used MBIC50 or MBRC50 (the lowest drug concentration that showed 50% or 
more inhibition on the formation of biofilm and 50% or more reduction of biofilm, 
respectively) to evaluate the activity of the agent against the biofilm. Unlike MIC and 
MBC for planktonic cells, the test agents did not exhibit 90% or more reduction of the 
biofilm even at the highest concentration of the agent. However, in terms of MBIC50 or 
MBRC50, we found that MUC7 peptides exhibited not only an inhibitory effect on the 
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formation of S. mutans biofilm, but also reduction activity against 1 day S. mutans 
biofilm developed in batch culture on a polystyrene microtitre plate.  
The biofilm-forming potential of a strain would depend on the extent of its growth, 
i.e. the better a strain grows, the better it forms a biofilm. The inhibition by the test 
agents on the formation of the biofilm may be the result of the inhibition of the bacterial 
growth since the growth and biofilm varied in parallel. However, this did not occur for 1 
day S. mutans biofilm developed in batch culture on a polystyrene microtitre plate. The 
inhibition of the biofilm was higher than that of the growth as shown in Figure 3, 
indicating that MUC7 peptides exerted reduction effect on the developed biofilm. 
Similar results, but measured in terms of viability of the biofilm, were also obtained on 
the reduction of 1 day biofilm preformed on a vertical surface of the CBD pegs, as 
shown in Figure 4. In order to get some information regarding the mechanism of 
inhibition or reduction of the biofilm by MUC7 peptides, we have examined MUC7 
peptide effect on glucosyltransferases (GTF) or fructosyltransferases (FTF) activity 
(one time only) using the PAS reagent stain method. However, no inhibition was found 
against GTF or FTF activity (data not shown). This suggests that the inhibition or 
reduction of the biofilm may not be as the result of inhibition of extracellular 
polysaccharides.  
Some factors, such as the starvation of the bacteria, pH and sucrose may affect 
the growth of the biofilm in the batch culture. To solve or minimize these problems, we 
set up appropriate controls in parallel and replaced the medium when the culture was 
grown for more than 24 h.  
We cannot claim in the present study that MUC7 peptides at the test concentration 
exhibited inhibitory activity against the mature biofilm. However, early biofilm is more 
important than mature biofilm because once the early biofilm is inhibited, the mature 
biofilm may in turn be prevented.  
In conclusion, our findings that MUC7 peptides exhibit a preferential antibacterial 
activity for S. mutans compared with other species tested, and the prevention of 
biofilm formation and the reduction of 1 day developed S. mutans biofilm by MUC7 
peptides strongly suggest that MUC7 peptides may have a potential for clinical use. 
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However in the in vivo situation, S. mutans does not occur in monoculture, but rather 
in the microbial plaque or biofilm, a complex ecosystem. The in vitro biofilm assays 
employed in this study are essentially preliminary screens. In vitro assessment of 
activity against biofilms in a more clinically relevant, brief exposure model system will 
be needed in order to extrapolate the MUC7 peptide activities to caries inhibiting 
potential or for use as anti-biofilm agents.  
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I. SUMMARY AND DISCUSSION  
We investigated: a) relationships between molecular properties and antimicrobial 
function of MUC7 peptides, b) effects of host physiological factors including cations, 
EDTA, pH, temperature, protease and protease inhibitors on the antimicrobial activity 
of MUC7 peptides, c) enhancement of antifungal activity by combination of MUC7 
peptides with EDTA or other agents, d) antibacterial activity of MUC7 peptides against 
dental biofilm and e) toxicity of the MUC7 peptides. 
A. Cationic antimicrobial peptides 
Cationic antimicrobial peptides (CAMPs) represent promising novel antimicrobial 
agents because they may meet the criteria needed for clinical application. CAMPs 
have unique characteristics including being gene-encoded, small in size and cationic 
(or positively charged) with an amphipathic structure. CAMPs identify and eradicate 
pathogens through a variety of mechanisms, while having no or low toxicity and low 
tendency to elicit resistance (Chapter 1). Consequently, they are considered a new 
generation of antibiotics, as well as innate immune modulators [1]. However, in order 
to apply CAMPs for therapeutic treatment in vivo, there are still several problems to 
overcome, which include high production costs, susceptibility to high ionic strength 
and proteolytic degradation and toxicity against eukaryotic cells. In an effort to 
address these issues, this thesis presents investigations on the in vitro antifungal and 
antibacterial activity of salivary mucin MUC7 derived peptides, including studies on 
the effects of molecular and host physiological factors on the antimicrobial activity of 
MUC7 peptides, as well as possible strategies to enhance the activity under 
physiological like conditions.  
B. Effects of molecular properties 
Antimicrobial peptides derived from mucins exhibit antimicrobial activity against fungi 
and bacteria as shown in previous studies [2, 3]. Many molecular parameters such as 
chain length, amino acid composition, peptide secondary structure, net positive 
charge and amphiphilicity were reported to have influence on the activity and 
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selectivity of antimicrobial peptides [4-6]. Chapter 2 describes an investigation on the 
relationship between the molecular factors and the antifungal activity of MUC7 
peptides. Firstly, we determined the minimum peptide chain length and its location 
within the MUC7 20-mer region, which is required to retain potent antifungal activity 
against C. albicans and C. neoformans. A series (from 8-mer to 16-mer) of truncated 
peptides derived from MUC7 20-mer were prepared and tested. The results showed 
that 12-mer peptide exhibited the highest killing activity among the truncated peptides, 
exceeding the antifungal activity of 20-mer. In order to lower the cost of antimicrobial 
peptides, it is of significance to minimize fragment length while at least maintaining the 
antimicrobial activity of the parent molecule. In that regard, the cost of chemical 
synthesis of the 12-mer peptide would be much reduced compared to that of MUC7 
20-mer. Secondly, the effects of peptide net charge and cysteine residues on 
fungicidal activity were investigated. Several variants of the 12-mer peptide containing 
a lower or no net positive charge, with or without cysteine residues were synthesized 
and tested. A clear correlation between the net positive charge of the 12-mer and its 
antifungal activity was found in killing assays, fluorescence microscopy and fungal cell 
membrane potential measurements. 12-mer peptide with net 6 positive charges 
exhibited higher killing activities than those with less net positive charges. 
Furthermore, cysteine residues were found to have not played a critical role in the 
fungicidal activity of these peptides.  
These results identified MUC7 12-mer peptide, a fragment of a naturally occurring 
human salivary MUC7, as a potential candidate for development into a novel 
antifungal therapeutic agent. It was investigated further in the following studies 
presented in this thesis.  
C. Effects of cations, EDTA, pH and temperature 
Chapter 3 describes a study on the influence of physiological factors such as 
concentration of monovalent and divalent cations, pH and temperature on the 
antimicrobial activity of MUC7 12-mer. Salts sensitivity of antimicrobial peptides poses 
a major obstacle in their development as novel antibiotics. Many cationic antimicrobial 
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peptides including salivary histatins are salt sensitive and therefore reduce or lose 
their antimicrobial activity at elevated concentrations of mono- or divalent cations [7, 
8]. This study showed that the activity of MUC7 12-mer peptide also attenuated at 
high salt concentration. However, compared to histatin 5 12-mer, MUC7 12-mer is 
less sensitive to salt and it still showed potent activity at physiological concentrations 
of a variety of ions in the oral cavity.  
Some divalent cations are essential to the maintenance of microbial growth and at 
the same time they hamper CAMPs activity [9]. Ca2+ is a major divalent cation in 
saliva and is a potent inhibitor of histatin 5’s candidacidal activity at physiological 
concentrations [9]. In this study, Ca2+ was also found to have an inhibiting effect on 
MUC7 12-mer against C. albicans. However, the inhibition of calcium ions 
disappeared in the presence of EDTA (ethylenediaminetetraacetic acid), which 
removes Ca2+ by chelating. EDTA is a FDA approved food preservative and has been 
widely used as divalent cation chelators as well as metalloprotease inhibitor in many 
areas including medicine. Interestingly, EDTA was also found to enhance the activity 
of MUC7 12-mer in the absence of Ca2+. This suggests that the synergism of EDTA 
with MUC7 12-mer may be achieved not only by chelating the inhibitory Ca2+, but also 
through other mechanisms. Such mechanisms could include disturbance of the 
integrity of the microbial outer membrane [10], and prevention of the peptide 
degradation [11] as suggested in Chapter 5.  
This study also showed that the antimicrobial activity of MUC7 12-mer acted in a 
broad range of pH from neutral to slightly alkaline, suggesting that saliva (pH 6.2-7.6) 
is a suitable environment for the action of MUC7 12-mer. Moreover, even if combined 
with other slightly basic agents in saliva, this peptide will remain effective. In addition, 
MUC7 12-mer is thermo-stable. It retained significant antimicrobial activity after 
incubation at 600C for 30min. This thermal stability is probably due to the relatively 
simple secondary structure that the peptide possesses so that it cannot be easily 
denatured.  
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These results suggest that MUC7 12-mer peptide could potentially be applied as 
an alternative therapeutic agent for the treatment of human oral candidiasis, 
especially in combination with EDTA.  
D. Effect of proteases and protease inhibitors 
Proteolytic properties of the subgingival microbiota were examined in Chapter 4. The 
yield of the mixed culture was found to be limited by albumin. Proteolytic activity of the 
cultures in albumin broth was higher than in broth without albumin. Among the isolates 
from the enrichment cultures, Peptostreptococcus micros, Prevotella melaninogenica, 
Prevotella buccae and Prevotella bivia demonstrated proteolysis. The frequent 
occurrence of Streptococcus gordonii and Streptococcus anginosus in the albumin 
cultures is explained by their ability to utilize arginine as an energy source for growth. 
Albumin in the medium was partly degraded by pure cultures and was completely 
consumed in enrichment cultures, demonstrating synergy of bacterial proteases. The 
results suggest that bacterial proteases are an important source of proteolytic activity 
in the oral cavity. This observation is further confirmed by the study presented in 
Chapter 5.  
In an effort to establish a transition from in vitro activity into clinical efficacy, based 
on the results of previous studies, Chapter 5 presents the stability of the peptides, 
including L-isomers of MUC7 12-mer, histatin 5 12-mer, magainin II, and D-isomer of 
MUC7 12-mer, in unclarified saliva. The effect of protease inhibitor cocktails (PIC) or 
EDTA on the antifungal activity of peptides was also examined. The results showed 
that: 1) the three L-peptides were degraded to different degrees. However, compared 
to histatin 5 12-mer and magainin II, MUC7 12-mer showed less degradation and still 
exerted candidacidal activity in saliva, indicating that MUC7 12-mer is less susceptible 
to proteolysis and could be a better candidate to be used in saliva, 2) MUC7 12-mer 
D-isomer was resistant to degradation and retained its potent candidacidal activity in 
whole saliva. This is probably because the proteolytic enzymes do not recognize 
D-amino acids. It suggests that D amino acid substitution could be a useful technique 
to improve the antifungal activity of MUC7 12-mer, 3) addition of PIC or EDTA to 
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saliva caused enhancement of antifungal activities of all peptides. PIC enhanced the 
activity of the three L-peptides through inhibition of all classes of proteases including 
metalloproteases targeted by EDTA. These results suggest that the L-peptide could 
be made more effective when administered in combination with PIC. In combination 
with the observation mentioned in Chapter 3, EDTA, with its concurrent functions of 
divalent cations chelator and metalloproteases inhibitor, could be a potent promoter 
for the antifungal activity of MUC7 12-mer in saliva by removing antagonism of 
divalent cations and by protecting the peptides from enzymatic proteolysis. 
Combination of MUC7 peptides and EDTA may have a great therapeutic potential for 
the treatment of oral candidal infections. 
E. Combination with antifungal agents 
In another effort to optimize the antifungal activity of MUC7 12-mer, this peptide was 
investigated in combination with other antifungal agents. Antimicrobial agents in 
combination can, in certain cases, exhibit stronger efficacy due to different modes of 
action. Moreover, such combinations can reduce the development of resistant strains 
[12]. A combination of an antimicrobial peptide with conventional antimycotics has 
been investigated by several researchers in the past [13, 14]. It is therefore of interest 
to examine whether MUC7 12-mer has synergistic effect when combined with other 
antifungal agents. In Chapter 6, the antifungal effect of the combination MUC7 
12-mer with amphotericin B or miconazole and the combination MUC7 12-mer with 
histatin 5 12-mer against C. albicans and C. neoformans were investigated. Similar to 
the effects of histatin 5 12-mer on the activity of amphotericin B [13], MUC7 12-mer 
exhibited an additive effect on the antifungal activity of amphotericin B against C. 
albicans and C. neoformans, while exhibiting synergistic effect on the activity of 
miconazole against C. neoformans. Moreover, in this study, we showed for the first 
time that the combination of two salivary antimicrobial peptides, MUC7 12-mer and 
histatin 5 12-mer, exhibit additive activity against C. albicans and synergistic activity 
against C. neoformans. The enhanced activity of the peptides and antifungal drugs in 
combination may be attributed to the different modes of action of each agent [15]. The 
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results of this study suggest that the combination MUC7 12-mer with histatin 5 12-mer 
or MUC7 12-mer with miconazole could enhance the efficacy of antifungal therapy.  
F. Antibacterial activity 
Antimicrobial peptides usually have a broad antimicrobial spectrum. Like other 
CAMPs, MUC7 peptides exhibit antimicrobial activity against not only fungi but also 
against bacteria. In Chapter 7, we investigated the susceptibility of selected bacteria 
as well as Streptococcus mutans biofilm to several MUC7 peptides and two 
well-known CAMPs, histatin 5 12-mer and magainin-II as positive control. MUC7 
peptides exhibited antibacterial activity. Among the tested bacteria, S. mutans was 
most susceptible to all CAMPs tested. In addition, MUC7 peptides with lower MIC 
values and faster killing rate, exerted higher antibacterial activities against S. mutans 
than histatin 5-12-mer and magainin-II. Moreover, MUC7-12-mer-L4, a peptide 
lacking cysteine residues, exhibited low antibacterial activity against S. mutans. This 
is an indication that cysteine residues, which play a critical role in bacterial binding, 
appear to be important for the antibacterial activity of the MUC7 12-mer, although they 
do not influence the antifungal activity of the peptides as shown in Chapter 2.  
The oral bacteria in vivo are embedded in dental biofilm. Bacteria in biofilm are 
invariably less susceptible to antimicrobial agents than their planktonic counterparts 
[16]. In order to evaluate the antibacterial activity under physiological conditions, it is 
of significance to examine the antimicrobial effect of MUC7 peptides on the bacterial 
biofilm. In this study, MUC7 peptides were found to have an inhibiting effect on the 
formation of S. mutans biofilm and a reducing effect on the amount of early S. mutans 
biofilm developed in batch culture on a polystyrene microtiter plate. However, S. 
mutans does not occur in vivo in mono-species biofilm, but rather in a mixed-species 
dental plaque. The in vitro biofilm assays employed in this study are essentially 
preliminary screens. In vitro assessment of activity against biofilm in a more clinically 
relevant and brief exposure model system will be needed in order to extrapolate the 
MUC7 peptide activities for dental plaque inhibiting potential or for use as anti-biofilm 
agent. The present study suggests that MUC7 peptides have preferential antibacterial 
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activity against S. mutans and could potentially be used as a selective anti-dental 
plaque agent for the prevention of a cariogenic biofilm.  
G. Cytotoxicity 
Safety is one of the most important parameters for the clinical use of any antimicrobial 
agent including CAMPs. Despite the fact that most CAMPs have no toxicity to host 
cells, we must realize that some CAMPs can induce lysis of erythrocytes at higher 
concentrations [17] or under normal physiological conditions [18]. The studies on the 
cytotoxicity of MUC7 peptides, along with other CAMPs and antifungal drugs to 
human epithelial cells are presented in Chapter 5 and 6. Fortunately, MUC7 peptides 
showed no toxicity to HOK-16B cell line derived from normal human oral keratinocytes, 
and very low toxicity to human erythrocytes compared to two classical antifungal 
therapeutic agents and magainin II. These results indicate that MUC7 peptides are 
not toxic to mammalian cells under normal physiological conditions.  
II. GENERAL CONCLUSIONS 
This thesis presents an investigation of the in vitro antifungal and bacterial activity of 
salivary mucin MUC7 derived peptides, including studies of the effects of molecular 
and host physiological factors on antimicrobial activity of MUC7 peptides, as well as 
possible strategies to enhance the activity under the physiological like conditions. 
Corresponding to the specific objectives, the following conclusions are drawn: 
1. MUC7 12-mer peptide, a fragment with minimum molecular size and maximum 
net positive charges, is a potential candidate for the development of a novel 
antifungal therapeutic agent.  
2. MUC7 12-mer is not sensitive to mono- or divalent cations except for calcium 
ions at oral physiological like concentrations. EDTA enhances the antifungal 
activity of MUC7 12-mer by removing the inhibiting effect of calcium ions. MUC7 
12-mer is thermo-stable and possesses a broad optimal pH value that ranges 
from neutral to slightly alkaline. 
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3. MUC7 12-mer is less susceptible to degradation by salivary proteases derived 
from oral bacteria, compared to other CAMPs. 
4. MUC7 12-mer with D-amino acid substitution is resistant to proteolysis while also 
retaining an effective antifungal activity. PIC and EDTA enhance the activity of 
MUC7 12-mer; EDTA could be a potent promoter for the antifungal activity of the 
peptide in saliva.  
5. The combination MUC7 12-mer with histatin 5 12-mer or MUC7 12-mer with 
miconazole could potentially enhance the efficacy of antifungal therapy. 
6. MUC7 peptides have preferential antibacterial activity against S. mutans and 
may potentially be used as promising selective anti-dental plaque agent for the 
prevention of a cariogenic biofilm. 
7. MUC7 peptides are not toxic to mammalian cells under normal physiological 
conditions.  
 
The findings presented in the thesis strongly suggest that:  
z MUC7 12-mer peptide is an effective antimicrobial agent and could potentially be 
used as a promising agent for the development of novel drugs for the control of 
oral microbial infection. 
z Use of MUC7 12-mer D-enantiomers as well as the combinations of MUC7 
12-mer and EDTA or other antimicrobial agents may potentially enhance their 
therapeutic efficacy.  
III. FUTURE PERSPECTIVE 
New drugs must meet many criteria such as efficacy, safety, stability and low cost 
before it can be used clinically. Despite the encouraging outcomes obtained through 
the studies in vitro, there is still a long way to go towards the ultimate goal of using 
MUC7 peptides as therapeutic agents for the control of oral infectious diseases.  
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The outcome of this study leads to the following recommendations for future research. 
1) Development of a ȕ-peptide by incorporating synthetic ȕ-substituted amino 
acids into MUC7 12-mer. MUC7 12-mer D exhibits potent antifungal activities and is 
not susceptible to proteases. Unfortunately, this peptide is very costly so that the high 
cost may limit its therapeutic application. ȕ-peptides contain residues that form a 
stable helical structure and their unnatural backbone makes them resistant to 
proteases. ȕ-peptides that mimic natural peptide-based antibiotics, such as magainins, 
were found to have similar antibacterial activity [19]. Recently, ȕ-peptides were 
reported to have a potent antifungal activity against planktonic and biofilm C. albicans 
cells [20]. I hypothesize that ȕ-MUC7 12-mer may exhibit potent antifungal activity 
against planktonic and biofilm C. albicans cells in saliva and is therefore expected to 
be a new drug for the treatment and prevention of systemic C. albicans infections.  
2) Study the effect of iron and iron chelators on antifungal activity of MUC7 12-mer 
in saliva. Iron is an important ion in human whole saliva. It also influences the growth 
of C. albicans. Iron chelation (deferoxamine) was found to be a promising novel 
therapeutic strategy for refractory mucormycosis infections [21]. It is interesting to 
evaluate the efficacy of a combination of MUC7 12-mer and iron-chelating agents. 
3) Study the effect of MUC7 12-mer and its derivatives on multi-culture biofilm. 
There is a need to set up multi-culture biofilms which include S. mutans, S. gordonii, 
Fusobacteria and other indigenous bacteria of dental plaque. The rationale is that the 
multi-culture biofilm is closer to in vivo dental biofilm compared to the single-culture 
biofilm. Based on the observation that MUC7 12-mer has preference activity against S. 
mutans, MUC7 12-mer could be expected to inhibit the formation of multi-culture 
biofilm. Moreover, it will be of interests to examine the effects of the combination of 
MUC712-mer and EDTA on formation or eradication of the biofilm. 
4) In vivo study with experimental model. Since the results of previous in vivo 
studies were not conclusive [22, 23], further in vivo investigations are recommended 
on antimicrobial efficacy of MUC7 peptides alone or in combination with other agents 
against fungal and bacterial infections in animal models. Antifungal activity of MUC7 
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peptide (16-mer) was found in a murine model of vaginal candidiasis [22]. However, 
the model of vaginal candidiasis is not applicable to oral candidiasis because of the 
low pH and high ionic strength in the vaginal environment. An in vivo study with MUC7 
12-mer peptide in a model of murine oral candidiasis showed antifungal activity, but 
consistent results were not obtained in the second trial [23]. These results urge more 
investigations by making use of modern animal models [24, 25]. Up to now, there are 
no reports on in vivo antibacterial activity of MUC7 12-mer against mutans 
streptococci. 
I hypothesize that, based on the results of in vitro studies described above, MUC7 
12-mer in combination with EDTA and MUC7 12-mer-D isomer or ȕ-MUC7 12-mer will 
exert effective therapeutic activity in vivo, since these drugs are relative insensitive to  
proteolysis in saliva. 
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I. SAMENVATTING EN DISCUSSIE 
Deze studie betreft een onderzoek naar: a) het verband tussen moleculaire en 
antimicrobiële eigenschappen van MUC7 peptiden, b) invloeden van gastheer 
fysiologische factoren zoals kationen, EDTA, pH, temperatuur, protease en 
proteaseremmers op de antimicrobiële activiteit van MUC7 peptiden, c) verhoging van 
de antischimmel activiteit door combinatie van MUC7 peptiden met EDTA of andere 
agentia, d) antibacteriële activiteit van MUC7 peptiden tegen tandplaque en e) 
toxiciteit van de MUC7 peptiden. 
 
A. Kationische antimicrobiële peptiden 
Kationische antimicrobiële peptiden (CAMPs) vormen een veelbelovende groep 
nieuwe antimicrobiële middelen omdat zij mogelijkerwijs voldoen aan de gestelde 
criteria voor klinische toepassing. CAMPs hebben unieke eigenschappen, het zijn 
kleine, gen gedecodeerde positief geladen amphipatische peptiden. CAMPs 
herkennen en doden pathogene kiemen op verschillende manieren terwijl ze 
nauwelijks tot niet toxisch zijn en slechts geringe resistentie veroorzaken (Hoofdstuk 
1). Daarom worden ze beschouwd als een nieuwe generatie antibiotica en als 
natuurlijke modulatoren van de immuniteit1. Desalniettemin zijn er nog een aantal 
problemen op te lossen, zoals hoge productiekosten, gevoeligheid voor hoge ionische 
lading, proteolytische afbraak en toxiciteit voor eukaryotische cellen, voordat CAMPs 
in therapeutische behandeling in vivo toegepast kunnen worden. In een poging deze 
belangrijke problemen op te lossen richt dit proefschrift zich op de invloed van 
moleculaire en gastheer fysiologische factoren op de in vitro antischimmel en 
antibacteriële werking van peptiden uit speeksel mucine (MUC7) en op strategieën 
om de activiteit onder fysiologische omstandigheden te verhogen. 
 
B. Effecten van moleculaire eigenschappen 
Zoals eerder onderzoek laat zien2,3, vertonen van mucine afgeleide peptiden 
antimicrobiële activiteit tegen schimmels en bacteriën. Van verschillende moleculaire 
parameters zoals ketenlengte, aminozuursamenstellingen, netto positieve lading en 
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de ruimtelijke structuur is beschreven dat ze invloed hebben op de activiteit en 
specificiteit van antimicrobiële peptiden4-6. In hoofdstuk 2 wordt een onderzoek 
beschreven naar het verband tussen de moleculaire factoren en de antischimmel 
werking van MUC7 peptiden. Allereerst werd de minimum lengte van de peptide keten 
binnen de MUC7 20-mer regio vastgesteld die nodig is om de krachtige antischimmel 
werking tegen C. albicans en C. neoformans te behouden. Een serie ingekorte 
peptiden van 8-mer tot 16-mer, afgeleid van MUC 20-mer werden geprepareerd en 
getest. De 12-mer peptide bleek onder de ingekorte peptiden de hoogste dodelijke 
antischimmel werking te hebben, de werking was zelfs hoger dan die van 20-mer. Om 
de kosten van de antimicrobiële peptiden zo laag mogelijk te houden, is het van 
belang om de lengte van de peptide zo kort mogelijk te maken terwijl op zijn minst de 
antibacteriële werking van het oorspronkelijke molecuul in tact blijft. In dat opzicht zijn 
de kosten van chemische synthese van de 12-mer peptiden veel lager dan die van 
MUC7 20-mer. Vervolgens werd het effect van peptide netto lading en cysteïne 
residuen op de schimmeldodende werking onderzocht. Verschillende varianten van 
de 12-mer peptide met een lagere tot geen positieve lading en met dan wel zonder 
cysteine residuen werden gesynthetiseerd en getest. Een duidelijke correlatie tussen 
de netto positieve lading van 12-mer en zijn antischimmel werking werd gevonden in 
afdodingstesten, fluorescentie microscopie en bij potentiaal metingen aan het 
celmembraan van schimmels. De 12-mer peptide met een 6+ lading vertoonde een 
hogere dodelijke werking dan peptiden met lagere positieve ladingen. Bovendien 
bleek dat cysteine residuen geen cruciale rol spelen in de schimmeldodende werking 
van deze peptiden. 
 
Door deze resultaten is MUC7 12-mer peptide, een fragment van het natuurlijk 
voorkomende menselijk speeksel mucine geclassificeerd als een potentiële kandidaat 
voor verdere ontwikkeling tot een nieuw antischimmel middel. Het is nader 
bestudeerd en dit onderzoek wordt beschreven in de volgende hoofdstukken. 
 
C. Invloeden van kationen, EDTA, pH en temperatuur 
Samenvatting 
 186 
Hoofdstuk 3 beschrijft een onderzoek naar de invloed van fysiologische factoren 
zoals de concentratie van mono- en bivalente kationen, pH en temperatuur op de 
antimicrobiële werking van MUC7 12-mer. Gevoeligheid voor zouten van 
antimicrobiële peptiden is een serieus obstakel in hun ontwikkeling tot nieuwe 
antibiotica. Vele kationische antimicrobiële peptiden, waaronder speeksel histatine, 
zijn zoutgevoelig waardoor hun antimicrobiële werking wordt gereduceerd of verloren 
gaat bij verhoogde concentraties van mono- of bivalente kationen7,8. Dit onderzoek 
toont aan dat de werking van MUC7 12-mer ook afneemt bij een hoge 
zoutconcentratie, maar vergeleken met histatine 5 2-mer, is MUC7 12-mer minder 
zoutgevoelig en vertoont het nog steeds effectieve werking bij fysiologische 
concentraties van verschillende ionen in de mond. 
 Sommige bivalente kationen zijn essentieel voor microbiële groei en tegelijkertijd 
belemmeren ze de werking van CAMPs9. Ca2+ is een belangrijk kation in speeksel en 
in fysiologische concentraties remt het sterk de anti-candida werking van histatine 59. 
In het huidige onderzoek werd aangetoond dat Ca2+ ook een remmende invloed heeft 
op de werking van MUC7 12-mer tegen C. albicans, maar de inhibitie van 
calciumionen verdween in de aanwezigheid van EDTA (ethylenediamine tetraacetic 
acid), dat Ca2+ verwijdert door chelatie. EDTA is een door de FDA goedgekeurd 
voedingsconserveermiddel en wordt veelvuldig gebruikt als chelator (binder van 
kationen) en als proteaseremmer op vele gebieden waaronder het medische. 
Interessant genoeg bleek EDTA de werking van MUC7 12-mer ook te versterken bij 
afwezigheid van Ca2+. Dit lijkt erop te wijzen dat de synergetische werking tussen 
EDTA en MUC7 12-mer niet alleen komt door de binding van Ca2+ maar dat er ook 
andere mechanismen in het spel zijn. Zoals in hoofdstuk 5 wordt gesuggereerd 
kunnen dat mechanismen zijn als verstoring van de integriteit van de microbiële 
celmembraan10 en preventie van peptide degradatie. 
 Dit onderzoek liet ook de antimicrobiële werking van MUC7 12-mer in een breed 
pH-gebied zien, van neutraal tot licht alkalisch, hetgeen erop wijst dat de 
speekselzuurgraad (pH 6.2 – 7.6) gunstig is voor de werking van MUC7 12-mer. 
Bovendien blijft deze peptide effectief zelfs indien gecombineerd met andere licht 
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basische agentia in speeksel. Daarbij is MUC7 12-mer thermostabiel. Het behield  
significante antimicrobiële werking na incubatie bij 60’ C gedurende 30 minuten. Deze 
thermostabiliteit is waarschijnlijk te danken aan de relatief eenvoudige ruimtelijke 
structuur van de peptide die niet gemakkelijk gedenatureerd wordt. 
 Deze bevindingen doen vermoeden dat MUC7 12-mer peptide kan worden 
toegepast, mogelijk in combinatie met EDTA, als alternatief geneesmiddel bij de 
behandeling van candida infecties van het mondslijmvlies. 
 
D. Invloed van protease en proteaseremmers 
In hoofdstuk 4 wordt verslag gedaan van het onderzoek naar proteolytische 
eigenschappen van de subgingivale microflora. De groeiopbrengst van de gemengde 
culture bleek afhankelijk van albumine. De proteolytische activiteit van de cultures in 
albuminebouillon was sterker dan in bouillon zonder albumine. Onder de geïsoleerde 
stammen van de verrijkte cultures, toonden Peptostreptococcus micros, Prevotella 
melaninogenica, Prevotella buccae en Prevotella bivia proteolysische activiteit. Het 
frequente voorkomen van Streptococcus gordonii en Streptococcus anginosus in de 
albumine cultures wordt verklaard door hun vermogen arginine te gebruiken als groei 
energiebron. Albumine in het medium werd gedeeltelijk afgebroken door pure cultures 
en werd compleet verbruikt in gemengde cultures, hetgeen wijst op synergie tussen 
bacteriële proteasen. De bevindingen suggereren dat in de mond bacteriële 
proteasen een belangrijke bron van proteolytische activiteit zijn. Deze waarneming 
werd later bevestigd in het onderzoek beschreven in hoofdstuk 5. 
 Gebaseerd op de resultaten van vorig onderzoek wordt in hoofdstuk 5 
onderzoek beschreven dat poogt een transitie te bewerkstelligen van in vitro werking 
naar klinische werkzaamheid, door de stabiliteit van de peptiden, waaronder 
L-isomeren van MUC7 12-mer, histatine 5 12-mer, magainin II en D-isomeer van 
MUC7 12-mer, in natuurlijk speeksel vast te stellen. De invloed van 
proteaseremmende cocktails (PIC) of EDTA op de antischimmel werking van 
peptiden werd eveneens onderzocht. De resultaten lieten zien: 1) dat de drie 
L-peptiden in verschillende mate werden afgebroken. Echter, vergeleken met 
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histatine 5 12-mer en magainen II, vertoonde MUC7 12-mer minder degradatie en 
bleef in speeksel actief tegen Candida, wat erop wijst dat MUC7 12-mer minder 
gevoelig is voor proteolyse en waarschijnlijk een betere kandidaat is om gebruikt te 
worden in speeksel; 2) dat MUC7 12-mer D-isomeer resistent was tegen 
proteolitische afbraak en zijn krachtige anti candida werking behield in natuurlijk 
speeksel. De waarschijnlijke verklaring hiervoor is dat proteolytische enzymen 
D-aminozuren niet herkennen en daarmee is de suggestie gewekt dat D-aminozuur 
substitutie een waardevolle techniek kan zijn om de antischimmel werking van MUC7 
12-mer te verbeteren; 3) dat toevoeging van PIC of EDTA de antischimmel werking 
van alle peptiden versterkt door inhibitie van alle proteasen. De bevindingen lijken 
erop te wijzen dat L-peptiden effectiever gemaakt kunnen worden indien toegepast in 
combinatie met PIC. EDTA met zijn simultane werking als bivalente kationenbinder 
(hoodstuk 3) en proteaseremmer kan een versterker zijn van de antischimmel werking 
van MUC7 12-mer in speeksel door het verwijderen van antagonistische bivalente 
kationen en door bescherming van de peptiden tegen enzymatische proteolyse. Een 
combinatie van MUC7 peptiden en EDTA heeft mogelijk een groot therapeutisch 
vermogen bij de behandeling van orale candida infecties. 
 
E. Combinaties van antischimmel middelen 
In een tweede poging om de antischimmel werking van MUC7 12-mer te 
optimaliseren is deze peptide onderzocht in combinatie met andere antischimmel 
middelen. Gecombineerde antimicrobiële middelen kunnen in bepaalde gevallen een 
sterkere werkzaamheid vertonen die toe te schrijven is aan verschillende 
werkingsmechanismen. Bovendien kunnen zulke combinaties de ontwikkeling van 
resistente stammen reduceren12. Combinaties van antimicrobiële peptiden met 
conventionele antimycotica zijn in het verleden door verschillende onderzoekers 
onderzocht13,14. Het is daarom interessant te onderzoeken of MUC7 12-mer 
synergetische werking heeft indien gecombineerd met andere antischimmel middelen. 
In hoofdstuk 6 werd het antischimmel effect onderzocht van de combinatie MUC7 
12-mer met amphotericin B of miconazole en de combinatie MUC7 12-mer met 
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histatine 5 12-mer tegen C. albicans en C. neoformans. Vergelijkbaar met de invloed 
van histatine 5 12-mer op de werking van amphotericin B13, vertoonde MUC7 12-mer 
een additionele werking op de antischimmel werking van amphotericin B tegen C. 
albicans en C.neoformans en een synergetische werking op miconazole tegen C. 
neoformans. Bovendien liet het huidige onderzoek voor het eerst zien dat de 
combinatie van twee antimicrobiële speekselpeptiden, MUC7 12-mer en histatine 5 
12-mer, additionele werking vertonen tegen C. albicans en synergetische werking 
hebben tegen C. neoformans. De verhoogde activiteit van de gecombineerde 
peptiden en antischimmel middelen kan wellicht toegeschreven worden aan de 
verschillende werkingswijzen van ieder agens afzonderlijk15. Deze 
onderzoeksresultaten suggereren dat de combinatie MUC7 12-mer en histatine 5 
12-mer of de combinatie van MUC7 12-mer en miconazole de effectiviteit van 
antischimmel therapie kunnen vergroten. 
 
F. Antibacteriële werking 
Antimicrobiële peptiden hebben gewoonlijk een breed antimicrobieel spectrum. Zoals 
andere CAMPs vertonen MUC7 peptiden niet alleen antimicrobiële werking tegen 
schimmels maar ook tegen bacteriën. In hoofdstuk 7 wordt onderzoek beschreven 
naar de gevoeligheid van zowel geselecteerde bacteriën als die van een biofilm van 
Streptococcus mutans voor verschillende MUC7 peptiden en twee bekende CAMPs, 
te weten histatine 5 12-mer en magainin II, als positieve controle. MUC7 peptiden 
vertoonden antibacteriële werking. Onder de onderzochte bacteriën bleek S. mutans 
het meest gevoelig voor alle geteste CAMPs. Bovendien vertoonden MUC7 peptiden 
met lagere MIC-waarden en een hogere dodingsnelheid, sterkere antibacteriële 
werking tegen S. mutans dan histatine 5 12-mer en magainin II. Daarnaast vertoonde 
MUC7 12-mer-L4, een peptide waaraan cysteine residuen ontbreken, lage 
antibacteriële werking tegen S. mutans. Dit is een indicatie dat cysteine residuen die 
een cruciale rol spelen bij de binding van bacteriën, belangrijk zijn voor de 
antibacteriële werking van de MUC7 12-mer, hoewel ze de antischimmel werking van 
de peptiden niet beïnvloeden zoals in hoofdstuk 2 is beschreven. 
Samenvatting 
 190 
 De orale bacteriën in vivo zijn ingebed in een biofilm op de tanden. Bacteriën in 
biofilm zijn onveranderlijk minder gevoelig voor antimicrobiële middelen dan hun 
planktonische tegenhangers16. Om de antibacteriële werking onder fysiologische 
omstandigheden te kunnen evalueren is het van belang om de antimicrobiële werking 
van MUC7 peptiden op de bacteriële biofilm te onderzoeken. In dit onderzoek bleken 
MUC7 peptiden de vorming van S. mutans biofilm te remmen en de hoeveelheid S. 
mutans te reduceren in biofilm die zich vormde in batch culture op een polystyreen 
microtiter plaat. S. mutans komt echter in vivo niet voor in mono culture biofilm, maar 
alleen in gemengde culture in tandplaque. De in vitro biofilm cultures in dit onderzoek 
moeten worden gezien als oriënterende set-ups. Het zal nodig zijn in vitro bepalingen 
van de werking tegen biofilm in een meer klinisch relevante proefopstelling te toetsen 
om de MUC7 peptide werking tegen tandplaque te kunnen extrapoleren voor klinisch 
gebruik. De huidige studie suggereert dat MUC7 peptiden  een voorkeur hebben 
waar het gaat om antibacteriële werking tegen S. mutans en dat ze in potentie kunnen 
worden gebruikt als een selectief antiplaque middel bij de preventie van een 
cariogene biofilm. 
 
G. Cytotoxische werking 
Veiligheid is een van de belangrijkste parameters bij het klinische gebruik van welk 
antimicrobieel middel dan ook, dus ook CAMPS. Ondanks het feit dat de meeste 
CAMPs niet toxisch zijn voor gastheercellen, moeten we ons realiseren dat sommige 
CAMPs lysis van erythrocyten kunnen veroorzaken17,18. Het onderzoek naar toxiciteit 
van MUC7 peptiden, samen met andere CAMPs en antischimmel medicijnen op 
humaan epitheelcellen wordt beschreven in hoofdstuk 5 en 6. Gelukkig bleken 
MUC7 peptiden niet toxisch te zijn voor de HOK-16B cellijn van normale menselijke 
orale keratinocyten en bleken ze een zeer lage toxiciteit te vertonen voor menselijke 
erythrocyten, in vergelijking tot twee klassieke antischimmel middelen en magainin II. 
Deze resultaten laten zien dat MUC7 peptiden onder normale fysiologische 
omstandigheden niet toxisch zijn voor zoogdiercellen. 
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II. ALGEMENE CONCLUSIES 
Dit proefschrift beschrijft een onderzoek naar de in vitro antischimmel en anti 
bacteriële werking van uit speekselmucine verkregen MUC7 peptiden, waaronder 
studies naar de effecten van moleculaire en gastheer fysiologische factoren op de 
antimicrobiële werking van MUC7 peptiden, als ook onderzoeken naar mogelijke 
strategieën om de werking ervan onder fysiologische omstandigheden te verhogen. 
Corresponderend met de specifieke doelen kan het volgende geconcludeerd worden: 
 
1. MUC7 12-mer, een positief geladen peptide van minimale moleculaire afmeting, 
is een potentiële kandidaat voor een nieuw antischimmel middel. 
 
2. MUC7 12-mer is niet gevoelig voor mono- of bivalente kationen met 
uitzondering van calciumionen in fysiologische concentraties. EDTA vergroot 
de antischimmel werking van MUC7 12-mer door de remmende werking van 
calciumionen ongedaan te maken. MUC7 12-mer is thermostabiel en is 
werkzaam in een pH-gebied van neutraal tot licht alkalisch. 
 
3. MUC7 12- mer is minder gevoelig voor afbraak door bacteriële speeksel 
proteasen vergeleken met andere CAMPs. 
 
4. MUC7 12-mer met D-aminozuur substitutie is resistent tegen proteolyse en 
behoudt een effectieve antischimmel werking. PIC en EDTA verhogen de 
werking van MUC7 12-mer; EDTA kan de antischimmel werking van de peptide 
in speeksel ondersteunen. 
 
5. De combinatie van MUC 12-mer met histatine 5 12-mer of van MUC7 12-mer 
met miconazole kan in potentie de werkzaamheid van antischimmel therapie 
versterken. 
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6. MUC7 peptiden hebben een antibacteriële werking vooral gericht S. mutans en 
kunnen in potentie gebruikt worden als veelbelovend selectief antiplaque 
middel om de vorming van een cariogene biofilm te voorkomen. 
 
7. MUC7 peptiden zijn niet toxisch voor zoogdiercellen onder normale 
fysiologische omstandigheden. 
 
De resultaten beschreven in dit proefschrift suggereren ten stelligste het volgende: 
x MUC7 12-mer peptide is een effectief antimicrobieel middel en kan in potentie 
gebruikt worden als een veelbelovend middel voor de ontwikkeling van nieuwe 
geneesmiddelen om orale microbiële infecties onder de duim te krijgen  
 
x Gebruik van MUC7 12-mer D-isomeren zowel als van de combinaties van 
MUC7 12-mer en EDTA of in combinatie met andere antimicrobiële middelen 
kunnen in potentie de therapeutische effectiviteit vergroten. 
 
III. TOEKOMSTPERSPECTIEF 
Nieuwe geneesmiddelen moeten voldoen aan vele criteria zoals werkzaamheid, 
veiligheid, stabiliteit en lage kosten voordat ze klinisch toegepast kunnen worden. 
Ondanks de bemoedigende resultaten verkregen door onderzoek in vitro is er nog 
een lange weg te gaan om het ultieme doel  te bereiken namelijk MUC7 peptiden 
gebruiken als therapeutisch middel voor beheersing van orale infectueuze ziekten. 
 
Het resultaat van deze studie leidt tot de volgende aanbevelingen voor toekomstig 
onderzoek. 
1) Ontwikkeling van een ȕ-peptide door synthetisch ȕ-substituut aminozuren te 
incorporeren in MUC7 12-mer. MUC 12-mer D vertoont sterke antischimmel werking 
en is niet gevoelig voor proteasen. Jammer genoeg is deze peptide zo duur, dat de 
hoge kosten de toepassing ervan in de weg staan. ȕ-peptiden bevatten residuen die 
een stabiele spiraalvormige structuur vormen en hun onnatuurlijke structuur maakt ze 
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resistent tegen proteasen. Van ȕ-peptiden die natuurlijke, op peptiden gebaseerde 
antibiotica zoals magainines nabootsen, werd ontdekt dat ze eenzelfde antibacteriële 
werking hebben19. Recent is beschreven dat ȕ-peptiden een krachtige antischimmel 
werking hebben tegen planktonische C. albicans  en tegen C. albicans in biofilm20. Ik 
veronderstel dat ȕ-MUC7 12-mer sterke antischimmel werking zal vertonen tegen 
planktonische en biofilm C. albicans cellen in speeksel en dat de verwachting daarom 
is dat het een nieuw geneesmiddel zal worden voor de behandeling en de preventie 
van systemische C. albicans infecties. 
 
 2) Onderzoek naar het effect van ijzer en ijzer chelatoren op antischimmel 
werking van MUC7 12-mer in speeksel. IJzer is een belangrijk ion in natuurlijk 
menselijk speeksel. Het beïnvloedt ook de groei van C. albicans. IJzerbinding lijkt een 
veelbelovende nieuwe therapeutische strategie bij moeilijk te genezen 
mucomycosis21. Het is interessant de werkzaamheid van een combinatie van MUC 
12-mer en ijzerbindende middelen te onderzoeken. 
 
 3) Onderzoek naar de invloed van MUC7 12-mer en zijn derivaten op biofilm 
bestaande uit meerdere bacteriestammen. Er moeten biofilms ontwikkeld worden 
bestaande uit meerdere bacteriestammen waaronder S. mutans , S. gordonii, 
Fusobacteria en andere inheemse plaque bacteriën. De achterliggende gedachte is 
dat een biofilm bestaande uit meerdere bacteriestammen dichter de in vivo dentale 
biofilm benadert dan een monocultuur biofilm. Op grond van de observatie dat MUC7 
12-mer antibacteriële werking een voorkeur heeft voor S. mutans, ligt het in de lijn der 
verwachting dat MUC7 12-mer de vorming van biofilm bestaande uit meerdere 
bacteriestammen tegengaat. Verder is het van belang de effecten te onderzoeken op 
de vorming van de biofilm door de combinatie van MUC7 12-mer en EDTA. 
 
 4) In vivo onderzoek in experimenteel model. Aangezien de resultaten van 
eerdere in vivo onderzoeken niet beslissend zijn22,23, worden verdere in vivo 
onderzoeken aanbevolen naar antimicrobiële werkzaamheid van alleen MUC7 
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peptiden of van MUC7 peptiden in combinatie met andere middelen tegen schimmel 
en bacteriële infecties in diermodellen. Antischimmel werking van MUC7 peptide    
(16-mer) tegen vaginale candida infectie werd aangetoond in een rattenmodel22. Het 
model voor vaginale candida infectie is niet bruikbaar voor orale candida infecties 
vanwege de lage pH en hoge ionische sterkte in het vaginale milieu. Een in vivo 
onderzoek naar de antischimmel werking van MUC7 12-mer peptide tegen orale 
candida infectie in een rattenmodel bleek in een eerste studie effectief, maar 
consistente resultaten werden in de tweede studie niet verkregen23. Deze resultaten 
pleiten voor meer onderzoek waarbij gebruik gemaakt wordt van moderne 
dierproefopstellingen24,25. Tot op heden is er niet gerapporteerd over in vivo 
antibacteriële werking van MUC7 12-mer tegen mutans streptococcen. 
 
Ik neem aan, op basis van de beschreven resultaten in dit proefschrift over in vitro 
onderzoek, dat MUC7 12-mer in combinatie met EDTA en MUC7 12-mer-D isomeer 
of ȕ-MUC7 12-mer effectieve therapeutische werkzaamheid in vivo hebben, 
aangezien deze geneesmiddelen relatief ongevoelig zijn voor proteolyse in speeksel. 
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GLOSSARY LIST 
 
Term / 
Abbreviation 
Synonym Description / Explantion Related Terms 
AMPs  Antimicrobial peptides. CAMPs 
Amphipathic Amphiphilic A molecule having a polar, water-soluble 
group attached to a nonpolar, water-insoluble 
hydrocarbon chain. 
CAMPs / attraction 
BHI  Brain heart infusion  
BHIS  Brain heart infusion sucrose BHI 
CAMPs:  Cationic antimicrobial peptides  AMPs 
CBD  Calgary biofilm device (MBEC Bioproducts, 
Calary Canada) 
 
CF  Cystic fibrosis  
ED50  Fifty percent effective doses IC50 
EDTA  Ethylenediamine tetraacetic acid, a divalent 
cation chelator and a metal dependent 
protease inhibitor 
PIC 
FICi  Fractional inhibitory concentration index, sum 
of FIC 
FIC 
HA  Hydroxylapatite  
KOK-16B  Cell line derived from normal oral 
keratinocytes. 
Human 
erythrocytes  
HAAT  highly active anti-retroviral therapy HIV /AIDS 
Histatin 5 12-
mer 
Hsn5 12-
mer / P113 
A histatin 5 peptide with 12 L-amino acid 
residues 
MUC7 12-mer 
    
IC50  Fifty percent inhibitory concentration ED50 
    
IGP  Isotonic glucose phosphate buffer PB / PBS 
LYM  Modified RPMI 1640 medium 25% BHI 
MBC  Minimal bactericidal concentration MIC / MFC 
MFC  Minimal fungicidal concentration  
MBIC  Minimal biofilm inhibitory concentration MBRC 
MBRC  Minimal biofilm reduction concentration MBIC 
MIC  Minimal inhibitory concentration MBC / MFC 
MUC7 peptides   Peptides derived from human salivary mucin, 
MUC7 
 
MUC7 12-mer MUC7 12-
mer-L 
MUC7 peptide with 12 L-amino acid residues  MUC7 20-mer 
MUC7 12-mer-D  MUC7 peptide with 12 D-amino acid residues  P113-D / MUC7 12-
mer-L 
MUC7 20-mer  MUC7 peptide with 20 L-amino acid residues MUC7 12-mer 
PBG  Phosphate buffer containing glucose  
PBS  Phosphate buffered saline  
PI  Propidium iodide  
PIC  Protease inhibitor cocktails EDTA 
SDA:  Sabouraud dextrose agar SDB 
SDB  Sabouraud dextrose broth SDA 
SDS-PAGE  Sodium dodecyl sulfate-polyacrylamid gel 
electrophoresis 
 
SEM  Scanning electronic microscope  
SL  Human whole saliva  
Clarified saliva  Filter sterilized saliva Unclarified saliva 
TSBY  Tryptic soy broth yeast extract  
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